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  Hypertension has been associated with causing deleterious effects to the 
cerebrovasculature, which are thought to underlie the formation of white matter 
lesions (WML) and predispose individuals to age related cognitive decline. In 
humans hypertension frequently occurs concomitantly with other vascular risk 
factors making it difficult to ascertain the primary mechanisms of hypertension in 
isolation. Animal models of hypertension have been used in an aid to establish the 
mechanisms of hypertension in isolation. To date the knowledge gleaned from 
animal models has undoubtedly provided an insight as to the role of hypertension and 
cerebrovasculature remodelling but, these models have limitations such as lack of 
genetically matched controls and the inability to control the severity of hypertension, 
restricting the understanding of the underlying mechanisms. All studies within this 
thesis used the Cyp1a1 Ren2 inducible hypertensive rat model, induced by dietary 
addition of Indole-3-carbinol (I3C), allowing the severity and duration of 
hypertension to be tightly controlled and compared to genetically matched controls. 
This thesis set out to address the hypothesis that sustained hypertension will lead to 
alterations to the structural integrity of the cerebrovasculature and white matter, 
which will be exacerbated with age and that hypertension will be associated with 
alterations to gene expression and cognitive function.  
Initially this thesis sought to investigate the effect of hypertension on the 
structural integrity of the vasculature in the Cyp1a1 Ren2 rat model. Firstly, blood 




dietary addition of I3C, caused a sustained level of increased blood pressure in all 
three cohorts.  
Cerebrovascular alterations were found to consist of increased eNOS 
expression in the young brain, which progressed with increased duration of 
hypertension to vascular morphological alterations of decreased vessel width and a 
redistribution of tight junction protein claudin-5. With age, hypertensive vascular 
alterations consisted of increased eNOS expression and vascular density. 
Additionally, there was evidence that hypertension caused a vascular inflammatory 
response in the young and aged brain.  
Secondly, this thesis investigated the effect of hypertension on gene 
expression. Overall it was found that hypertension altered genes related to collagen  
growth factors, ion channels, eNOS related Map-Kinase pathway and inflammatory 
genes.  
Thirdly, this thesis sought to investigate the impact of hypertension on the 
overall structural integrity of the brain and white matter examining neurons, myelin, 
oligodendrocytes, axons and microglia, in several regions of the young and aged 
brain. In general, this study found that hypertension did not cause overt structural or 
myelin alterations in the majority of regions analysed, with only evidence of myelin 
alterations occurring within the subcortex of hypertensive animals from each of the 
young cohorts analysed. However, an adverse subcortical inflammatory response was 
found in hypertensive animals of the young 6-month cohort and also in hypertensive 




exclusive to the subcortex of hypertensive animals but also occurred in  multiple 
white matter tracts.  
Lastly this thesis chose to examine the effect of hypertension on cognitive 
function, specifically spatial reference and working memory using the Morris water 
maze and found no evidence of alterations in the cognitive functions examined.  
 Conclusions 
The results presented within this thesis demonstrated that hypertension in 
isolation leads to modest alterations to the integrity of the cerebrovasculature and 
white matter, with no evidence of alterations to specific cognitive functions 
examined, demonstrating the importance of studying hypertension in isolation. 
Additionally, this study highlights the initial hypertensive induced alterations to the 
cerebrovasculature, such as endothelial signalling, vascular structure and 
inflammation, providing a window for therapeutic intervention at a time point when 
there are minimal alterations to the overall structural integrity of the brain. Future 
studies in this model should concentrate on examining different severities of 
hypertension and also hypertension concomitantly with other vascular risk factors to 
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The structural and functional integrity of the brain requires a continuous, 
uninterrupted supply of energy (oxygen and glucose), through circulating blood flow. 
Under normal conditions, cerebral blood flow (CBF) must be sufficient to meet the 
energy demands imposed by neuronal activity within that region. This co-ordination 
of supply and demand is made possible by the close association of neurons, glia and 
vascular cells forming the conceptual ‘neurovascular unit’ (Fig 1.1) (del Zoppo and 
Mabuchi, 2003; Woolsey et al., 1996).  In humans, hypertension is associated with 
causing deleterious actions to the structural integrity of the  cerebrovasculature, 
which is thought to lead to a de-harmonistion between neuronal demand and vascular 
supply. This de-harmonisation is thought to underly gross structural and function 
alterations, which are often found in the aged brain, making hypertension a risk 
factor for the formation of white matter lesions and cognitive decline (Iadecola and 
Davisson, 2008). However, in humans hypertension is frequently present 
concurrently with other metabolically linked vascular risk factors, with less than 20% 
occurring in isolation (Kannel, 2000). Therefore, animal models are required to 
investigate the mechanisms of hypertension in isolation. Studies contained within 
this thesis sought to investigate hypertensive induced structural and functional 
alterations to the brain using the Cyp1a1 Ren2 inducible hypertension animal model, 
in which comparisons are drawn from genetically matched litter-mate control 








Figure 1.1: Components of the neurovascular unit  
The neurovascular unit is a conceptual unit comprising of neurons, glia and blood 
vessels.  The grey matter of the brain is made up of cell bodies and the white matter 
consists of oligodendrocytes, astroglia, microglia and axons. The capillaries form the 
cerebrovascular network supplying nutrients to the brain and the close association 







  Hypertension is a substantial cause of premature morbidity and mortality 
within the UK, accounting for more than £1 billion in National Health Service (NHS) 
pharmaceutical costs alone (National Guideline Centre, 2011). Clinically 
hypertension is a chronic elevation of blood pressure, above the normal range of 
≥140/90mmHg, commonly of unknown aetiology. Demographically, hypertension 
affects a quarter of the UK adult population, with more than half of those over the 
age of 60, showing a strong prevalence towards the ageing population (Fig 1.2) 
(Krause et al., 2011).  
1.1.1. Risk factors for the development of hypertension 
The cause of hypertension is commonly unknown, being attributed to a 
combination of environmental and genetic factors (Messerli et al., 2007; Staessen et 
al., 2003). Along with age, and in part gender, the occurrence of hypertension is also 
influenced by environmental lifestyle factors most of which are preventable, such as: 
smoking, poor diet, lack of exercise, type 2 diabetes and obesity (Fig 1.3) 
(Madhukumar and Gaikwad, 2012; Staessen et al., 2003). A genetic factor has also 
been identified with hypertension, with the majority of genes identified forming 
functional pathways concerning the renin-angiotensin-aldosterone and kallikrein-
kinin system (two systems controlling blood pressure, fluid retention and 
coagulation) and also several ion transport genes (Kraja et al., 2011; Weder, 2007). 
The combination of environmental and genetic factors is the basis for the treatment 
of hypertension, with patients advised to undertake lifestyle alterations and 




angiotensin-aldosterone system such as angiotensin II inhibitors (Higgins et al., 

























Figure 1.2: Prevalence of hypertension in men and women ranked by aged. 
In 2010, UK national statistics found that hypertension (classified as those with 
blood pressure readings of ≥ 140/80 mmHg or those taking anti-hypertensive 
medication), increased in prevalence with age regardless of gender, with more than 
2/3
rd’s
 of the population over the age of 65 reported as hypertensive or taking 
















Table 1.1: Risk factors for the development of hypertension 
Hypertension is associated with multiple risk factors, namely a mixture of genetic 
and lifestyle dependent. This multifactorial nature of hypertension is one of the 
complications in understanding the mechanisms of hypertension in isolation in 
humans. BMI (body mass index) was calculate by dividing the subject mass over 
height and grouped into those with a BMI of more or less than 25. Family history 
was characterised by a positive or negative history of hypertension. Additional salt 
intake was characterised as more than two pinches of salt in each meal. Smoking was 
defined as yes or no and alcohol intake was define as yes for regular alcohol 
consumption and no for no alcohol consumption/occasional consumption  (Image 






1.2. Cerebral blood flow 
1.2.1. Cerebral blood flow in the normal brain 
 
The human brain occupies around 2% of the total body mass, but demands 
~20% of the total cardiac output for normal brain function, due to a lack of energy 
stores and high energy requirements (Sokoloff, 1989).  Under normal physiological 
conditions, CBF is regulated by the brains metabolic requirements imposed by 
neuronal activity. Thus, during periods of increased neuronal activity, cerebral blood 
vessels are able to increase blood flow to regions of higher activity, a process known 
as functional hyperaemia (Cox et al., 1993; Ngai et al., 1988; Silva et al., 2000). 
Evidence suggests that there is a co-ordinated signalling between neurons, astrocytes 
and vascular cells during activity leading to an increased vasodilatory response. 
These properties of the vasculature and the close proximity with surrounding cells, 
endow the brain with hemodynamic control mechanisms, ensuring adequate CBF 
during fluctuations in activity (Astrup et al., 2008; Iadecola and Nedergaard, 2007; 
Niwa et al., 2001).  
These hemodynamic control mechanisms also ensure that CBF is maintained 
at a constant level during alterations in blood pressure, by a combination of cerebral 
perfusion and vascular resistance. The cerebrovasculature is able to adapt to 
fluctuations in perfusion pressure by vasoactive responses, ensuring vasoconstriction 
in response to increased pressure and vasodilation in response to decreased pressure. 
This is known as cerebral autoregulation, which maintains constant blood flow 
within arterial pressures of 60-150mmHg during normal daily fluctuations (Paulson 




neurogenic, endothelial, metabolic and hormonal derived mechanisms (Farkas and 
Luiten, 2001). In turn, other vasoactive factors include ions, which can be induced by 
action potentials and synaptic transmissions (Drake and Iadecola, 2007). The 
existence of these above mechanism is a critical component in maintaining the 
homeostasis of normal brain function and structural integrity. 
1.2.2.1. Cerebral blood flow in the hypertensive brain 
 
Hypertension has been associated with leading to alterations in CBF by 
disrupting cerebrovascular control mechanisms. Paulson et al., found cerebral 
autoregulation was altered in chronic hypertensives, with a shift towards higher 
blood pressures, resulting in higher pressures required to maintain adequate blood 
flow. These alterations were postulated to be due to altered vasoreactivity, which 
may expose hypertensive patients to periods of decreased CBF (Paulson et al., 1990). 
In addition, hypertension appears to target specific regions of the brain as described 
by Fujishima et al., providing evidence of decreased CBF and oxygen metabolism 
within in the supratentorial regions: cortex, striatum and thalamus (Fujishima et al., 
1995a). Additionally, a 7 year longitudinal study examining rCBF in aged 
hypertensive and normotensive individuals, found hypertensives to have decreased 
CBF in the prefrontal, anterior cingulated, occipital areas and also in the thalamus 
and cerebellum (Beason-Held et al., 2007). These findings suggest that hypertension 
primarily targets regions supplied by the perforating penetrating arterioles. 
Moreover hypertension has also been associated with alterations to functional 
hyperaemia. Jennings et al., found that during cognitive testing normotensive 




hypertensive individuals in the posterior parietal area, middle posterior arterial 
watershed region and thalamus, which impacted negatively on cognitive function 
(Jennings et al., 2005). Overall, there is evidence that hypertension may influence 
CBF, which could impair the structural and functional integrity of the brain. 
1.3. Normal brain structure 
The human brain is not homologous, rather it was discovered in the early 
eighteenth century to be divided into two distinct parts: the grey and white matter 
(Clarke and O'Malley, 1996), with the WM found to occupy over half of the brain 
(Fields, 2008). The WM contains oligodendrocytes, astrocytes and microglia but, 
unlike the grey matter is devoid on neuronal cell bodies. It was established that the 
brain’s WM tracts contain the axons extending from neurons, with the axons forming 
part of the connection between the brains white and grey matter, facilitating the flow 
of electrical signals by synaptic transmission throughout the brain over long 
distances (Clarke and O'Malley, 1996). In turn, normal brain function is made 
possible by the close association of neurons, vascular cells and glia, forming the 
conceptual ‘neurovascular unit’, allowing the microcirculation to be highly 
responsive to the energy demands within each region of the brain (del Zoppo and 
Mabuchi, 2003; Woolsey et al., 1996).   
1.3.1. Neurons 
Neurons form the signalling unit of neurotransmission and are highly 
sensitive to changes in their environment, with the ability to regulate both their 
internal and external electrolyte concentration, preventing the entry of toxic calcium 




allows neurons to encode and transmit information via action potentials throughout 
the brain (del Zoppo, 2006). Notably, it was discovered that there is a form of 
hemodynamic coupling between neurons and the cerebrovasculature, mediating CBF 
to sufficient levels for neuronal activity (Buxton et al., 2004). In turn, the close 
association of neurons with glia allows for sufficient neuronal transmission by 
neurotransmitter trafficking between neurons and glia, forming a bridge between the 
demands of neurons and the delivery of sufficient energy by vascular cells (Haydon 
and Carmignoto, 2006; Zonta et al., 2002). 
1.3.2. Cerebrovascular structure  
Higher mammals are endowed with a cerebrovascular structure designed to 
maintain CBF uniformly throughout the brain. Blood is supplied through the internal 
carotid arteries supplying the forebrain, the basilar artery and the hind brain. These 
arteries feed into the circle of Willis and due to its circular structure allow for 
collateral circulation; in the event of occlusion to one artery, more distal arteries can 
receive their blood supply from another artery (Liebeskind, 2003).  The cerebral 
blood vessels arise from the Circle of Willis, branching into smaller arteries and 
arterioles, penetrating from the surface of the brain deep into the brain’s substance 
and differ in cellular constituents with size in occurrence with their temporal location 
(Fig 1.4) (Drake and Iadecola, 2007). These surface arteries are collectively termed, 
the pial arteries (Jones, 1970) and contain a layer of both endothelial and smooth 
muscle cells, surrounded by an outer layer of leptomeningeal cells (collagen and 
fibroblasts) and perivascular nerves arising from the autonomic and sensory ganglia 
(Hamel, 2006; Peters, 1991). The vascular wall of the pial arteries is separated from 




As pial arteries and arterioles penetrate deeper into the substance of the brain, 
they retain their same cellular composition, but are contacted by the end-feet of the 
astrocytic processes, forming a glial limitans membrane on the outermost side of the 
Virchow-Robin space (Takano et al., 2006). As these vessels penetrate even deeper 
into the brain, there is a progressive loss of the Virchow-Robin space and smooth 
muscle layers. These vessels are known as intracerebral arterioles, which branch to 
produce smaller arterioles and capillaries, whose density is regionally heterogeneous 
and activity dependent. These vessels have astrocytic end-feet and neural processes 
in primary contact with the basal lamina (Girouard and Iadecola, 2006). In the 
capillaries, smooth muscle cells are replaced by pericytes, which have many similar 
characteristics to smooth muscle cells and are able to modulate capillary diameter in 
response to stimulation (Cohen et al., 1996; Rennels and Nelson, 1975). These 
pericytes form processes which wrap around the endothelium, contacting endothelial 
cells through distinct ‘peg like socket’ contacts, and are an essential component in 
microvascular stability and function (Von Tell et al., 2006). These small penetrating 
arterioles and capillaries constitute the vascular supply to the deep subcortical WM 
regions of the brain, branching off at right angles, producing short non-furcating 
capillaries with few anatosomes. This leaves the deep subcortical WM regions of the 
brain particularly sensitive to alterations in blood flow, due to a lack of collateral 












Figure 1.3: Cerebrovascular structure within the brain 
As vessels penetrate into the substance of the brain, they branch off and differentiate 
from those vessels forming the circle of Willis. As vessels penetrate deeper into the 
brain, there is a progressive loss of the Vinchrow-Robin space and smooth muscle 
cell layer, which is eventually replaced by pericytes in the smallest most deeply 








1.3.2.1. The endothelial blood-brain barrier 
Along with energy supply the cerebrovasculature is also equipped with the 
crucial role of preventing the entry of harmful stimuli into the brain, maintaining the 
neuroparenchymal microenvironment, by the formation of the endothelial blood-
brain barrier (BBB), allowing effective neuronal function, ensuring concentrations of 
ions are maintained within narrow limits (Hodgkin 1951).  The endothelial BBB was 
firstly discovered by Paul Ehrlich who observed that the injection of water soluble 
dyes into the circulatory system stained all organs apart from the spinal cord and the 
brain (Ehrlich 1885). Following studies using high resolution EM found that the 
capillary endothelial cells within the cerebral vasculature were bridged by tight 
junctions and were responsible for the establishment of an impermeable membrane 
and the anatomical substrate of the BBB (Reese and Karnovsky 1967 and 
Brightman). Endothelial cells forming the BBB are distinct from those found within 
the periphery by lack of fenestration (Febstermacher 1988), low pinocytotic activity 
(Sedlakova 1999), high mitochondrial content (Oldendorf 1977) and the presence of 
tight junctions (Kniesel and Wolburgh 2000).  
The function of the endothelial BBB is primarily to limit paracellular flow of 
ions and harmful stimuli, serving as the brain’s protective filter (Fig 1.5) (Begley et 
al., 1990; Risau and Wolburg, 1990). Hydrophobic molecules can cross the BBB, 
across the endothelium by transcellular mechanisms of carrier mediated transport, 
ion transport, active efflux transport, receptor mediated transport and caveolae 
mediated transport (Zlokovic, 2008). These endothelial cells lining the vessels form a 
chain of cells and as described above are connected by tight junctions (Kniesel and 




but there are also other junctional proteins connecting the endothelial cells, forming 
the endothelial BBB namely: adheren (Schulze and Firth, 1993) and gap junctions 
(Fig 1.5) (Braet et al., 2001; Kojima et al., 2003; Simard et al., 2003; Tao-Cheng et 
al., 1987). These linking junctions have specific roles within the vasculature, with 
tight junctions and adheren junctions mainly limiting permeability across the BBB, 
whereas gap junctions are thought to participate in intercellular communication 
(Bazzoni and Dejana, 2004).  
1.3.2.2. Endothelial tight junctions 
Tight junctions of the endothelium are proposed to be the key structures 
responsible for barrier properties (Brightman and Reese, 1969; Kniesel and Wolburg, 
2000; Mollgard and Saunders, 1986; Nabeshima et al., 1975). Freeze fracture studies 
identified tight junctions as intra-membranous networks of multiple strands forming 
occluded intracellular clefts (Brightman and Reese, 1969; Farquhar and Palade, 
1963). Characterisation of molecular structure has led to the identification of 
different types of endothelial tight junctions and association proteins, namely 
occludin (Ando-Akatsuka et al., 1996; Furuse et al., 1993; Hirase et al., 1997), 
claudins (Liebner et al., 2000a; Liebner et al., 2000b; Lippoldt et al., 2000; Morita et 
al., 1999) and submembranous zona occludens (Fig 1.4) (Balda and Anderson, 1993; 
Haskins et al., 1998; Jesaitis and Goodenough, 1994; Stevenson et al., 1986). Both 
7H6 (Zhong et al., 1994) and cingulin (Citi et al., 1989) are also tight junction 
association proteins, firstly characterised in the periphery and have also been 
observed to be located within the  endothelial BBB (Wolburg and Lippoldt, 2002). 
Occludin was the first tight junction molecule to be discovered, although its 




evidence that structural formation of occludin is not necessary for the formation of 
the BBB but maintains a role in regulation of BBB properties (Lacaz-Vieira et al., 
1999; Saitou et al., 2000). 
The claudins are a family of tight junction molecules and are associated with 
the formation of the endothelial BBB and its barrier properties in many studies 
(Furuse et al., 1998a; Furuse et al., 2001; Furuse et al., 1998b; Furuse et al., 1999; 
Morita et al., 1999; Tsukita and Furuse, 1999). Claudin -1 and -5 have been located 
within endothelial cells of the brain (Liebner et al., 2000a; Liebner et al., 2000b; 
Lippoldt et al., 2000; Morita et al., 1999), as well as peripherally. Structurally these 
proteins share 4 transmembrane domains with occludin, but they do not contain 
sequence homology (Wolburg and Lippoldt, 2002). 
Zona occludens (ZO) are tight junction association proteins, as they tether 
tight junctions to the cytoskeleton (Furuse et al., 1994; Itoh et al., 1999). These 
proteins are classified to form 3 members- ZO-1, -2 and -3 and are membrane 
associated guanylate kinases (MAGUK) (Wolburg and Lippoldt, 2002).  There have 
also been reports that ZO interacts with adhesion molecules such as junctional 
adhesion molecule (JAM) -1 (Bazzoni et al., 2000; Hamazaki et al., 2002). Adhesion 
molecules include JAM, platelet endothelial cell adhesion molecule (PECAM) -1 and 
endothelial cell-selective adhesion molecule (ESAM), which are also localised at 

































Figure 1.4: The endothelial blood-brain barrier 
Schematic of the endothelial BBB. One key feature of the cerebrovasculature is the 
endothelial blood-brain barrier, which prevents the entry of toxic and harmful 
products into the brain. The endothelial cells are organised in a line within the blood 
vessels and are connected by tight junctions, gap junctions and adheren junctions, 





The other type of cells which form part of the neurovascular unit are the glia, 
the most numerous group of non-neuronal cells within the brain, forming active 
partners with neurons, providing multiple roles such as maintaining environmental 
homeostasis, cell-cell signalling, trophic support, innate immunity, regulation of 
blood flow and ensuring signals sent from neurons evoke the correct vascular 
response (Bezzi and Volterra, 2001). 
1.3.3.1. Astrocytes  
Astrocytes are uniquely positioned as an anchor between neurons and blood 
vessels. Astrocytes form specialised end-feet, which cover around 90% of the 
vascular abluminal membrane, contacting both neurons and synapse (Kacem et al., 
1998; Peters et al., 1991). On blood vessels, these astrocytic end-feet become 
anchored to components of the basal lamina and play a crucial role in volume and ion 
regulation (Abbott et al., 2006). One mechanism by which astrocytes can induce 
alterations to blood flow is by their response to glutamate released by neural activity, 
activating astrocytic metabotrophic glutamate receptors, leading to increased Ca
2+
 
and local vasodilation (Abbott et al., 2006; Takano et al., 2006; Zonta et al., 2003). 
Astrocytes also use Ca
2+
 signalling to activate other surrounding glia such as 
oligodendrocytes and microglia (Hansson and Ronnback, 2003).  
1.3.3.2. Microglia 
  In the normal brain, microglia are located sporadically, surrounding arterioles 
and capillaries, forming one of the cellular components of white matter (Esiri and 
McGee, 1986). Microglia are the main form of innate immune response and are 




Morphologically, under normal conditions microglia have a small circular cell body, 
in conjunction with outwards extending processes (Garden and Moller, 2006; Perry 
and Gordon, 1988). These cells were previously thought to be in a ‘resting’ state, but 
through advances in in-vivo imaging, these cells have been shown to be continually 
‘surveying’ their microenvironment by extending and contracting their processes 
(Davalos et al., 2005; Nimmerjahn et al., 2005). In response to alterations in the 
homeostasis of their microenvironment, which may be due to CNS injury, ischemia, 
inflammatory stimuli or cellular signalling, microglia are recruited and differentiate 
into an active phenotype, migrating to the source of injury. Once recruited to the site 
of injury, microglial cells are able to phagocytose dead or dying cells and their 
debris, which can lead to the enlargement of their cell bodies. Recruitment of 
microglia can also be self-perpetuating, in that active microglia release a range of 
inflammatory mediators, which further recruit microglia (Garden and Moller, 2006). 
1.3.3.3. Oligodendrocytes and myelinated axons 
 
Oligodendrocytes play a critical role in the connectivity of the CNS by 
producing the myelin sheath. Myelin is a substance composed of a high lipid content 
(70/30%, lipid to protein ratio) and low water content. The composition of myelin is 
the reason for the characteristic ‘pale white’ colour of WM and a feature that 
multiple imaging techniques such as magnetisation transfer imaging (MRI) have 
taken advantage of (Barkhof and Scheltens, 2002; Quarles et al., 2006).  
In the normal brain, the oligodendrocytes form the myelin sheath by 
extending their myelin comprising processes onto neighbouring axons. Once in 




around the axons to form a multilayer insulting sheath. This insulting sheath allows 
for rapid propagation of axon potentials, which are 100x faster in comparison to non-
myelinated axons, allowing faster signal transfer between distant regions of the brain 
(Baumann and Pham-Dinh, 2001; Fields, 2008; Hodgkin, 1951) and shelters axons, 
preventing them from exposure to toxic stimuli (Nave, 2010). The myelin sheath 
does not cover the entire length of the axon, periodic ‘gaps’ exist termed the Nodes 
of Ranvier, with the segments of myelin in between known as the internodes. 
Although species and location dependent, these internodes are round 100-1700 µm in 
length compared to the Nodes of Ranvier, which are within the region of 1µm and 
these gaps function to facilitate saltatory conduction of action potentials along the 
axon, as leaps of current from one Node of Ranvier to the other (Edgar and Nave, 
2009). 
The abundance of oligodendrocytes within the CNS does not limit them to 
the myelination of a single axon. In fact, they can extend their processes to multiple 
axons and likewise, each axon can be myelinated by multiple oligodendrocytes 
(Peters, 1991). The calibre of the axon also affects the type of oligodendrocyte 
producing the myelin, with oligodendrocytes categorised into type I to IV based on 
the size of axons they myelinate, ranging from small to large diameter axons 
respectively (Butt et al., 1995). 
Additionally, oligodendrocytes also provide trophic support to neurons (Du 
and Dreyfus, 2002) and link neurons to capillaries through connections with 
astrocytes (Paspalas and Papadopoulos, 1998).  Furthermore, oligodendrocytes are 
able to use Ca
2+
 signalling to signal to surrounding glia (Verkhratsky and 




as brain derived neurotrophic factor and insulin like growth hormone (Hansson and 
Ronnback, 2003).  
In the normal brain myelin develops as we age. At birth, the human brain 
consists of a small amount of myelin with development of myelin in a 
heterochonological pattern, until the 5
th
 decade of life. The temporal and parietal 
lobes are the last to myelinate and have shown to be the first to be lost with age 
(Marner et al., 2003). This loss of WM integrity, commonly referred to as WML, 
with age is strongly associated with decreased cognitive function in many long term 
epidemiological studies, such as The Rotterdam scan study, Honolulu Asia aging and 
Lothian birth cohort 1936 (De Groot et al., 2000; Deary et al., 2007; Launer et al., 
1995). These studies have utilised imaging techniques and found that WML occur 
with ageing at a frequency of 50% in individuals over the age of 65 (Enzinger et al., 
2006). Although the cause of WM loss with age is unknown, imaging studies have 
investigated risk factors, which may predispose individuals to WM loss and 
cognitive decline. In particular, vascular risk factors have been associated with the 
formation of WML, with a large body of evidence pointing towards hypertension 
being a major risk factor (Pantoni and Garcia, 1995). 
1.4. The structural integrity of the hypertensive brain 
 
Hypertension has been associated with causing deleterious effects to the 
structural integrity of the brain, being the number one risk factor for stroke and age 
related cognitive decline (Dahlof, 2007). Recent advances in our knowledge of 
neurovascular regulation and the concept of the neurovascular unit has led to clues of 




the brain. It has been proposed that hypertension leads to deleterious alterations to 
the cerebrovasculature, associated with the promotion of atherosclerotic plaques in 
the cerebral arteries and arterioles, which may progress to arterial occlusions and 
ischemic injury (Dahlof, 2007; Lammie, 2002). In turn, hypertension has also been 
associated with inducing fibrinoid necrosis (lipohyalinosis) of the penetrating arteries 
and arterioles, the main vascular supply to the WM leading to small WM lesions and 
depending on the severity, brain haemorrhage. These observations are largely 
credited to Miller Fisher who characterised hypertension related vascular alterations, 
by the examination of post-mortem brains from hypertensive patients (Fisher, 1969, 
1972, 1977; Fisher, 1978; Fisher, 1982; Fisher, 1998; Fisher and Caplan, 1971; 
Fisher and Tapia, 1987). Fisher examined the vasculature by serial section 
reconstruction of the blood supply and observed that lacunar infarcts are located 
distal to occluded small perforating arteries. Fisher characterised two main types of 
vascular lesions namely: intracranial atherosclerosis and lipohyalinosis, which were 
associated with lacunes. Future studies described these alterations to the 
cerebrovasculature as vasculature remodelling, characterised as the ability of the 
vessel wall to re-organise both cellular and extracellular components in response to a 
chronic stimulus (Gibbons and Dzau, 1994).  
Firstly, Fisher identified that hypertension appears to drive atherosclerosis 
into the most distal cerebrovasculature observing large lacunes associated and thus 
attributed to atherosclerotic plaques in 200 to 800µm diameter vessels. Additionally, 
Fisher identified another destructive lesion of segmental disorganisation found in 




commonly located in the striatocapsule and thalamus being attributed to over two 
thirds of lacunes identified (Fig 1.6) (Fisher, 1969; Fisher, 1978).  
Many of these lipohyalinotic lesions observed were old and characteristic by 
the loss of normal wall architecture, collagenous sclerosis, mural foam cell 
accumulations and microbleeds. These features may represent early evidence of 
alterations to the BBB and it was also postulated that these lesions may lead to 
alterations in blood flow. These lipohyalinotic lesions were traditionally viewed as a 
consequence of severe hypertension, but have been found in relation to lacunar 
infarcts, even in the modern era of ‘controlled’ treated hypertension (Fisher, 1991; 
Lammie et al., 1997; Masuda et al., 1983).  Pathological evidence has suggested that 
there is an acute non-healed form of lipohylinotic lesions known as fibrinoid 
necrosis, which has been found to be most commonly associated with hypertension 
(Feigin I, 1959; Fisher, 1971; Masuda et al., 1983; Rosenblum, 1977; Takebayashi 
and Kaneko, 1983). Identification of fibrinoid necrosis requires the use of 
histological techniques and has been characterised to be circumferential, focal or 
segmental and particularly prevalent in the basal ganglia; as a result of moderate 
hypertension and within the pons; as a result of severe hypertension (Feigin I, 1959; 
Masuda et al., 1983; Rosenblum, 1977).        
Throughout the literature the term lipohyalinosis has been wrongly used for a 
variety of small vessel pathologies. Mostly, the common small vessel pathology 
characterised by concentric hyaline wall thickening of the small arteries and 
arterioles, which is most commonly found in the aged brain and has been associated 
to be exacerbated by hypertension, diabetes and other vascular disorders (Fig 1.6) 




begins in the forth decade of life and has been shown to increase in severity with age 
(Baker and Iannone, 1959a, b; Furuta et al., 1991).  
Clinically these small vessel lesions are defined in severity by wall thickness 
to lumen ratio, which has been found to correlate with systolic blood pressure. 
Pathological investigations have found these vasculopathies to consist of: 
degeneration of tunica media smooth muscle cells and internal elastic lamina 
degeneration, which are replaced by fibroblasts, deposits of collagens I, III, V, VI 
and basement membrane specific; lamina and collagen IV (Zhang and Olsson, 1997). 
In the brains of hypertensive individuals, these vascular alterations may be preceded 
by ‘onion skinned’ concentric smooth muscle cell proliferation (Kalimo et al., 1997). 
Overall, the vasculature is left elongated, tortuous, stiffened and remodelled with 
decreased external wall diameter. 
In the modern day, hypertension is still associated with these cerebrovascular 
alterations, however, to date small vessels pathologies have been studied post 
mortem, preventing the identification of the initial mechanisms, rather the gross 
structural alterations, which are readily identified by neuroimaging and are taken as 












Figure 1.5: Small vessel pathologies in the human brain 
Histological evidence of small vessel pathologies. (A) Small vessel atherosclerosis in 
the putmen -an eccentric atherosclerotic plaque within a penetrating vessel. The 
presence of the atherosclerotic plaque leads to luminal narrowing (*) and occlusion 
of the vessel. (B) Lipohyalinosis in the basal ganglia - vessel wall appears thickened 
and dilated, with overall general disorganisation. There is also focal fibrosis, 
fibrinoid degeneration (*) and commonly mural cell infiltration (arrow). (C-D) 
Images within the globus pallidus- arteriolosclerosis, (C) concentric hyaline wall 
thickening, loss of layers of smooth muscle cells and often moderate luminal 
narrowing, (D) characteristic of an aged brain, with mineralisation of the tunica 







1.4.1. Vascular inflammation 
In addition with hypertension being associated with alterations to the 
structural integrity of the cerebrovasculature there is also a large body of evidence 
linking hypertension and vascular inflammation. Although it is not fully understood 
why there is a link between hypertension and vascular inflammation it may represent 
a response of the brain to vascular alterations. Clinically hypertensive patients have 
been found to have increased serum levels of inflammatory markers such as C-
reactive protein, which were found to correlate to increased blood pressure (Bautista 
et al., 2001), (Boos and Lip, 2006; Li, 2006; Sung et al., 2003). Although limited, 
lesion characterisation studies in hypertensive brains have found that the vessel wall 
becomes a compressed cavity with a gliotic, neovascularised, fibrotic peripheral zone 
(Takasugi et al., 1985). In addition, Akiguchi et al., carried out pathological 
assessments of the structural integrity of the brain from patients who had suffered 
cerebrovasculature disease (Akiguchi et al., 1997). Their observations were in 
agreement with early characterisations carried out by Brun and Englund, finding 
numerous activated microglia and macrophages associated with the 
cerebrovasculature in areas with signs of WM loss (Brun and Englund, 1986).  
Interestingly, the arteriosclerotic lesions originally characterised by Fisher, 
were described to show endothelial proliferation, splitting of the lamina densa with 
vascular leakage and marked accumulation of lymphocytes and macrophages in the 
surrounding area (Fisher, 1969; Fisher, 1978; Fisher, 1991). From the description it 
could be hypothesised that the leakage of plasma from the vasculature was due to 




As described previously, the endothelium plays many crucial roles within the 
CNS, influencing vascular tone and inflammatory response through signalling 
mechanisms. Oxidative stress is also associated with endothelial dysfunction and 
vascular remodelling in hypertension (Cai and Harrison, 2000; Ross, 1999). During 
vascular remodelling (in particular atherosclerosis), endothelial dysfunction is an 
initial event followed by vasoconstriction, leukocyte and platelet aggregation 
(Bonetti et al., 2003; Gonzalez and Selwyn, 2003; Heitzer et al., 2001). The main 
associated cause of endothelial dysfunction is decreased bioavailability of NO, a 
potent vasodilator that inhibits leukocytes and platelet adhesion and can release 
modulatory signalling, controlling smooth muscle cell proliferation (Heitzer et al., 
2001). Alterations in NO found in cerebrovascular disease may be due to increased 
breakdown of NO by reactive oxygen species (ROS), forming the highly reactive 
toxic peroxynitrite. The production of ROS can also contribute to the uncoupling of 
the nitric oxide synthase enzymes, crucial for the formation of NO, leading to a 
further increase in levels of ROS (Munzel et al., 1997). In turn, increased levels of 
ROS can lead to cellular damage and have highly negative consequences to the 
structural integrity of the vasculature (Portaluppi et al., 2004).  
This is highly relative to hypertension as patients are consistently found to 
express higher circulating levels of plasma ROS, such as malondialdehyde, 8-
isoprostane and 8-oxo7,8-dihydro-2-deoxyguanosine, and these markers have been 
associated with the severity of vascular alterations (Portaluppi et al., 2004; Redon et 
al., 2003). In turn, hypertension has been found to be associated with the activation 
of members of the redox signalling pathways such as mitogen-activated protein 




which influence the vascular expression of NO through the expression of endothelial 
specific nitric oxide synthase (eNOS) (Lassegue et al., 2001; Ungvari et al., 2003).  
Increased levels of ROS associated with hypertension can stimulate an 
inflammatory response through the expression of transcription factors such as NFκB, 
an inflammatory mediator that can stimulate the expression of inflammatory cells. In 
turn, inflammatory factors such as IL-6 and IL1β can induce endothelial dysfunction 
(Bhagat and Vallance, 1997; Cleland et al., 2000; Hurlimann et al., 2002; Paffen and 
deMaat, 2006; Wang et al., 1994). There is at present an overwhelming association 
with hypertension, vascular remodelling, oxidative stress and vascular inflammatory. 
However, the exact mechanisms as yet are not fully elucidated and it would be 
interesting to carry out studies investigating alterations to vascular related genes 
before and after signs of vascular remodelling.   
1.4.2. Hypertension related vascular alterations and associated gene changes 
With recent advances in gene profiling techniques the ability to investigate 
alterations in gene expression with hypertension and in comparison to structural 
alterations, has provided a new approach to identify the underlying mechanisms. As 
described previously, the initial genetic studies identified a few candidate genes 
associated with hypertension, which are related to the renin-angiotensin-aldosterone 
system (RAAS), kallikrein-kinin system and ion transport (Adragna and Lauf, 2007; 
Ji et al., 2008; Schild et al., 1996), with many of these gene alterations forming the 
basis of pharmacological targets (Arnett and Claas, 2009; Levy et al., 2009).  
Many large Genome wide association studies have been carried out to 




been relatively unsuccessful, due to the inherent variation in population samples 
according to duration of hypertension, age and vascular pathology. The CHARGE 
Consortium GWAS included 29,136 participants aged between 38-72, whom had 
previously undergone blood pressure measurements in 6 population based studies: 
Age, gene/Environment Susceptibility Reykjavik study (AGES), Atherosclerosis 
Risk in the Communities (AIC) study, Cardiovascular Health study (CHS), 
Framingham Heart study (FHS), Rotterdam Study (RS) and the Rotterdam Extension 
Study (RES) (Levy et al., 2009). In general, these studies provided evidence of 
alterations to the RAAS, Ion transport, Calcium and NO signalling pathways with 
hypertension (Levy et al., 2009; Salvi et al., 2012). Furthermore studies have also 
identified missense variants of the NO endothelial receptor, eNOS in hypertensive 
patients (Lacolley et al., 1998; Shimasaki et al., 1998; Yoshimura et al., 1998) and 
more specifically the HYPERGENES European population study, in which 
hypertensive  patients were followed for a period of 5-10 years, found several eNOS 
related single nucleotide polymorphisms, and in particular the rs3918226, were 
strongly associated with hypertension. This study also found a significant interaction 
between the expression of rs3918226 and the expression of both actin and heat shock 
protein genes in hypertensive patients (Salvi et al., 2012). Overall the current studies 
have identified genes, which are altered with hypertension but it is unknown if these 
genes are associated with causing hypertension or caused by hypertension. 
1.4.3. White matter integrity and hypertension 
Not only is hypertension thought to alter the structural integrity of the 
cerebrovasculature but these alterations are thought to underlie WML, thus making 




observe WML in elderly brains and these are associated with decreased cognitive 
function. Additionally, arteriolosclerosis of the small penetrating arteries and 
arterioles, (which hypertension is thought to target),  is commonly found in brains of 
the elderly with diffuse WML (Pantoni, 2010). Thus, establishing the role of 
hypertension in the formation of WML is critical. 
Our knowledge of the structural alterations to the WM with age and ability to 
correlate these changes to vascular risk factors has been influenced by advances in 
in-vivo imaging techniques, such as CT and MRI (Figure 1.7) (Pantoni and Garcia, 
1995). The co-application of imaging findings and post-mortem pathological studies 
has characterised these WML as areas of demyelination, loss of oligodendrocytes 
and vaculation (Brown and Thore, 2011; Brun and Englund, 1986; Pantoni and 
Garcia, 1997a).     
In general, the use of these imaging techniques has lead to a large body of 
evidence showing an association between hypertension and the severity of WML. 
Early studies using CT imaging found that a large number of individuals with WML 
were hypertensive and also exhibited impaired cognitive function (Blennow et al., 
1991; Bogousslavsky et al., 1987; Hijdra et al., 1990; Rezek et al., 1987). With the 
induction of MRI scans many more studies have been carried out and have shown a 
strong correlation. Namely the atherosclerosis risk in the communities study, which 
found that around a third of the population aged 55-72 years had WML, with half of 
those hypertensive (Liao et al., 1996) and similar findings have reported in both The 
Cardiovascular Health study (Longstreth et al., 1996) and Rotterdam study (Breteler 
et al., 1994). As previously stated WML do occur in normal aging and in the absence 




Sierra et al., 2002), but at a lower rate and severity (Liao et al., 1996; Pantoni and 
Garcia, 1995). Therefore, hypertension is thought to exacerbate features of the 
ageing brain. 
Further evidence supporting hypertension as a risk factor for WML was 
established by a study carried out by Sawn et al., finding that hypertension in midlife, 
predisposed individuals to WML in late life. They examined a population of 68-79 
community dwelling men, carrying out MRI examinations and cognitive testing over 
a 10 year period. It was found that those subjects who had high midlife systolic blood 
pressure, experienced a greater severity and prevalence of WML with a 
corresponding decrease in cognitive function in late-life, reinforcing the hypothesis 
that hypertension midlife is a predictor for WML in late-life (Swan et al., 1998). 
Nonetheless, vascular risk factors such as diabetes (which often co-exists with 
hypertension in humans), have been linked with the presence of WML (van Harten et 
al., 2006),  proposing that several different pathogenic pathways may be present in 
the formation of WML. 
The evidence that hypertension alters CBF further supports the association 
due to the anatomical location of WML being frequently found within the 
periventricular and subcortical regions of the brain (De Groot et al., 2002; De Leeuw 
et al., 2002; Matsushita et al., 1994; van Dijk et al., 2004), which have been found to 
be sensitive to alterations in CBF (Pantoni and Garcia, 1995). Histological studies 
have been undertaken to correlate WML observed on CT and MRI scans with 
autopsy findings and these studies have identified pathological differences between 
periventricular and subcortical WML (Pantoni and Garcia, 1995). Periventricular 




fluid and ventricular enlargement (Chimowitz et al., 1992; Fazekas et al., 1991; 
Fazekas et al., 1993; Grafton et al., 1991; Jungreis et al., 1988; Leifer et al., 1990; 
Moody et al., 1995; Scarpelli et al., 1994; Sze et al., 1986; Van Swieten et al., 1991).  
Deep subcortical white matter abnormalities on the other hand, correlated with 
enlarged perivascular spaces, small infarcts, cysts, and de-myelinated plaques with 
no evidence of axonal loss (Braffman et al., 1988; Chimowitz et al., 1992; Jungreis et 
al., 1988; Marshall et al., 1988; Munoz et al., 1993; Scarpelli et al., 1994) . There 
was also evidence of astrogliosis and thickening of the wall of small vessels (Fazekas 
et al., 1993; Leifer et al., 1990; Lotz et al., 1986; Marshall et al., 1988; Revesz et al., 
1989; Van Swieten et al., 1991).   
In addition further supporting the link between hypertension and WML, many 
studies have found antihypertensive treatment beneficial in preventing the formation 
and progression of WML. It has been shown that treated hypertensive patients with 
controlled blood pressure have a lower volume and decreased severity of WML, 
when compared to untreated hypertensive patients (Liao et al., 1996). The 
Perindopril protection against recurrent stroke study (PROGRESS), used 
Perindropril; a long acting angiotensin converting enzyme (ACE) inhibitor and 
examined its ability to prevent WML. Patients exposed to this form of anti-
hypertensive treatment had a reduction in the formation of new WML compared to 
untreated hypertensive individuals (Dufouil et al., 2005), although the specific 
mechanisms are not yet known. Many other studies have examined different anti-
hypertensive treatments and have found similar results, suggesting that controlling 




brain. However, antihypertensive medications have a broad spectrum of targets 
































Figure 1.6: White matter lesions 
Magnetic resonance imaging (MRI), showing different severities of white matter 
hyperintensities, in two 80 year old patients. The hyperintensities appear as bright 
white spots, which reflect areas where tissue contains more fluid than the 
surrounding tissue, with pools of free water and these spots are thought to represent 
white matter lesions within white matter tracts of the brain. White matter lesions are 
frequently found within the periventricular and deep subcortical regions of the brain. 
White matter lesions can be seen in the above image with the patient on the left 
having a lower severity, than those observed to be more extensive in the patient on 










1.4.4. Hypertension and cognitive function  
Cognitive decline is becoming an ever important issue in our aging society, 
with hypertension associated as a risk factor for cognitive decline. In addition to 
WML, increased blood pressure and decreased cognitive function are two attributes 
commonly found with increasing age particularly in those ≥60 years of age and 
beyond (Botwinick, 1977; Kausler, 1982), with hypertension firstly being associated 
with cognitive decline in individuals over 60 years of age several decades ago 
(Wilkie and Eisdorfer, 1971). 
The most robust evidence has come from longitudinal epidemiological 
studies, with the majority of studies finding a relationship between midlife 
hypertension (around 50 years of age) and cognitive decline in late-life (see table 
1.1). One of the first longitudinal studies, to find a correlation between initial blood 
pressure measurements and the development of cognitive decline a decade later was 
the Framingham Study (Elias et al., 1993).  Subsequently, a 20 year long population-
based study found that cognitive function at the age of 70 was inversely related to 
initial arterial blood pressure measurements at 50. Therefore, high blood pressure at 
midlife was associated with cognitive decline in late-life (Kilander et al., 1998a). 
The epidemiology of vascular aging (EVA) population study is another key 
study examining hypertension in relation to cognitive decline. Using a shorter follow 
up period of 4 years, they found that patients who had high blood pressure at baseline 
exhibited cognitive decline after the 4-year follow-up. Interestingly, it was found that 
hypertensive patients had a 2.8 times higher risk of developing cognitive decline than 
normotensive individuals (Tzourio et al., 1999). Although, the EVA study examined 




risk in communities study (ARIC), with a follow up period of 6 years and found that 
hypertension and diabetes are associated with the formation of cognitive decline 
(Knopman et al., 2001).  
Overall, the studies that provided evidence of cognitive decline as a result of 
hypertension showed impairments in attention, learning and memory, executive 
function, visuospatial skills, psychomotor abilities and perceptual skills (Deshmukh 
et al., 2009; Elias et al., 2004; Waldstein, 2003). These impairments in attention, 
perceptual processing and executive function, can be associated with cognitive 
deficits frequently found in individuals with subcortical vascular dementia, whom 
exhibit pathological alterations to deep subcortical WM circuits (Cummings, 1998). 
Furthermore, within the literature there was a discrepancy as to whether high 
or low blood pressure is more detrimental to cognitive function. A study by Skoog et 
al., provided some clarity demonstrating that high blood pressure measurements 
found in individuals ~70 years of age were associated with a high prevalence of 
developing cognitive decline, specifically dementia some 10-15 years later, than 
those whose blood pressure was within a normal range (Skoog et al., 1996). 
Interestingly this study found that upon the development of dementia symptoms, 
individuals who had previously been reported as having high blood pressure had 
developed low blood pressure. 
Further supporting evidence of a link between hypertension and cognitive 
decline has come from the findings that anti-hypertensive treatment can act to 
preserve cognitive function. Findings from non-randomised trials are overall 




affect on cognitive function (Khachaturian et al., 2006; Lindsay et al., 2002; Mielke 
et al., 2007; Morris et al., 2001; Qiu et al., 2003). In general, most of the 
observational studies, which have been carried out have found that anti-hypertensive 
medications are neuroprotective to cognitive functions. This has been shown in the 
EVA cohort study, in which the risk of developing cognitive decline after a 4-year 
follow-up was significantly decreased in treated versus non-treated hypertensive’s 
(Tzourio et al., 1999) and a 5-year period with treatment is associated with a 38% 
reduction in cognitive impairment compared to non-treated hypertensive patients 
(Murray et al., 2002).  
Several large placebo-controlled clinical trials have been carried out but 
overall the results of these trials are heavily dependent on the type of treatment used, 
duration of hypertension and follow-up period. The first study to find a reduction in 
development of cognitive decline was the SYST-EUR trial, examining patients >60 
years of age with isolated systolic hypertension, receiving treatment with a calcium 
channel antagonist, combined with an angiotensin converting enzyme inhibitor; 
enalapril and/or a diuretic; hydrochlorothiaziade, compared to over 1000 placebo 
treated patients.  Over a 2-year period, the incidence of dementia was remarkably 
decreased by 50% in the treated group compared to the placebo group (Forette et al., 
2002; Forette et al., 1998). There have been several other clinical trials which aim to 
validate and expand on the above finding, such as the HOPE trial (Bosch et al., 
2002), PROGRESS (Tzourio et al., 2003) and SCOPE (Lithell et al., 2003), with 
regard to increasing severity of hypertension and comparisons between different 
medications.  Overall, the majority of data indicates that hypertension can impact 







Table 1.2: Key longitudinal studies examining cognition in relation to 
hypertension  
The above table shows the findings from several studies examining cognitive decline 
and dementia.  
 
Key longitudinal studies investigating the association between hypertension and 
cognitive decline  
Reference Age (years) Follow-up 
(years) 
Association  
Elias et al. 1993 55-88 12-14 Yes 
Launer et al. 1995 






Yes- high blood 
pressure at 70 predicted 
cognitive decline some 
10-15 years later  
Starr et al. 1997 >69 4 Yes  
Guo et al. 1997 75-101 3 Yes- J curve 
relationship  
Kilander et al. 1998 50 20 Yes 
Swan et al. 1998 45 25-30 Yes  
Tzourio et al. 1999 59-71 4 Yes  
Glynn et al. 1999 65-102 9 Yes- J curve 
relationship 
Knopman et al. 2001 47-70 6 Yes 
Bohannon et al. 2002 65-105 3 Yes- J curve 
relationship  
Reinprecht et al. 2003 68 13 Yes  
Piguet et al. 2003 ≥75 6 Yes 
Elias et al. 2003 55-88 4-6 Yes 
Tervo et al. 2004 60-76 3 No 
Solfrizzi et al. 2004 65-54 3.5 No 
Waldstein et al. 2005 70 6 Yes 
Kuo et al. 2005 65-94 2 Yes 
Waldstein et al. 2008 57 5 Yes 






1.5. Animal models of hypertension 
Hypertension in humans commonly occurs concomitantly with other vascular 
risk factors, such as diabetes, which has also been associated with cerebrovascular 
pathology. For this reason, animal models are required to unravel the mechanisms of 
hypertension in ‘isolation’ on the structural and functional integrity of the brain.  
Due to the multifactorial nature of hypertension, many animal models have 
been created by genetic, pharmacological and surgical manipulation (see (Lerman et 
al., 2005) for an in-depth review of hypertensive animal models). In general, rat 
models are most commonly used due to the similarities in the structure of the Circle 
of Willis in comparison to humans (Figure 1.8). The best characterised experimental 
models of hypertension are the spontaneously hypertensive rat (SHR) and (SHR) 
stroke prone (SHRSP), therefore they will be the extensively covered models in this 
thesis. These models have dramatically improved our knowledge in this field and 
have remained the gold-standard models for several decades. However, the 
limitations of these models have left the initial mechanism of hypertension on the 
structural integrity of the brain unknown. Thus, this thesis sought to investigate the 
effect of hypertension on the structural and functional integrity of the brain using the 
Cyp1a1 Ren2 rat model, in which the severity and duration of hypertension can be 












Figure 1.7: The anatomy of the Circle of Willis in humans and rats 
The Circle of Willis is relatively similar between humans and rats, allowing rats to be 
used to study conditions which alter the cerebrovasculature and cerebral blood flow. 
Some of the differences include the anterior communicating artery, which is found in 
humans but not rats and the olfactory artery, which is found in rats but not humans. 
Abbreviations: ACA- anterior cerebral artery, ACOA- anterior communicating 
artery, AICA- anterior inferior cerebral artery, ASA- anterior spinal artery, BA- 
basilar artery, ICA- internal carotid artery, MCA- middle cerebral artery, PCA- 
posterior cerebral artery, PCOA- posterior communicating artery, SCA- superior 






1.5.1. The spontaneously hypertensive rat and spontaneously hypertensive 
stroke prone rat 
 
The spontaneously hypertensive rat (SHR) model was created by the selective 
breeding of Wistar Kyoto (WKY) rats that were found to have the highest blood 
pressure compared to other rats. In this model blood pressure rises by the fifth week 
of life and rapidly reaches levels of systolic blood pressure around 200 mmHg. 
Although the SHR model exhibits target end organ damage, they are not prone to 
develop strokes (Okamoto and Aoki, 1963). The spontaneously hypertensive stroke 
prone rat (SHRSP) is a sub-strain of the  SHR bred specifically for the development 
of malignant hypertension (systolic blood pressure >220mmHg by 8 weeks of age) 
and stroke (Yamori, 1994; Yamori and Horie, 1977).  The phenotype of both the 
SHR and SHRSP models includes several differentially expressed genes, many of 
which are unknown, but are known to be associated with the over-reactivity of 
RAAS (Yamori and Horie, 1977). Overall the SHR and SHRSP models have 
provided a wealth of knowledge as described below, but there is one main limitation 
to the majority of these studies in that the control strain used is the WKY, which is 
not genetically identical and thus strain individual differences exist (Johnson et al., 
1995).    
1.5.1.2. Animal models of hypertension and cerebral blood flow 
In the majority of studies carried out there is evidence of alterations to CBF 
in both the SHR and SHRSP models. Yamori et al., measured regional cerebral blood 
flow in SHRSPs using the hydrogen clearance method and found that frontal cortical 




200mmHg.  This was postulated to be due to alterations in cerebrovascular reactivity, 
which was found to be decreased in 9 month old SHRSPs (Yamori and Horie, 1977). 
Similar findings were shown in the SHR model by Fujishima et al., who used the 
hydrogen clearance technique to measure rCBF in young (3-4 month old) and aged 
(16-17 month old) SHR. Fujishima et al., found that cortical and thalamic rCBF was 
decreased in aged SHR, when compared to WKY. This decreased rCBF was asso 
ciated with structural alterations to the cerebrovasculature and also a deficit in 
cognitive function (Fujishima et al., 1995a).  
In turn, cerebral autoregulation has been found to be altered in the SHR 
model (Harper and Bohlen, 1984), when compared to normotensive WKY controls. 
This shift in autoregulation means that with chronic hypertension there is an 
exacerbation of the vasoconstrictive response to acute increased pressure, which may 
be an underlying factor of vascular dysfunction (Faraci et al., 1990). The change in 
cerebral autoregulation has been linked with alterations in the distensibility of the 
vasculature. With chronic hypertension, the larger arteries of the SHR and SHRSP 
become stiffened and less distensible, whereas the smaller arterioles become more 
distensible (Baumbach and Heistad, 1988; Baumbach and Hajdu, 1993; Baumbach 
and Heistad, 1989). This change in distensibility of the vasculature is linked with 
structural alterations, which may predispose the brain to a decrease in activity-
dependent energy. 
Therefore, alterations in CBF may be due to vascular remodelling or altered 
reactivity. Alterations in cerebrovascular reactivity have been found in the SHR 
model, which during periods of hypercapnia has an attenuated dilatory response, 




been reported in the SHRSP as a result of increased mean arterial pressure 
(Sadoshima et al., 1983). Overall there is evidence that CBF is altered in the SHR 
and SHRSP models, which may be a response of cerebrovascular alterations. 
1.5.2. Animal models of hypertension and alterations to the cerebrovasculature 
In general, both the SHR and SHRSP models have found cerebrovascular 
alterations similar to those found in humans with evidence of vascular wall 
thickening, smooth muscle hypertrophy and BBB disruption. These features were 
originally observed in initial characterisation studies demonstrating gross 
cerebrovascular structural alterations in both SHRs and SHRSPs, when compared to 
normotensive WKY (Okamoto and Aoki, 1963; Okamoto, 1974; Yamori et al., 
1976a; Yamori et al., 1976b). Since the development of both the SHR and SHRSP 
models several studies have been carried out examining how hypertension affects the 
different populations of vasculature within the brain over different durations. The 
key findings from these studies will be described below. 
1.5.2.1. Animal models of hypertension and large artery structure (≥150µm) 
Many of the initial studies focused on examining large arterial structure in 
response to hypertension, with the most consistent finding being that both the SHR 
and SHRSP exhibit vascular wall thickening. One of the initial studies was carried 
out by Nordborg & Johansson, aimed to determine arterial structure both during the 
development of hypertension, and as a result of hypertension, examining SHRs and 
WKYs, 15 to 200 days old.  Measurements of the vessel wall (media/radius ratio) 
were calculated from postfixed vessels stained using a modified elastine- van Gieson 
method. They found that by 15 days of age the large arteries of the SHR model 




matched, normotensive WKY (Nordborg and Johansson, 1980), indicating that the 
vasculature of the SHRs is altered prior to the development of hypertension. These 
early signs of vascular remodelling have also been reported in the large arteries of 
SHRSP model at 15 days of age (Okamoto, 1974). Additionally,  the external 
diameter of the carotid artery has also been found to be decreased in SHRSPs, 4-8 
weeks of age (Zanchi et al., 1997).  
Moreover, vascular wall thickening has also been observed in SHRs and 
SHRSPs with established hypertension. Nordborg et al., 1985 examined the 
extraparenchymal cerebral arteries in 7 and 12 month SHRs, SHRSPs and WKYs 
and found that the vasculature had an increased media/radius ratio, which 
represented a thicker media and/or smaller internal radius in the SHRs but, only a 
smaller internal radius in the SHRSPs. In addition Hart et al., carried out wall/lumen 
ratio measurements in large arteries and arterioles of 13 month old SHRSPs and 
found evidence of severe vessel hypertrophy, which was most pronounced in the 
parenchymal vessels (Hart et al., 1980).  
Along with the morphological alterations reported above, histological studies 
have been carried out in an attempt to analyse the corresponding cellular alterations. 
Mangiarua et al., investigated the cerebral arteries of 28 week old SHRs, SHRSPs 
and WKYs, using electron microscopy and observed that the hypertensive models 
exhibited increased number of smooth muscle layers in the basilar and superior 
cerebral arteries (Mangiarua and Lee, 1992). A following study by Sabbatini et al., 
analysed the structural integrity of intracerebral arteries in 24 week old SHRs and 
observed that vessel wall thickening corresponded with hypertrophy of the smooth 




normotensive controls (Sabbatini et al., 2001). Additionally immunohistochemical 
studies have found that smooth muscle actin levels were unchanged in 20 week old 
SHRs but were markedly increased in the more severe malignant hypertensive 
SHRSP model (Lin et al., 2001). Overall the above findings in both the SHR and 
SHRSP models represent that the large arteries undergo structural alterations, 
although the early occurrence of this prior to hypertension in both models leaves 
uncertainty as to the impact of hypertension.  
1.5.2.2. Animal models of hypertension and the structure of small arteries, arterioles 
and capillaries (<80µm) 
 
Early lesion characterisation studies in the SHRSP model, observed that 
cerebrovascular lesions frequently occurred within arterial ‘boundary zones’ supplied 
by branching penetrating arterioles and capillaries, commonly located within the 
subcortical basal ganglia region of the brain, implying that the smaller calibre vessels 
supplying these regions are susceptible to structural alterations (Yamori et al., 
1976b). Evidence of alterations to smaller arterial vessels (≤80 µm) has also been 
observed by Nordborg & Johansson., examining 200 day old SHR and providing 
evidence of vascular wall thickening (Nordborg and Johansson, 1980). These 
vascular alterations have also been found to increase in severity with age as shown 
by Knox et al., who examined the ultrastructure of the frontal cortical 
cerebrovasculature in young and aged SHR and WKY. Subtle structural alterations 
were found within the vasculature of the SHR model aged >3 months, which 
increased in intensity, frequency and severity with age compared to the WKY. The 
vessels of SHR were observed to have overt structural alterations, consisting of 




muscle cells. Interestingly in agreement with the idea that hypertension exacerbates 
features of normal aging in humans this study found that cerebrovascular alterations 
such as wall thickening, were also observed in aged WKY when compared to young, 
but were reported to be less severe than the hypertensive animals (Knox et al., 1980). 
These histological findings have also been shown in-vivo by Harper et al., who 
analysed both structure and functional characteristics of parietal cortical arterioles 
and capillaries of 18-21 week old SHRs. As with the other studies they found 
evidence of vascular wall thickening but the main findings of this study were that 
under normal pressure values the vasculature appeared constricted with no overall 
change in diameter, whereas during induced decreased pressure the overall diameter 
of the vasculature was decrease (Harper and Bohlen, 1984). 
More recently, a histological study was carried out to investigate 
cerebrovascular structure in different regions of the brain. Sabbatini et al., examined 
the cerebrovascular structure in the cortex, striatum and hippocampus of 24 week old 
SHRs and WKYs, finding regional differences in cerebrovascular alterations. Within 
the frontal cortex, the vasculature was found to exhibit wall hypertrophy and 
narrowing of the lumen. On the other hand, the vasculature within the striatum was 
found to have an overall increased wall area, indicative of hypertrophy without 
vasoconstriction. Lastly, the hippocampal vasculature was found to undergo vascular 
remodelling in the form of luminal narrowing (Sabbatini et al., 2001). The regional 
differences in cerebrovascular remodelling found in this study represent that 
hypertension in the SHR model does not affect the brain uniformly.  
In general, similar vascular alterations have been reported in the SHRSPs as 




shortly after the onset of hypertension (aged <10 weeks), there are structural 
alterations to the smaller arterioles (~30µm, in diameter), arising from the 
lenticulostriate arteries (Mies et al., 1999). In turn, during the development of 
hypertension, the arterioles have been reported to be decreased in diameter. Coyle et 
al., injected latex into the MCA of 10 week old SHRSPs to measure the internal 
diameter of the collateral capillaries and found a marked decrease in the internal 
diameter of capillaries from the SHRSPs in comparison to WKYs (Zanchi et al., 
1997).  However, it is unclear if these early vascular alterations are due to the 
development of hypertension or cause a predisposition for vascular alterations.  
To profile cerebrovascular alterations during the development of 
hypertension, Tagami et al., carried out a characterisation of the penetrating 
arterioles (<100µm) of SHRSPs aged 4-52 weeks, compared to age matched WKYs. 
Along with a decrease in the internal diameter of the penetrating arterioles, it was 
reported that SHRSPs with established hypertension at 16 weeks have focal areas of 
collagen deposition and cytoplasmic necrosis in the outermost medial layers (Tagami 
et al., 1987). In turn, the vessels of SHRSPs have also be found to have increased 
expression of smooth muscle actin at 16 weeks (Bailey et al., 2011). These vascular 
alterations increased in severity with age, with widespread necrosis and medial 
atrophy reported at around 28 weeks of age (also shown in (Yamori et al., 1976b)). 
The outermost medial layers were found to be replaced by basement membrane like 
material, fibrous collagen and cellular debris. In turn, by 28 weeks the arterioles, in 
the surrounding areas to cerebral lesions, have been reported to show hyaline 
degenerations, fibrinoid necrosis and areas of thrombosis (Tagami et al., 1981). 




diameter during the development of hypertension and with chronic sustained 
hypertension.  
However, the level of hypertension evoked in the SHRSP model is more 
severe than the SHR model and ultimately leads to stroke. Tagami et al., also studied 
the structure of the cerebral perforating arteries in SHRSPs exhibiting signs of stroke, 
(aged between 28-50 weeks) and compared them to aged matched WKY. The 
vasculature was found to be severely thickened, narrowed and often occluded. They 
also described layers of smooth muscle to be lost within the medial layers, which had 
been replaced by deposition of basement membrane and collegenous-like material. In 
turn, plasma leakage was observed with surrounding monocyte adhesion and it was 
reported that this luminal narrowing in 9 month old SHRSPs was accompanied with 
thrombosis of the deep penetrating arterioles (Fredriksson et al., 1985; Tagami et al., 
1987).  However, a recent paper examining vascular integrity in stroke free 10 month 
old SHRSPs found no evidence of vasculopathies in the deep penetrating arterioles, 
therefore many of the previous vascular alterations may be in relation to stroke 
(Brittain et al., 2012). Overall evidence exists that both the SHR and SHRSP 
demonstrate similar features to those observed in the human studies and highlights 
that the severity and duration of hypertension are critical features.   
1.5.2.3. Animal models and the integrity of the blood brain barrier  
 
Along with morphological alterations, cerebral endothelial function has been 
found to be altered, manifesting as endothelial BBB dysfunction in both the SHR and 
SHRSP models. One of the earliest reports of impairments to the BBB in the SHR 




the BBB were identified through the administration of intravenous horse radish 
peroxidase (HRP), providing evidence of BBB disruption in the SHRs. In young 3 
month old SHRs, the HRP reaction product was found within vessel walls, 
endothelial cells, perivascular cells (including the processes of astrocytes) and 
occasionally within perivascular macrophages, with no evidence in the aged matched 
WKYs examined. In 12 month old SHRs there was more HRP product found within 
the basal lamina of arterioles, capillaries and venuels, with perivascular macrophages 
exhibiting large amounts HRP.  The BBB disruption further increased with age in 24 
month old SHRs, providing evidence of HRP accumulation within vessel wall 
segments of most arterioles and venuels, spanning 20-30µm. There was also 
evidence of HRP reaction in endothelial cells, smooth muscle cells, pericytes and 
perivascular cells (Knox et al., 1980). Interestingly, the aged WKYs also provided 
evidence of BBB disruption but this was exacerbated in the hypertensive animals, 
thus further supporting the hypothesis that hypertension appears to exacerbate 
cerebrovascular alterations which occur with normal ageing.  
More recently Ueno et al., examined vascular permeability and endothelial 
function within the hippocampus and hypothalamus of 3 month old SHRs and 
SHRSPs (Ueno et al., 2004a; Ueno et al., 2004b). Using the HRP technique they too 
reported BBB leakage within both regions, localised within abluminal pits and layers 
of the basal lamina, in both hypertensive models, which was absent in normotensive 
controls. This study also investigated endothelial dysfunction, by analysing the 
endothelial glycocalyx, a proteoglycan surface layer surrounding endothelial cells, 
which was diminished in the hypertensive models compared to controls (Ueno et al., 




SHRSP model compared to SHRs and highlighted that these alterations were located 
exclusively within the arterioles. 
Similarly Fredriksson et al., examined the integrity of the BBB using evans 
blue technique and found evidence of BBB leakage in 4 month old SHRSPs, which 
progressed in severity with age. It was reported that in SHRSPs aged 5-9 months, 
BBB leakage was found in several vessels, in around 33% of the cohort compared to 
none in the WKY controls. Fredrinksson et al, commented that, although BBB 
leakage was found, it was not observed in every vessel and commonly occurred in 
animals whose blood pressure had reached values higher than 200mmHg 
(Fredriksson et al., 1985; Fredriksson et al., 1987; Fredriksson et al., 1988). The age 
at which BBB leakage became more frequent was in contemporaneous, with reports 
of high frequency of microinfarcts and stroke like symptoms (Ogata et al., 1982). 
Therefore the majority of evidence in both the SHR and SHRSP models indicates 
BBB disruption, although the mechanisms are not fully understood. 
1.5.2.4. Animal models and vascular inflammation 
 
As described above, the initial characterisation studies in SHRs and SHRSPs 
analysed the overt structural alterations to the cerebrovasculature. However, many of 
these studies observed increased numbers of surrounding macrophages, microglia 
and other inflammatory cells, similar to human studies. Evidence of this has been 
provided by Knox et al., who examined SHRs 3-24 months old, observing 
perivascular macrophages surrounding remodelled vessels. It was reported that the 
number of macrophages increased in aged hypertensive animals and in those with 




inflammatory cells in aged normotensive rats, but not to the same extent of 
hypertensive (Knox et al., 1980). Analogous to SHRs, an earlier study by Hazama et 
al., found proliferation of macrophages and microglia surrounding cerebrovascular 
lesions in SHRSPs at various ages from around 8 to 52 weeks. Along with severity 
and duration of hypertension, they also observed an increased proliferation of 
inflammatory cells in response to areas of BBB leakage (Hazama et al., 1975). These 
findings have been added to, with immunohistochemical findings, by Lin et al., 
directly comparing the presence of microglia between SHR and SHRSP at 12 and 20 
weeks of age (Lin et al., 2001). Vascular alterations were reported to be minimal in 
the SHR model, with a small number of microglia associated with the vasculature. 
On the other hand, the SHRSP were observed to have more severe vascular 
remodelling and a high prevalence of microglial cells surrounding the vasculature. 
This form of vascular inflammation associated with vascular remodelling has been 
found in 16 week old SHRSPs, with concurrent alterations to the endothelial BBB 
and increased severity in those fed a high salt diet (Bailey et al., 2011). Overall, there 
is strong evidence that cerebrovascular alterations in the SHR and SHRSP models 
are associated with an increased inflammatory response. 
1.5.2.5. Animal models of hypertension and differential gene expression 
 
Hypertension is a complex polygenetic trait, which can further alter gene 
expression within the brain. Unmasking the genes which are altered by hypertension 
in response to structural alterations in the brain would provide novel information 
about cerebrovascular alterations, and in turn allow for therapeutic insight. Animal 




examining gene alterations.  In the last decade, the decreased cost and increased 
efficacy of microarray technology has driven a number of studies towards gene 
profiling (Miller and Tang, 2009). Microarrays are miniaturised arrays consisting of 
thousands of deoxyribonucleic acid (DNA) fragments or signal oligonucleotides, 
which are attached to a substance and allow for identification of genes within several 
tissue samples simultaneously. They are complex extensions of the traditional 
Southern and Northern hybridization blots, and improvements in technology have led 
to microarrays becoming efficient, cost effective, discriminatory powered, 
reproducible, sensitive and specific (Miller and Tang, 2009; Schena et al., 1998; 
Stears et al., 2003).   
Due to the novelty of microarray technology, the literature is still within its 
infancy. However, studies have begun to examine alterations in gene expression 
during hypertension and in response to vascular alterations. Waki et al., have carried 
out a serious of microarray examinations of the nucleus tractus solitarius region of 
the brain in prehypertensive SHRs aged 3 weeks and those with established 
hypertension aged 15 weeks compared to aged match WKYs. Firstly, they found 
increased expression of proinflammatory JAM-1 in both prehypertensive and 
established hypertensive SHRs compared to WKYs. Follow-up studies found 
increased expression of another inflammatory marker gp39 in SHRs pre-
hypertension and in those with established hypertension, but overall there were no 
differences in the expression of the majority of cytokines and chemokine genes 
assessed in the pre-hypertensive SHRs compared to WKYs (Waki et al., 2008).  
However, the previous studies did not give an insight into gene alterations, 




overcome this, Zhou et al, carried out a microvascular dissection from the whole 
brain of SHRs and WKYs aged 12 weeks. In general, they found alterations in the 
expression of genes within the following functional gene categories: metabolism 
enzymes, kinases, transporter, defence/immunity proteins, receptor binding, signal 
transducers, enzyme regulators, structural molecules, translation regulators, cell 
adhesion molecules and stress response. The key genes that were found to be 
upregulated in the SHR model were various members of the Heat shock protein 
family, RAAS, TNFα, nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) and several cytokines (Zhou et al., 2005; Zhou et al., 2006). As a result of 
these studies, a novel gene has been identified in the hypothalamus and brain stem of 
SHR; soluble epoxide hydrolase (sEH), which is thought to play a role in 
vasodilation (Sellers et al., 2005). Within these series of studies they also compared 
gene expression in SHR treated with candersartan and found that the main change 
was a normalisation in inflammatory related gene expression (Ando et al., 2004). 
  The most recent microarray study examined gene expression within the 
frontal cortex of prehypertensive 2 month old SHRs and those with established 
chronic hypertension at 9 months of age. In general, only a small number of genes 
were differentially expressed between hypertensive and normotensive animals at 
both ages. Those included genes involved in energy and lipid metabolism, 
mitochondrial functions, oxidative stress and ischemic response but did not provide 
any evidence of alterations in genes involved in collagen expression. In SHRs with 
established hypertension, genes involved in cell death and lipid metabolism were 
upregulated and those involved in ion homeostasis and neurotransmitter receptor 




hypoxic state, which cannot exclusively be explained by hypertension (Ritz et al., 
2012).  
The number of studies carrying out microarray examination using the SHRSP 
model is also quite limited, with many of them examining differential gene 
expression in comparison to SHR. A key study carried out by Iwanaga et al., aimed 
to examine alterations in gene expression in vessels from SHRSP, which showed 
signs of remodelling and BBB leakage (Iwanaga et al., 2008). They manually micro-
dissected vessels from the hippocampus and isolated a key gene altered in 
expression. Osteopontin gene was found to be increased in the SHRSP when 
compared to WKY. Osteopontin is an argine-glycine-aspartatic-acid-containing 
adhesion glycoprotein, which is known to interact with integrins and CD44 receptors. 
It has also been shown to be phenotypically similar to contractile smooth muscle 
cells and has been found to be expressed on perivascular macrophages and microglia. 
Other studies have found alterations in gene expression of brain derived neutrophic 
factor receptor (TrkB), MAPK/kinase pathway, including c-Jun NH(2)-terminal 
kinase (JNK), protein kinase B (AKT) and phosphoinositide -3- kinase (PI3K), many 
of which are involved in eNOS expression in 8 week old SHRSPs compared to SHRs 
(Fornage et al., 2003). At this time point, the SHRSPs have evidence of more severe 
vascular remodelling, when compared to SHRs and these genes may be play a crucial 
role in vascular remodelling. Overall, the above studies point towards alterations in 







1.5.3. Animal models of hypertension and white matter alterations  
 
As addressed previously, evidence in humans indicates that WML may be a 
sign of hypertensive induced structural alterations within the brain. In general, the 
number of studies providing evidence of WM alterations in the SHR and SHRSP 
models is quite limited. An early histological study by Hazama et al., described 
structural alterations within the WM of the SHRs as small cortical and subcortical 
areas of WM edema, gliosis and cystic formations, which were not observed in 
normotensive WKY (Hazama et al., 1977). More recent studies using 
immunohistochemistry to examine WM integrity, have reported that at around 20 
weeks of age, SHR exhibit a loss of hippocampal WM, which progresses with age to 
a marked loss of grey matter associated with gliosis (Sabbatini et al., 2000). In turn, a 
study by Lin et al., examined several cortical and subcortical regions in the brains of 
12 week and 20 week old SHRs but only found subtle WM loss within the striatum 
(Lin et al., 2001). However, the previous studies have examined overall structural 
integrity using histology or the expression of specific proteins to examine white 
matter integrity. Yang et al., took advantage of recent advances in in-vivo imaging 
combined with immunohistological techniques and carried out an extensive analysis 
of the structural integrity of the brain in SHRs. Overall, analysing 4 month old SHRs 
they found that in comparison to normotensive controls the WM was only modestly 
altered. This was quantified by an increase in T2 weighted MRI in the corpus 
callosum and internal capsule, which correlated to a subtle decrease in MBP (Yang et 




In the SHRSP model of malignant hypertension, there is stronger evidence of 
WM alterations throughout several regions of the brain but it is possible this is more 
of a feature of stroke than hypertension. Ogata et al., carried out initial crude 
histological characterisation of WM integrity using serial sections through multiple 
regions of the brain in SHRSPs of varying ages. They observed, with increased 
duration of hypertension, areas of rarefied and cystic cortical WM, associated with 
remodelled and often occluded vessels (Ogata et al., 1981).  Following on from these 
observations, Fredriksson et al., used EM to analyse the ultrastuctural integrity of 
WM in 8 month old SHRSPs. They frequently observed ‘spongy’ and ‘cystic’ tissue 
destruction in the cerebral cortex and basal ganglia, with loosening of the WM fibres. 
This study also found evidence of cystic lesions within the grey matter. Importantly, 
both white and grey matter lesions where found to be associated with alterations to 
the vasculature (Fredriksson et al., 1988). Chue et al., carried out an 
immunohistochemical assessment of WM alterations in the SHRSP and found that 
the subcortical WM lesions observed were associated with gliosis and proliferation 
of inflammatory cells. Similar results were found in 20 week old SHRSPs with 
marked WM loss in the corpus callosum, anterior commissure, internal capsule and 
caudate putamen, which was also associated with vascular remodelling and 
inflammation. Interestingly, a recent study examining WM integrity in 10 month old 
SHRSPs, without any evidence of stroke symptoms found no evidence of WM 
alterations even though there was evidence of vascular thickening (Brittain et al., 
2012).  Thus, it is unclear as to whether hypertension alone in the SHR and SHRSP 




1.5.4. Animal models of hypertension and cognitive function 
 
In humans, the effect of hypertension on cognitive function is difficult to 
study in isolation due to the coexistence with multiple vascular risk factors and the 
various treatment regimes. In turn, the use of cognitive assessments to replicate the 
key areas of cognitive function affected in humans, can also pose a problem in 
animal models. The SHR model has been the most widely assessed due to its 
decreased severity of hypertension, in comparison to SHRSPs and their ability to 
carry out tasks at an older age. However, the first behavioural characteristic studies 
were limited to a small set of avoidance based paradigms available. One of the first 
studies was carried out by Hect et al., using a basic conditional avoidance task in 8-
50 week old SHRs and WKYs. They found that in general the SHRs performed 
poorer than WKYs at varying ages (Hecht et al., 1978) but, other studies using 
similar tasks have found that SHRs have superior performance versus WKY (Sutterer 
et al., 1980), (Boller et al., 1977; Campbell and Di Cara, 1977). These findings were 
in agreement with the hypothesis suggested by Santinder et al., that strains 
selectively bred for a physiological feature may differ behaviourally by central 
arousal, which in turn may impair task performance (Satinder, 1977). 
The design of the radial arm maze (Olton and Samuelson, 1976) and the 
Morris water maze (Morris, 1981), revolutionised the ability to assess more specific 
behavioural alterations, which can be compared to humans’ abilities, without the use 
of painful stressors. Even with more sensitive measurements of cognitive function, 
performance issues between the WKY and SHR models still exist making it difficult 
to decipher the relationship between hypertension and cognitive function.  Mori et 




young (3-4 month old) and aged (16-17 month old) SHRs compared to age matched 
WKYs. They found that hypertension per se, in the young SHRs did not cause 
impairment in performance when compared to WKY. Overall, in both strains age 
was found to cause a decrease in cognitive performance, with hypertension thought 
to exacerbate the impairment in SHRs (Mori et al., 1995). These results are in 
agreement with an earlier study carried out by Wyss et al., comparing 3 to 12 month 
old SHRs to normotensive Sprague Dawley strain and additionally SHRs on 
antihypertensive treatment (Wyss et al., 1992). They found that cognition was 
impaired in the SHRs compared to Sprague Dawley rats at 12 months of age and that 
anti-hypertensive treatment improved cognitive function. They also reported that the 
3 month old SHRs showed superior performance when compared to Sprague Dawley 
rats (Wyss et al., 1992).  On the other hand, Nakamura-palacios et al., carried out the 
radial arm maze test with a protocol which also assessed long term memory in 3 
month old SHRs and WKYs. They found that SHRs performed worse than 
normotensive WKYs and this impairment was more apparent when assessing long 
term memory (Nakamura-Palacios et al., 1996).  Similarly impaired radial arm maze 
performance was reported in SHRs aged 3 to 9 months, when compared to WKYs 
(Hernandez et al., 2003).  
Other forms of cognitive testing have been used to examine cognitive 
function in the SHRs, such as the Morris water maze. Gattu et al., examined both 
spatial and reversal memory in 4 week old pre-hypertensive SHRs and in those with 
established hypertension at 12 weeks of age, compared to age-matched normotensive 
WKYs and wistar rats. It was reported that prior to the development of hypertension, 




compared to normotensive controls. When examining SHRs with established 
hypertension they found evidence of impaired function in both spatial reference and 
reversal memory (Gattu et al., 1997a; Gattu et al., 1997b). A follow up study in 
SHRs aged 15 months was carried out and they were found to have impaired 
performance when compared to WKY (Terry Jr et al., 2000).  On the other hand, a 
study by Widy-Tyszkiewicz et al., examined spatial reference memory in 12 week 
old SHR and WKY using the Morris water maze and found SHRs to have superior 
performance, suggestive of cognitive superiority (Widy-Tyszkiewicz et al., 1993). 
Overall in the SHR model there is evidence of cognitive impairment but 
discrepancies in the performance of normotensive WKY prevent these findings from 
being robust. 
The SHRSPs have been found to exhibit behavioural abnormalities such as 
inattention, hyperactivity and impulsivity prior to the development of hypertension 
(Ueno et al., 2002). This makes the SHRSP a commonly used model for attention 
deficit - hyperactivity disorder (AD/HD) research, and may suggest some limitations 
in their use for hypertensive research, with overall cognitive data being quite sparse 
in this model. In general, the SHRSP have been found to display no overt 
neurological deficit prior to the development of stroke (Jiwa et al., 2010), with 
impairments reported in passive avoidance behaviour at 30 weeks of age (Kimura et 
al., 2000). Similar deficits in passive avoidance and Y-maze paradigms have been 
reported (Kimura et al., 2000; Minami et al., 1997; Sugimachi et al., 1994; Togashi 
et al., 1996). Spatial reference memory has also been examined in the SHRSP 
models. Interestingly, a study comparing the performance of 15 week old SHRSPs, 




SHRSP model had impaired performance compared to WKYs, whereas SHRs did 
not. They also observed that the SHRSPs showed impaired swim durability during 
the Biel maze (Matsuo, 2007). Overall, it is not yet known whether hypertension in 
both the SHR and SHRSP models leads to alterations in cognitive function. 
1.6. Cyp1a1 Ren2 inducible hypertensive rat model 
 
Invaluable as they have been, the SHR and SHRSP models have their 
limitations, which have produced gaps within the understanding of the mechanisms 
of hypertension. No animal model recapitulating a human condition is perfect and 
often a true understanding of the disease requires the investigation of several animal 
models. To model the effect of hypertension on the structural integrity of the 
cerebrovasculature, WM and cognitive function, this thesis used the Cyp1a1 Ren2 rat 
model, which allows the expression of hypertension in a controlled, sustained 
manner without the need for surgical intervention, with genetically matched litter-
mate controls and the ability to map hypertensive mechanisms in aged animals, 
comparative to ages at which hypertension occurs in humans. 
Cyp1a1 Ren2 rat model is an inducible hypertensive transgenic model 
generated by the insertion of a mouse Ren2 renin gene fused to cytochrome P450 1a1 
(Cyp1a1) promoter on the background strain of the Fischer 344 rat (Kantachuvesiri 
et al., 2001). Expression of this transgene is induced by the addition on an aryl 
hydrocarbon; Indole-3-carbinol (I3C), allowing induction of the Cyp1a1 promoter 
via the aryl hydrocarbon receptor leading to the primarily hepatic expression of 




et al., 1975). These transgenic rats are born normotensive since the promoter is not 
constitutively expressed (Kantachuvesiri et al., 2001). 
The level and duration of hypertension is tightly controlled by the addition of 
I3C, which is a naturally occurring agent found in cruciferous vegetables (Loub et 
al., 1975). The short half-life of I3C allows for the reversal of hypertension in this 
model, with early studies showing blood pressure can return to normotensive values 
within 72 hours of I3C removal. Critically non transgenic animals, which are given 
I3C even at very high doses do not become hypertensive (Kantachuvesiri et al., 
2001). 
Early characterisation studies of this model demonstrated two methods of 
hypertension induction, by means of gastric gavage or dietary induction 
(Kantachuvesiri et al., 2001).  I3C can be mixed with standard powdered rat chow, 
allowing transgenic induction in a non-surgical and non-stressful manner. Dietary 
induced I3C produces a dose-dependent increase in blood pressure, with studies 
showing a dose of 0.3% I3C leads to malignant hypertension, whereas 0.15% I3C 
leads to a milder form of hypertension (Mitchell et al., 2006). Transgenic animals 
induced with 0.3% have rapidly increased blood pressure by 1 day, whereas those 
induced by 0.15% develop increased blood pressure within 2 weeks (Mitchell et al., 
2006).  
The majority of studies in this model have focused on the periphery providing 
evidence of increased levels of plasma renin, 48 hours post induction 
(Kantachuvesiri et al., 2001). These studies have shown target organ damage to the 




necrosis of small arteries in the mesentery and heart, which lead to microinfarction in 
both the left and right ventricles and evidence of eutrophic remodelling to the 
mesenteric vasculature (Kantachuvesiri et al., 2001). The kidneys showed evidence 
of myointimal hyperplasia, tubular dilation, glomerulosclerosis, tubulointerstitial 
inflammation and proliferation (Graciano et al., 2007; Kantachuvesiri et al., 2001; 
Mitchell et al., 2006). A crude characterisation of the brain provided no evidence of 
haemorrhage, infarction or gross vascular pathology (Kantachuvesiri et al., 2001). 
Therefore, a robust characterisation of the structural integrity of the brain with 
hypertension has not yet been established in this model. This model allows 
hypertension to be studied in a controlled and sustained fashion, without the need for 
surgical intervention and comparisons can be made with litter-mate transgenic 
normotensive controls.   
1.7. Summary  
 
Overall, previous studies in both humans and animal models of hypertension 
have allowed for an insight as to the consequence of chronic high blood pressure on 
the structural and functional integrity of the brain. However, the mechanisms which 
underlie these associations are not yet fully understood. In humans this is partly due 
to the frequent coexistence of hypertension with other vascular risks factors and the 
inability to model hypertension at a set duration, in a large untreated population of 
similar age and severity. The SHR and SHRSP models have provided invaluable 
knowledge as to the effect of hypertension on the cerebrovasculature, but it is unclear 
the exact influence of hypertension alone and not genetic predisposition. The studies 




impaired structural integrity of cerebrovasculature and WM and whether 
hypertension in isolation is a sufficient insult to impair cognitive function.  These 
features were investigated using an inducible hypertensive rat model, in which the 
severity, duration and onset of hypertension were tightly controlled, and findings 
compared to genetically matched littermate normotensive controls. Additionally, the 
use of genetically matched controls will also allow for the profiling of differentially 





















Figure 1.8: Induction of hypertension in the Cyp1a1 Ren2 rat model 
Hypertension is induced in the Cyp1a1 Ren2 rat model by the expression of the 
Cyp1a1 promoter. Cyp1a1 is not constitutively expressed but is activated upon 
exposure to various aryl hydrocarbons. In this study Indole-3-carbionol represented 
as ‘Ligand’ in the image, acts via the aryl hydrocarbon receptor (Ah receptor), to 
induce the expression of the Cyp1a1 promoter, which then allows the expression of 
the mouse ren 2 gene causing increased expression of renin and ultimately increased 









1.8. Thesis hypothesis 
It was hypothesised that sustained hypertension will lead to alterations to the 
structural integrity of the cerebrovasculature, WM and associated alterations in gene 
expression within the young and aged brain and that hypertension will be associated 
with impairments to cognitive function.  
1.8.1. Experimental chapters hypotheses and aims 
 
 Hypothesis: Hypertension will lead to vascular alterations within the 
subcortex of the young and aged brain consisting of remodelling of the 
basement membrane, loss of BBB integrity and altered endothelial signalling. 
Aim: To investigate the impact of hypertension on the structural integrity of 
the vasculature - vascular width and density, endothelial signalling, 
endothelial blood-brain barrier integrity and the inflammatory response. The 
differences in structural integrity of the vasculature were investigated in the 
young and aged brain of normotensive and hypertensive animals.  
  
 Hypothesis: Hypertension will lead to alterations in gene expression in 
particular those related to vascular remodelling, endothelial signalling and 
inflammation. 
Aim: To investigate the effect of hypertension on gene expression and 
functional pathways using microarray technology in the young brain and in 





 Hypothesis: Hypertension will lead to alterations to the integrity of white 
matter in the young and aged brain.  
Aim: To investigate the impact of varying durations of hypertension on the 
structural integrity of WM with an examination of myelin, oligodendrocytes, 
axons and microglial response, in specific regions of the young and aged 
brain.   
 
 Hypothesis: Hypertension will lead to impaired cognitive function in spatial 
reference and working memory 
Aim: To investigate the effect of hypertension on cognitive function, 
examining spatial reference and working memory in hypertensive versus 










2. Materials and methods 
2.1. Animals 
Studies within this thesis chose to examine the integrity of the brain using the 
Cyp1a1 Ren2 transgenic rat model. This model allows the induction of hypertension 
in a controlled, gradual and sustained manner, without any surgical intervention. In 
turn, all comparisons made in this model can be compared to genetically matched 
litter-mate controls.    
The Cyp1a1 Ren2 transgenic rat model is generated by the insertion of a 
mouse ren-2 gene fused to the cytochrome P450 1a1 (Cyp1a1) promoter on the 
Fischer 344 background, which was created by Prof. John Mullins. Characterisation 
studies described that these transgenic rats were originally created by the isolation of 
the rat Cyp1a1 promoter through NotI-SalI double digest of pAhIR1-LacZ, yielding 
an 11.5 kilobase fragment, which was placed upstream of the Ren-2 cDNA and SV40 
poly(A) signal in pBluescript SK2(+).  NotI-BssHII digestion was then used to excise 
the injection fragment, which was introduced into single-cell embryos of Fischer 
F344 by microinjections and was found to be integrated on the Y chromosome 
(Kantachuvesiri et al., 2001). Transgenic rats used for studies within this thesis were 
bred from a male and female transgenic rat obtained from Prof. John Mullins at the 
University of Edinburgh. Harems were set up in which the one male was housed with 
3 female rats, which were removed once pregnant. As the transgene is Y 
chromosome specific, only male transgenic rats were used for the study of 
hypertension.  As introduced in section 1.5 (Figure 1.9), mouse renin gene 
expression is activated by the addition of the aryl hydrocarbon I3C allowing the 




2.1.1. Indole-3-Carbinol administration 
 
Hypertension was modelled in the Cyp1a1 Ren2 rat model by dietary 
induction of I3C based on the protocol devised in previous characterisation studies 
(Kantachuversiri et al., 2001). All animals were housed in 12 hour light/dark cycle 
and had access to food and water ad libitum, except from during experimental 
testing, when food intake was controlled and weight monitored (throughout the 
duration of the study). Experiments were conducted under approval of the UK Home 
office licence and regulations (Specific procedures Act 1986). Animals were either 
fed a control diet containing a mashed version of standard commercial rat chow (40g 
per animal) (Special diet services, Witham, Essex) or a hypertensive diet with 0.15% 
of I3C, mixed into a mashed version standard chow (40g per animal). Each animal 
was given a glass jar containing either normotensive or hypertensive diet, and this 
was replaced with fresh diet daily. Daily monitoring throughout the study found that 
the animals ate the majority of the diet each day, with only a small amount left over. 
2.1.2. Study cohorts of animals 
Experiments were conducted in both young and aged Cyp1a1 Ren2 rats, 
dietary induced for different durations. Studies were conducted on young animals 
aged 3 to 4 months prior to dietary induction, induced for a period of either 4 or 6 
months and referred to throughout this thesis as the young 4- or 6-month cohort 
respectively. Initially the 4 month time point was chosen as several of the studies in 
SHRs reported cerebrovascular alterations occurring at 3 months of age (Knox et al., 
1980; Ueno et al., 2004a). Since blood pressure rises slowly in these animals it was 




hand was chosen as the animals began to show some subtle features of possible 
progression towards malignant hypertension, such as piloerection and lethargy thus, 
the study was terminated prior to the animals becoming ill. The young 4-month 
cohort was separated into two groups; n=12 normotensive and n=16 hypertensive 
animals, which were processed for immunohistochemical analysis and n=12 
normotensive and n=12 hypertensive animals for cognitive assessment. During 
dietary induction the young 4-month cohort processed for immunohistochemistry 
were housed in Little France animal unit, whilst the young 4-month cohort 
designated towards behavioural assessment were housed in George Square animal 
unit thoughout the duration of the study. The young 6-month cohort was separated 
into two groups run concurrently; n=13 normotensive and n=13 hypertensive for 
immunohistochemical assessment and n=8 normotensive and n=8 hypertensive 
animals for biochemical and gene assessments. These animals were originally bred in 
Little France animal unit but were transferred to George Square animal unit prior to 
the start of the study and were housed there until study termination. The study also 
ran an aged cohort of n=10 normotensive  and n=12 hypertensive animals, which 
were allowed to age naturally to around 14-15 months of age then dietary induced for 
a period of 4 months and referred to as the aged 4-month cohort. These animals were 
bred in the George square animal unit but then moved to Little France animal unit to 
age and for the duration of the study. 
 2.1.3. Animal monitoring 
2.1.3.1. Weight 
 
Throughout the duration of the study weight measurements were taken to 




weight measurements can be found in Figure 2.1. During the experimental period the 
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Figure 2.1: Weight measurements  
Representative graphs of weight measurements for each cohort throughout the 
duration of the study.  Dietary induction began at week 1 with statistical significance 
of weight readings between groups examined by repeated measures ANOVA. (A) 
Weight measurements for animals from the young 4-month cohort. All animal 
continued to gain weight within the first few weeks post dietary induction. There was 
no significant difference in weight between the two treatment groups p= 0.153 but 
there was a significant difference between weight over time p<0.001. (B) Weight 
measurements for the young 6-month cohort provided evidence of weight gain after 
initial weeks of dietary induction. However, there was a significant difference in 
weight between the two treatment groups p=0.006 and over time p<0.001. (C) In the 
aged 4-month cohort animals gained weight in the first few weeks after dietary 
induction but by week 6 there is a significant difference between the two treatment 





2.1.3.2. Blood pressure 
 
Blood pressure was monitored using tail-cuff plethysmography (LE5002; 
Panlab, Harvard appliances). All rats were trained for 4 weeks prior to dietary 
induction with blood pressure measurements taken throughout the duration of the 
study.  
Within each blood pressure recording session the order of which animals 
were monitored was randomised. Prior to blood pressure recordings animals were 
habituated in the blood pressure room for 20 minutes, then one animal at a time was 
placed in an incubator of ambient temperature (no more than 35°C, no less than 
30°C) for 5 minutes. During blood pressure recordings rats were restrained in a 
cylinder plexiglass chamber with tail access, under a heater maintaining a 
temperature of around 35°C. Animals were habituated in the restraint and tail-cuff 
prior to blood pressure recordings for 5 minutes. Blood pressure was measured using 
an electro-sphygmomanometer and pneumatic pulse transducer. Tail blood was 
occluded by an 11 mm tubular cuff that was inflated by an automatic cycling cuff 
pump, with automated deflation of the cuff at appropriate pressures calculated from 
each animal’s initial systolic reading. NIBPchart (Panlab, Harvard appliances) 
software was used to track recordings ensuring a steady state pulse was achieved 
with the average of three recordings taken per animal. Measurements were excluded 
if the animal moved during recordings. Within a session animals were excluded if 
they failed to habituate and were retested a few hours later. Throughout this thesis 
blood pressure is reported by systolic blood pressure measurements due to a close 
correlation between indirect tail cuff measurements and measurements obtained 




2.2. Tissue processing  
 
2.2.1. Perfusion fixation 
 
Animals were terminated by transcardiac perfusion carried out by Dr P 
Holland.  Anaesthesia was induced with 5% isoflurane in an anaesthetic chamber and 
then maintained at approximately 2% isoflurane. Transcardiac perfusion was carried 
out by opening of the thoracic cavity exposing the diaphragm.  The diaphragm was 
cut through, exposing the heart, which was cleared of connective tissue. Once the 
connective tissue was cleared a needle was inserted and clamped into place in the left 
ventricle and a second incision was made in the right ventricle to allow drainage of 
blood. Perfusion rate was matched to each animal’s end stage blood pressure 
measurement to provide optimal perfusion. 200mL of heparinised 0.9% saline in 
0.1% phosphate buffer was infused until the solutions ran clear. For biochemical 
studies, rats were perfused by heparinised saline only and the brains were then 
removed from the skull and snap frozen in liquid nitrogen. For 
immunohistochemistry rats were perfused with 4% paraformaldehyde in phosphate 
buffer (pH=7.4), decapitated and the whole head placed in 4% paraformaldehyde for 
2 hours.  Brains were removed from the skull and kept in 4% paraformaldehyde at 
4˚C for 48 hours following 24 hours in phosphate buffer solution. Heart, mesenteries 
and kidneys were also collected and postfixed by the same method.  
2.2.2. Paraffin embedding 
 
Brains perfused for immunohistochemistry were cut into 3mm blocks using a 




successive concentrations of alcohols and paraffin embedded (table 2.1). Both 
dehydration and embedding were carried out on an automatic tissue processor; 
Tissue Tek VIP 2 (Sakura Fintek Europe, Netherlands). Tissue for the young 4-
month and 6-month cohorts was processed using the automatic tissue processor in 
the Hugh Robson Building whereas; the tissue from the Aged 4-month cohort was 
processed using the automatic tissue processor in the Queen’s medical research 
institute facility. Post processing and embedding, the blocks were cut at 6µm using a 
microtome, with assistance from Miss Fiona Scott for the aged cohort. Sections were 
mounted onto charged slides (Super frost Plus, VWR International, Butterworth, UK) 
and allowed to dry on a hot plate for 2 hours before storage in plastic containers. The 
heart, mesenteries and kidneys were also collected and embedded by the same 
method as the brain sections. The heart and kidneys were sectioned in half prior to 
embedding but the mesenteries remained whole.  
2.2.3. Immunohistochemistry  
 
Brain sections used for immunohistochemical analysis Figure 2.2 (-3.14mm 
from Bregma to -5.14mm) (Paxinos and Watson, 1998) and for each 
immunohistochemical analyses, there were two brain sections mounted on each slide, 
both of which were analysed and an average value taken. All analyses were carried 
out blind to the experimenter. Each of the 3 cohorts used for immunohistochemistry 
were stained separately each on individual runs. Sections were deparaffinised at 
60°C, immersed in xylene and rehydration in a series of graded alcohol solutions. 3% 
H2O2 was used to block endogenous peroxidase activity for 30 minutes proceeded by 




required antigen retrieval was performed (Table 2.2). Sections were then washed in 
phosphate buffered saline (PBS) for 10 minutes following incubation in a blocking 
solution of 5% bovine serum, 10% normal serum (specific for the species the 
antibody is raised in blocking nonspecific activity) and PBS for 1 hour at room 
temperature. Primary antibody solution was added to the blocking solution; sections 
were drained of block and incubated overnight at 4°C.  
Day two of the immunohistochemical staining, sections were allowed to 
come to room temperature for 10 minutes, and then washed twice in PBS for 10 
minutes. The appropriate secondary antibody solution was made at a dilution of 
1:100 with PBS and applied to the sections that were then incubated for 1 hour at 
room temperature. After incubation the secondary was drained off and sections were 
washed twice in PBS for 10 minutes. For amplification, sections were incubated in 
avidin-biotin-peroxidase complex solution (Vector Labs, Peterborough, UK) for 1 
hour at room temperature then washed twice in PBS for 10 minutes. 
Diaminobenzidine (DAB) (Vector Labs, Peterborough, UK), used for antibody 
labelling was applied and developed for 3 minutes, then washed under running water 
for 10 minutes.  Sections were dehydrated in a series of alcohol solutions followed 
by xylene and then coverslipped with DPX mounting medium (Thermo Fisher, 
Loughborough, UK). When required counterstaining with haemotoxylin or periodic 
acid Schiff’s (PAS) was applied before the dehydration step. Prior to analysing all 
sections were screened including the negative to assess the success of staining.  
Details of each primary antibody used within this thesis, including their 
corresponding secondary antibody and antigen retrieval can be found in Table 2.2. 




different antibody concentrations and retrieval methods, using tissue from the same 
cohort of animals which staining was to be carried out on. In addition antibody 
specificity was controlled, as each experiment included one blank slide for each 
cohort that underwent all the immunohistological treatments apart from the addition 
of the primary antibody allowing the reader to decipher between non specific and 


























Solution Duration (minutes) Temperature (˚C) 
50% Ethanol 60 35 
80% Ethanol 60 35 
95% Ethanol 60 35 
100% Ethanol 60 35 
100% Ethanol 60 35 
100% Ethanol 60 35 
100% Ethanol 60 35 
Xylene 3 x 60 35 
Paraffin wax 3 x 60 60 
Paraffin wax Set for a minimum of 60 60 
Table 2.1: Tissue processing 
Prior to paraffin embedding the tissue was dehydrated by several washes with 










      
Collagen IV (2A) Fitzgerald, Massachusetts, USA 1:7500 Antigen retrieval unit (10 minutes in 
0.01mol/L citric acid buffer, followed by 10 
minutes in 0.02 mol/L Proteinase K buffer) 
Goat Anti rabbit 
α-Smooth muscle 
actin 
Millipore, Watford, UK 1:100 Antigen retrieval unit (5 minutes in 
0.01mol/L citric acid, followed by 10 minutes 
in 0.02 mol/L Proteinase K buffer) 
Horse Anti mouse 
Claudin-5 Invitrogen, Califonia, USA 1:100 Antigen retrieval unit (10 minutes in 
0.01mol/L citric acid and left for 10 minutes 
to cool) 
Horse Anti mouse 
ZO-1 Invitrogen, Califonia, USA 1:50 Antigen retrieval (30minutes in 0.01mol/L 
protease buffer at 37˚C) 
Goat Anti rabbit 
eNOS BD Biosciences, California, USA 1:150 N/A Goat Anti rabbit 
MBP Millipore, Watford, UK 1:5000 N/A Rabbit Anti rat 
APP Millipore, Watford, UK 1:10000 Antigen retrieval unit (10 minutes in 
0.01mol/L citric acid buffer) 
Horse Anti mouse 
Iba-1 Menarini, Berkshire, UK 1:1000 N/A Goat Anti rabbit 
CC1 (APC, Ab-
7) 
Novus Biologicals, Cambridge, 
UK 
1:150 Antigen retrieval unit (10 minutes in 
0.01mol/L citric acid buffer) 
Horse Anti mouse 
 
Table 2.2: Details of antibodies used in immunohistochemical assessment 
Details the antibodies use for immunohistochemical assessment in this thesis including manufacturer, dilution, antigen retrieval, normal 




2.2.4. Vascular integrity 
Several markers were used to analyse various components of the 
cerebrovasculature. All vessels examined were from the subcortical region of the 
brain as can be seen in figure 2.2 and were averaged for two adjacent sections. Each 
of the analyses described below required images to be taken using a light 
microscope. This was carried out separately for each cohort and light settings were 
set specifically for each cohort. 
2.2.4.1. Quantification of the cerebral vasculature  
 
The cerebral vasculature integrity was analysed through immunostaining the 
vasculature for α-smooth muscle actin (SMA) and collagen IV (specific for subunit 
2A).  SMA was quantified by examining the density through percentage area stained 
measurements using Image J (U.S. National Institutes of Health, Bethesda, USA). 
For each cohort, 2 images per hemisphere at x40 magnification were taken using 
QImaging QICAM MicroPulisher 3.3 camera (QImaging, Surrey, BC, Canada) 
connected to a Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK) 
with light settings maintained constant. Firstly, the region of choice was identified at 
the lowest magnification and then the magnification was increased. The first 
subcortical image taken used the edge of the fimbria and internal capsule as land 
marks and the second used the area underneath the dentate gyrus prior to third 
ventricle as a land mark, with the same process repeated for the opposite hemisphere. 
This method was used throughout and as much as possible the same location was 
used for each section from each animal. Density was calculated by setting a threshold 




The threshold value was set by the optimum value, allowing for identification of 
positive staining and eradication of background. This value was calculated for each 
animal within a cohort with the average threshold value used for the whole group.  
As with other techniques reproducibility was established by the triple repetition of 
the quantification of 3 randomly selected animals with values achieved between 10% 






















Figure 2.2: Regions analysed throughout this thesis. 
Image adapted from Paxinos and Watson brain atlas representative of regions 
analysed for immunohistochemistry and subcortical thalamic region dissected for 
microarray analysis (Paxinos and Watson 1998). (A) Corpus callosum, (B) fimbria, 
(C) internal capsule and (D) subcortical thalamic region were all analysed for 
assessment of white matter integrity. (D) subcortical thalamic region was analysed 











An antibody specific for collagen IV (2A), a marker of the basement 
membranes was used as a global marker of the vasculature. Firstly using QImaging 
QICAM Fast 1394 camera (QImaging, Surrey, BC, Canada) connected to an 
Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK), 2 images per 
hemisphere were taken at x200 magnification as described for smooth muscle actin. 
Collagen IV labelled vasculature in both a longitudinal and cross sectional 
orientation. Image J was used to calculate the vascular width of vessels in the 
longitudinal orientation. A grid was placed on the image and only vessels which 
crossed the grid were measured, with more than 20 vessel measurements taken per 
animal.  
As described for SMA, the density of Collagen IV staining was calculated 
allowing for an indication of overall Collagen IV levels. Additionally, the number of 
vessels within 0.25mm
2 
area of the subcortex was calculated, by applying a grid onto 
images and counting the number of vessels which crossed lines on the grid, ensuring 
that the vessels measured were chosen at random. 
2.2.4.2. Quantification of endothelial Nitric Oxide Synthase labelled vessels 
 
Endothelial signalling was investigated by the expression of endothelial 
specific antibody for endothelial nitric oxide synthase (eNOS). Localisation of eNOS 
with the vasculature was validated by haemotoxylin counterstain and could be clearly 
identified by brown DAB staining outlining the vasculature.  The number of vessels 
immunopositive for eNOS were counted within a 1mm
2
 area of the subcortex. 
Images were taken as described for smooth muscle actin at x100 magnification 




BC, Canada) connected to an Olympus BX51 microscope (Olympus UK, 
Southendon-Sea, UK) and the number of eNOS expressing vessels counted using 
Image J (U.S. National Institutes of Health, Bethesda, USA).  
2.2.4.3. Quantification of endothelial tight junctions 
 
The integrity of tight junctions was analysed using claudin-5 in which both 
the intensity and density of staining were calculated by taking relative optical density 
(ROD) measurements and percentage area stained respectively using Image J (U.S. 
National Institutes of Health, Bethesda, USA).  In the young 4- and 6- month cohort 
both imaging and quantification was carried out using QImaging QICAM Fast 1394 
camera (QImaging, Surrey, BC, Canada) connected to a Leica DMR microscope 
(Leica Microsystems UK, Milton Keynes, UK) calculated by MCID image analysis 
system (MCID 7.0, InterFocus Imaging Ltd, Cambridge, UK). Vascular ROD of 
claudin-5 was calculated within the subcortical thalamic region at a magnification of 
x400 and within an area 0.2mm
2
 per hemisphere by manually drawing around more 
than 20 vessels per animal. MCID was used for this experiment as it allows the user 
to manually draw around each vessel separately at the same time, yielding a reading 
for each individual vessel and also an average. As with collagen IV analysis, a grid 
was applied and only vessels which crossed the grid were analysed and an average 
reading was calculated per animal.  However, the aged 4-month cohort was analysed 
using different software as the MCID system had broken down prior to analysis of 
the aged cohort but the method was kept as similar to the young cohorts as possible. 
In the aged 4-month cohort ROD was measured from images taken using QImaging 




Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK) and ROD 
calculated by Image J (U.S. National Institutes of Health, Bethesda, USA). The same 
method was used for the aged 4-month cohort, as the young by manually drawing 
around vessels which crossed the grid in images taken at x400 magnification within 
an area of 0.2mm
2
. Reproducibility was verified by repeating measurements in 3 
animals from each cohort with median value less than 10%. 
The density of claudin-5 staining was calculated for each cohort using Image 
J (U.S. National Institutes of Health, Bethesda, USA). As described previously the 
percentage area stained was calculated within the whole area (0.2mm
2
) for each 
cohort by setting a threshold for positive staining.  
For the young 6-month cohort only, the width of longitudinal vessels 
immunopositive for claudin-5 was calculated using the same methodology as used 
for Collagen IV analysis. Images were taken at x200 magnification using QImaging 
QICAM Fast 1394 camera (QImaging, Surrey, BC, Canada) connected to an 
Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK) and width 
calculated using Image J (U.S. National Institutes of Health, Bethesda, USA). Width 
measurements were taken within an area 0.2mm
2
 per hemisphere and only vessels 
which crossed lines of the applied grid were measured. 
Antibody specific for ZO-1, a tight junction association protein which tethers 
claudin-5 to the cytoskeleton was used to further analyse tight junction integrity in 
the young 6-month cohort only. Subcortical images were taken at x400 magnification 
using QImaging QICAM Fast 1394 camera (QImaging, Surrey, BC, Canada) 




and percentage area stained in an area of 0.25mm
2
 was calculated using Image J 
(U.S. National Institutes of Health, Bethesda, USA). 
2.2.4.4. Microglial alterations 
Ionized calcium-binding adapter molecule 1 (Iba1) staining was used to 
investigate the localisation of microglial cells with the surrounding vasculature. Iba1 
sections were counterstained with PAS reagent labelling the basal lamina pink, 
clearly outlining the vasculature. Using a light microscope the presence or absence of 
microglial cells associated with the vasculature within the subcortical thalamic 
region were recorded. Microglial cells were counted to be associated with the 
vasculature if they were found to be surrounding or contacting the vessel wall. 
General region specific microglia activation was assessed by counting the number of 
IBA1 immunopositive cells, per defined area. In the young 4-month cohort images 
were taken at x250 magnification using QImaging QICAM Fast 1394 camera 
(QImaging, Surrey, BC, Canada), connected to a Leica DMR microscope (Leica 
Microsystems UK, Milton Keynes, UK). In the young 6-month and aged 4-month 
cohort images were taken at x200 using QImaging QICAM MicroPulisher 3.3 
camera (QImaging, Surrey, BC, Canada) connected to a Olympus BX51 microscope 
(Olympus UK, Southendon-Sea, UK). All images were taken at a fixed light intensity 
for each cohort and analysed blinded to a single experimenter. Numbers of cells were 





, internal capsule 0.15mm
2
 and subcortical thalamic region 
0.25mm
2
. To be counted, microglia had to satisfy specific criteria of having a cell 
body and processes. Iba1 immunopositive microglial processes without a cell body 




counts 3 times, for 3 animals, with median measurements less than 10% of each 
other. To ensure reproducibility did not deviate within a large data set, all 
measurements from the young 4-month cohort were carried out twice and deemed 
reproducible if they were less than 10% deviated from the median reading for their 
treatment group. In addition, prior to statistical analysis of the data, the data from 
each cohort was checked for outliers.  
2.2.5. Haematoxylin and eosin staining  
Structural integrity of the kidney and the brain were assessed using 
haematoxylin and eosin (H&E), with assistance from Miss Fiona Scott. Brain 
sections used corresponded to -3.14mm from bregma (fig.2.2) (Paxinos and Watson 
1998). Both histological and immunohistochemical analyses were carried out 
blinded.  
Sections were deparaffinised in an oven at 60°C, for 30 minutes followed by 
15 minutes in xylene. Rehydration was carried out by immersion through a series of 
decreasing alcohol concentrations and sections were finally immersed in running tap 
water for 5 minutes. Sections were then placed into Shandon haematoxylin solution 
(ThermoFisher, Loughborough, UK) for 2 minutes then briefly rinsed in tap water. 
Differentiation of stain to achieve blueing of the nuclei was carried out using acid 
alcohol solution (1% HCl in 70% ethanol) for 8 seconds, then briefly sections were 
rinsed in tap water before being placed in Scott’s tap water solution, (2% MgSO4, 
0.35% NaHCO3) for 2 minutes and then placed in running tap water for another 2 
minutes. Sections were placed in solution of eosin Y (ThermoFisher, Loughborough, 
UK) for 2 minutes, and then briefly rinsed in tap water. Dehydration was carried out 




by 15 minutes in xylene. Sections were then coverslipped using DPX mounting 
medium (ThermoFisher, Loughborough, UK). 
2.2.5.1. Kidney pathology  
 
A gross assessment of the overall kidney integrity of the kidney was 
conducted using H&E, examining for the presence or absence of vascular 
enlargement, tubule dilation, accumulation of inflammatory cells and protein 
accumulation or necrosis of the glomeruli based on previous findings in the model 
(Graciano et al., 2007). 
2.2.5.2. Structural integrity of the brain 
 
H&E staining was used as a marker of overall structural integrity of the brain. 
Neuronal damage was assessed in the hippocampus, fimbria and subcortical thalamic 
region (Fig 2.2). The structural integrity of overall tissue morphology was assessed 
in the cortex, corpus callosum, fimbria, hippocampus, thalamus and internal capsule 
for evidence of tissue pathological alterations such as pallor in staining, microbleeds 
and haemorrhages. The presence or absence of eosinophilic damage to neuronal 
perikarya and evidence of pathological tissue alterations were recorded. Damaged 
neurons could be identified by the cytoplasm appearing red eosinophilic and can be 
readily distinguished from dark cell change (Jortner, 2006). Small areas of 
microbleeds or larger haemorrhages could be identified by the presence of 






2.2.6. Quantification of myelin integrity  
 
Myelin integrity was assessed in the corpus callosum, fimbria, subcortical 
thalamic region and internal capsule using myelin basic protein (MBP) 
immunostaining.  Quantification of myelin damage was analysed by calculating 
ROD in a defined area using Image J (U.S. National Institutes of Health, Bethesda, 
USA). In the young 4-month cohort images were taken at x25 using QImaging 
QICAM Fast 1394 camera (QImaging, Surrey, BC, Canada), which was connected to 
a Leica DMR microscope (Leica Microsystems UK, Milton Keynes, UK). 
Additionally, to coincide with cognitive data, the hippocampus was also investigated 
within this cohort. Images were taken to encompass the entire hippocampus and the 
ROD was taken of the whole region. In the  young 6-month and aged 4-month cohort 
images were taken at x40 using QImaging QICAM MicroPulisher 3.3 camera 
(QImaging, Surrey, BC, Canada) connected to a Olympus BX51 microscope 
(Olympus UK, Southendon-Sea, UK). All images were taken at a fixed light intensity 
for each cohort and analysed blinded to a single experimenter. ROD measurements 







 and subcortical thalamic region 0.25mm
2
 with 
measurements averaged over hemispheres. Measurements are expressed as the 
percentage difference from normotensive control values.  In order to establish 
reproducibility within measurements, all measurement within three animals were 
carried out three times and deemed reproducible, by each measurement falling within 
10% of the median for each animal. Prior to breaking the codes the data sets were 




2.2.6.1. Quantification of number of oligodendrocytes 
 
Quantification of oligodendrocyte cell number was assessed by counting the 
number of adenomatous polyposis coli protein (CC1) positive cell bodies. For all 
cohorts images were taken at x200 within the subcortical thalamic region only using  
QImaging QICAM MicroPulisher 3.3 camera (QImaging, Surrey, BC, Canada) 
connected to a Olympus BX51 microscope (Olympus UK, Southendon-Sea, UK). A 
counting grid was applied to each image and oligodendrocyte cell bodies within this 
grid were counted. A total area of 0.25mm
2
 was measured within each animal.  
Sections single labelled for CC1 were analysed. The specificity of CC1 as a marker 
of oligodendrocytes was characterised by double labelling sections from the young 6-
month cohort with astrocytic marker glial fibrillary acidic protein (GFAP). Double 
labelling was carried out by labelling CC1 brown by DAB and GFAP violet by 
peroxidise chromogen VIP (Vector, VIP). Astrocytes could be clearly identified by 
the presence of cell bodies. Counting was carried out using a counting grid at x200 
magnification on a Leica DMR microscope within the same area of 0.25mm
2
. 
Astrocytes labelled with CC1 positive cells bodies were counted and found to 
represent less than 1% of the population of cells, validating CC1 as a specific marker 
of oligodendrocytes (fig 2.3). 
2.2.6.2. Quantification of axonal integrity 
 
Amyloid precursor protein (APP) was used as a marker of axonal integrity 
and assessed in the corpus callosum, fimbria, internal capsule and subcortical 
thalamic region. Sections were screened for the presence or absence of intense APP 




axonal integrity was analysed using a light microscope with sections screened for the 
presence or absence of axonal bulbs. Localisation of APP aggregation within the 












Figure 2.3: Specificity of CC1 as a marker of oligodendrocytes 
Investigation of the specificity of CC1 (brown) as a marker of oligodendrocytes was 
carried out by double labelling sections with astrocytic marker GFAP (purple). (A) 
Representative image of CC1/GFAP double labelling with insert showing 
colocalisation. (B) Quantification of the number of CC1/GFAP positive staining 
compared to CC1 alone was found to present less than 1% of the population of the 




2.3. Tissue preparation for biochemistry  
Animals selected for biochemical and microarray analysis were saline 
perfused and the brains snap frozen. Prior to freezing the brain was sectioned using a 
rat matrix (Fisher scientific, UK).  A slice including the region corresponding to -
3.14mm to -5.15mm from bregma (Paxinos and Watson 1998) was used for 
microarray analysis, with the remaining hemisphere processed for biochemical vessel 
enriched analysis.  
2.3.1. Vessel enriched homogenate 
 
Tissue was processed as a vessel enriched homogenate by density 
centrifugation using Ficoll™ (Sigma-Aldrich, Missouri, US). Gentle homogenisation 
of the tissue was carried out using ice cold PBS with a loose fit Dounce 
homogeniser. Cellular debris were removed by low speed centrifugation in an 
Eppendorf temperature controlled centrifuge (Eppendorf UK Ltd., Stevenage UK) at 
250g for 15 minutes and the supernatant discarded.  17.5% Ficoll™ (Sigma-Aldrich, 
Missouri, US) solution in distilled water was added to the pellet, centrifuged for 25 
minutes at high speed 3200g and a temperature of 4˚C. The supernatant was removed 
and the pellet washed with 1% BSA in PBS. Following centrifugation the 
supernatant was removed and the pellet was washed with PBS. This solution was 
centrifuged at 2000g for 20 minutes discarding the supernatant; the pellet was snap-
frozen and stored at -80˚C.  
2.3.1.1. Homogenisation of vessel enriched fraction for biochemistry 
 
The vessel enriched fraction was homogenised for biochemical analysis in 




ethylenediaminetetraacetic acid (EDTA) and 1mM ethylene glycol tetraacetic acid 
(EGTA) in distilled water (tissue homogenisation buffer).  Protease and phospatase 
inhibitors (Merck, UK) were added to the tissue homogenisation buffer at 
concentrations of 1:100 and 1:50 respectively. Samples were homogenised in 150µl 
of buffer containing inhibitors using an electric homogeniser (Stuart, Bibby 
Scientific Ltd., Staffordshire, UK) at constant speed for 15 seconds. Samples were 
spun for 5 minutes at 3000rpm in a sigma 1-13 benchtop centrifuge (Sci Quip Ltd., 
Schrewsberry, UK), the supernatant removed and samples stored at -80˚C.  
2.3.1.2. Determination of the protein concentration of samples for biochemistry  
 
A bicinchoninic acid protein assay kit (Thermo Fisher Scientific, 
Cramlington, UK) was used to determine the protein concentration within samples. 
Standards were made as per manufacturer’s instructions and then pipette into 
appropriate wells of the 96 well plates. Samples were diluted in 1:10 in 
homogenisation buffer minus inhibitors onto a 96 well plate. The working reagent 
containing sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1M sodium hydroxide, mixed in a 50:1 dilution with 4% cupric sulphate 
solution and added to each well, then incubated at 37˚C for 30 minutes. The plate 
was allowed to cool for 15 minutes and absorbance was read at 562nm on a LT-4000 
MS microplate reader (Labtech, East Sussex, UK). Values generated from protein 
standards were used to plot a standard curve from which the protein concentration of 






2.3.2. Western blotting  
 
Samples were made up by concentrations of 1µg/µL with 0.25µL of 
NuPAGE® loading buffer (Invitrogen, Life technologies, New York, USA) and 
0.1µL of NuPAGE® reducing agent (Invitrogen, Life technologies, New York, 
USA) per µL and the same buffer which was used for tissue homogenisation. 
Samples were incubated in a water bath at 70˚C for 10 minutes to denature proteins 
then loaded with a molecular weight marker (Li-Cor, Cambridge, UK) on precast 4-
12% Bis/Tris gels (Invitrogen, Paisley, UK). Samples were loaded between two gels 
with a control sample repeated to check for consistency. Protein separation was 
carried out by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) with 2-(N-morpholino) ethanesulfonic acid (MES) running buffer 
(Invitrogen, Paisley, UK). Samples were run through the gel at 100V, until bands 
reached the middle of the gel where the voltage was increased to 150V, until samples 
ran to the bottom of the gel.  
Proteins were transferred on to polyvinylidene fluoride (PVDF) membrane 
(GE Healthcare, Little Chalfont, UK) in a XCell II Blot Module (Invitrogen, Paisley, 
UK) at 30V for 1.5 hours. To access the quality of transfer the membrane was stained 
with Ponceau S stain, which allowed for visualisation of banding. After assessment, 
if successful, membranes were washed with PBS then incubated in blocking solution 
of 1:1 odyssey blocking buffer (LI-COR, US) and PBS for 1 hour. Blocking was 
carried out in light proof containers, which were continually agitated. Primary 
antibody solution was made in blocking buffer, including α-Tubulin (Abcam, 





The following day primary antibody solution was drained off and membranes 
were washed in PBS 0.1% Tween; 6 times for 5 minutes each wash. Membranes 
were then incubated for 45 minutes in the appropriate secondary antibodies bound 
with infra-red dye (Li-Cor, Cambridge, UK) at concentration of 1/3000 mixed with 
blocking buffer containing 0.1% tween-20 and 0.01% sodium dodecyl sulphate.  
After secondary incubation membranes were washed 6 times in PBS 0.1% Tween for 
5 minutes with a final 5 minute wash in PBS only. Membranes were dried between 
two pieces of filter paper and stored in light proof packaging. To identify fluorescent 
banding, membranes were scanned using an Odyssey infrared scanner (Li-cor, 
Cambridge, UK). Details of all antibodies used can be found in table 2.3. 
2.3.2.1. Determination of protein levels by Western blotting 
 
After membranes were dried and scanned the protein levels of bands could be 
calculated. The membranes were analysed using odyssey software (version 3.0; Li-
Cor, Cambridge, UK), which allowed for the intensity of each band to be calculated. 
The intensity of each protein band of interest was expressed as ratio of the intensity 
of α-Tubulin band. All gels were run in duplicate to replicate findings and averaged 
for analysis.  
Prior to running the vessel enriched samples, characterisation of vessel 
homogenate were undertaken. One sample was run in comparison to a whole brain 
homogenate to examine protein content of vascular markers. As can be seen in figure 
2.4, the vessel enriched sampled allowed detection of vascular markers, whereas the 





Primary antibody Supplier Dilution Secondary antibody Amount of 
protein loaded 
α-Smooth muscle actin Millipore, Watford, UK 1:1000 Anti mouse 15 µg 
PECAM Abcam, Cambridge, UK 1:50 Anti rabbit 15 µg 
Claudin-5 Invitrogen, Califonia, USA 1:1000 Anti mouse 15 µg 
ZO-1 Invitrogen, Califonia, USA 1:500 Anti rabbit 15 µg 
α-Tubulin Abcam, Cambridge, UK 1:20000 Anti mouse 15 µg 
 
Table 2.3: Details of antibodies used in Western blotting assessment  
Details the antibodies use for western blotting protein assessment in vessel enriched homogenate including manufacturer, dilution and 











Claudin-5 – 18 kD





actin - 42 kD
Rat brain
Gentile Homogenisation with 
Dounce in PBS
Low speed Centrifuge
Suspended in 17.5% Ficoll™
High speed centrifuge 








Figure 2.4: Characterisation of vessel enriched homogenate 
Representative image of the methodology and the cellular components within the 
vessel enriched homogenate. (A) Flow chart of the gradient centrifugation steps 
required to extract vessels. (B) Representative visualisation of vessel enriched 
homogenate on a phase contrast microscope. The image demonstrates a sample, 
which is enriched in vessels and that the overall structural integrity of the vasculature 
is intact. (C) Characterisation western blots. Within equal protein levels the vessel 
enriched homogenate allows identification of vascular specific proteins which are not 
detected in the whole brain homogenate. α-Tubulin was used as a loading control 




2.3.3. Microarray  
2.3.3.1. RNA extraction 
 
Tissue processed for microarray was taken from a subcortical dissection of 
the same tissue used for biochemical analysis. Firstly the tissue slice was allowed to 
thaw and the subcortex was carefully dissected with the remaining tissue disposed of.  
Ribonucleic acid (RNA) was extracted using Trizol™ protocol according to 
manufacturer’s instructions (Invitrogen, Paisley, UK). Succinctly, tissue was 
homogenised in 1ml/100mg of Trizol™ using lysing matrix tubes in a MP 
Biomedical FastPrep Homogeniser (Fisher scientific, Leicestershire, UK). Phase 
separation was carried out by addition of 1-bromo-3-chloro propane and samples 
were centrifuged at 12 000g for 15 minutes, with the upper phase transferred into a 
new tube. The upper phase was used for RNA precipitation with the addition of 
linear polyacrylamide and a further high speed centrifugation. RNA formed a gel-
like pellet, the supernatant was discarded and RNA was washed with 75% Ethanol 
followed by distilled water. After washing the pellet was allowed to air dry until the 
circumference of the pellet turned white and then re-suspended in distilled water for 
storage at -80˚C. 
2.3.3.2. Determination of RNA concentration and integrity 
RNA concentrations were determined using a NanoDrop 3300 
Fluorospectrometer (Thermo scientific, USA) and RNA integrity analysed using 
Agilent 2100 Bioanalyser (Agilent Technologies, Inc., Colorado, US), separating 
nucleic acid fragments by molecular weight and laser induced fluorescence. An 




with samples pipette onto the Nanochip, containing a sieving polymer fluorescent 
dye and external standards ladder. The Bioanalyser then electrophoretically separated 
the RNA within each sample by size and the intercalated fluorescent dye is detected 
at different speeds within different bands. The RNA ladder contains 6 fragments, 
from 0.2 to 6km, at a concentration of 150ng/µl and the Bioanalyser software 
compares the unknown samples to the ladder fragment to determine the 
concentration and ribosomal peaks. Data from the Bioanalyser was represented by 
the electrophoresis, showing band separation of RNA fragments by size and the  
integrity of RNA was evaluated by the electropherogram trace and RNA integrity 
number (RIN). The electropherogram of intact RNA will demonstrate two distinct 
ribosomal peaks corresponding to 18S and 28S RNA with no other peaks between 
the 18S and 5S peak (Fig 2.5). RNA integrity was also calculated by the RIN 
number, based on a software algorithm on a scale of 1-10, with 1 representing 
completely degraded RNA, whereas 10 is intact.  More samples were processed than 
were needed, with all samples having a high RIN number thus, samples used for 









Figure 2.5: Integrity of RNA 
Representative image of RNA integrity analysis. (A) Electrophoresis of RNA 
samples provided evidence of two distinct bands in each sample corresponding to 
18s and 28s RNA. (B) Representative electropherograms of study RNA 
concentration showing two distinct 18s and 28s peaks with no degradation between 
the two or between the early 5s peak. RIN number is representative of the integrity of 
RNA within the sample on a scale of 1 to 10, fully degraded to fully intact 





2.3.3.3. Microarray gene expression profiling 
Procedures such as cDNA preparation, microarray assay and analysis were 
carried out with the assistance of Alison Downing (Ark Genomics, Roslin Institute, 
UK). Firstly sense strand cDNA preparation from RNA samples was generated and 
labelled using Ambion WT expression kit (Affymetrix, US) and Affymetrix 
GeneChip WT terminal labelling kit array (Affymetrix, US), as per manufacturer’s 
instructions. The gene expression console, GeneTitan® was used to hybridise cDNA 
from each sample onto a Genechip strip rat gene 1.1 array (Affymetrix, US), >27 000 
genes, followed by washes and scanning of the intensity of each probe. Signal 
intensities were screened for outliers by plotting the log probe cell intensity for each 
sample (Figure 2.6a) and data normalised by robust multichip average (RMA) 
analysis method, using the Expression console™ (Affymetric, US). Raw data was 
used to run principal component analysis (PCA) and the sum of squares analysis 
using Genomics suite (Partek® Inc, US) to visualised sources of variation (figure 
2.6b). Log2 transformed normalization signal intensities of annotated transcripts 
were analysed by one way analysis of variance (ANOVA), with the source of 
variation - perfusion date attributed as a factor (Partek® Inc, US).  An overall 
significance was set at p<0.005, but, the high variability and low level of 
differentially expressed signal intensities within the data set did not allow any 
differentially expressed genes to pass false discovery rate (FDR) correction. 
However, due to the previous findings in this study it was anticipated that 
differentially expressed genes would be relatively subtle, but it was not appreciated 




Pathway analysis was used to allow the mapping of biological functional 
networks, carried out using IPA software (Ingenuity systems, US) with differentially 
expressed genes of significance of p<0.01. The 4 most significantly altered networks 






















Figure 2.6a: Microarray intensity signal normalisation 
(A) Average log probe cell intensity for each animal prior to normalisation indicates 
no outliers. (B) Pearson’s correlation of average intensity values for each animal 








Figure 2.6b: sources of variation within microarray intensity signals 
Representative image of the variance within microarray log intensity signals. (A) 
Principle component analysis (PCA) plot representative of sources of variance within 
log signal intensities for each subject. Normotensive controls are show in red and 
hypertensive animals are shown in blue. The PCA plot highlights outliers within the 
study and provides evidence of clustering of subjects independent of treatment. (B) 
Pie chart representing the variation within the study. A high source of variation is 
labelled as error and of unknown cause. The other sources of variance observed 
within this study were perfusion date and attribute (treatment). The high level of 
unattributed variance compared to the attributed variance did not allow any 





2.4. Behavioural testing  
Prior to behavioural testing animals were habituated to handling due to 
frequent blood pressure recordings. Behavioural testing was carried out in pairs of 
experimenters blinded to treatment groups with the order of cognitive testing 
counterbalanced between treatment groups, allowing one individual to work the 
recording software and the other to place each animal in the maze. Water maze 
testing was run by myself, Dr Chen and Miss Smith and all the data was analysed by 
myself. 
2.4.1. Morris water maze  
 
Water maze protocols were conducted in a circular pool (200cm diameter, 
Figure 2.7), filled with 25 ± 1°C opaque water (by addition of 400ml latex liquid). 
The water maze room had many extra-maze 2D and 3D visual cues, encompassing 
brightly coloured geometric images.  During cognitive testing the experimenter and 
awaiting rats were hidden behind white curtains to prevent those becoming extra 
interchangeable cues. The maze activity of each rat was monitored via CCTV camera 
mounted above the pool. This allowed parameters such as the latency to find the 
platform to be tracked and monitored using Water Maze tracking software 
(ActiMetrics software version 2.6). 
2.4.1.1. Cue task 
  
Prior to water maze testing animals were trained with a cue task version of 
the water maze in which any gross motor or visual impairment could be observed. In 
the cue task the target platform had a diameter of 20cm and was visualised by a 




around the maze. The platform was located in a different quadrant for each trial on a 
given day. Animals were given 3 trials per day for 4 consecutive days. During a trial 
each animal was placed in the water maze facing the wall of the pool and allowed 90 
seconds of swimming to locate the platform. The animals starting position was 
counterbalanced between quadrant and platform location, so not to repeat a starting 
position on any day.  
2.4.1.2. Spatial reference learning and memory  
Spatial reference memory testing occurred 3 days after the Cue task. The 
Atlantis platform (13cm in diameter) was submerged approximately 1 cm below the 
surface of opaque water, uncued and not visible to animals. Animals were allowed 4 
trials per day for 5 days to locate the hidden platform. The platform location was 
constant throughout the trial but the animals starting location, counter balanced to 
platform location across the group and varied each trial. 10 minutes after the final 
spatial reference learning task animals were given a probe trial in which the platform 
is fully submerged in the location of the spatial reference trial and rises after 1 
minute of searching. 24 hours later the probe trial is repeated with no platform 
present.   
2.4.1.3. Delayed matching to place protocol  
 
Delayed matching to place protocol was carried out 3 days after the spatial 
reference learning task based on protocol devised by Steel and Morris (Steele and 
Morris, 1999). The 13cm platform was relocated each day, with animals given a 
longer 20 minute inter-trial interval between trails 1 and 2 and a shorter 15 second 




run for 4 consecutive days with the starting location of the animal varied and counter 




































Figure 2.7: The Morris Watermaze 
 
Image of the Morris Watermaze showing a selection of both 2D and 3D visual cues 















2.5. Statistics  
2.5.1. Blood pressure  
Statistical comparisons of systolic blood pressure between normotensive and 
hypertensive animals for each individual cohort separately (young 4 month, young 6 
month and age 4 month) was firstly analysed using repeated measures ANOVA with 
significance set at p<0.05, to allow an understanding of the significance throughout 
the duration of the study. Following posthoc analysis was carried out using student t-
test at specific time points of week 0, 5 and end-stage to confirm significance 
throughout with significance set at p<0.01.  
2.5.2. Pathology 
2.5.2.1. Vascular pathology  
The majority of immunohistochemical data was presented as mean ± standard 
error of the mean, apart from vessel width measurements presented as cumulative 
frequency and the number of eNOS positive vessels presented as percentage of 
controls. All the relative optical density measurements (ROD) and count data were 
examined by Student’s t-test. Density measurements analysed by percentage area 
stained, were examined by Mann Whitney U test. Vascular width measurements 
were examined by Kolmogorow - smirnov test. Microglial vascular association data 
were examined by Fishers exact test. The significance for immunohistochemical data 
was set at p<0.02. Throughout this thesis each cohort is analysed separately and 
comparisons were not made between cohorts. Unfortunately as each was ran distinct 
to each other, there were several variable factors such as housing during the study, 




statistical assessment were made per cohort the significance was set more stringently 
to p<0.02, in an aid to account for false positives. 
2.5.2.2. White matter pathology  
The majority of data was presented as mean ± standard error of the mean, 
apart from MBP intensity and microglia count data, presented as percentage of 
controls. Data for MBP intensity values, CC1 positive cell counts and number of 
microglia were analysed using Student’s t-test. APP data was analysed by Fisher’s 
exact test. The significance was set at p<0.02, as described above and each cohort 
was analysed separately. 
2.5.2.3. Western blotting data 
 The integrated intensity measurements taken from western blotting 
experiments were expressed in relation to α-tubulin, data presented as mean ± 
standard error of the mean and examined by Student’s t-test. Significance was set at 
p<0.05.  
2.5.2.4. Microarray Gene expression data 
The normalized log2 signal intensities were analysed using ANOVA with 
perfusion date as a factor and significance set at p<0.005. A separate analyse was 
carried out with a significance of p<0.01 for pathway analysis.  
2.5.2.5. Behavioural assessments  
Behavioural data was presented as mean ± standard error of the mean, 






3. The effect of inducible hypertension on the structural integrity of the 
cerebrovasculature in young and aged rats 
3.1. Introduction  
The structural integrity of the cerebrovasculature is crucial for normal brain 
function. Hypertension has been associated with cerebrovascular remodelling in 
humans, commonly located within the subcortical structures of the brain and thought 
to underlie gross structural and functional alterations (Fisher, 1969, 1971; Lammie, 
2002). Data from the SHR and SHRSP models of hypertension have also found 
evidence of vascular remodelling (Baumbach and Heistad, 1988; Baumbach and 
Hajdu, 1993; Knox et al., 1980; Sabbatini et al., 2001; Tagami et al., 1987). The 
present study sought to investigate the effect of sustained hypertension on subcortical 
cerebrovascular structure in the young and aged Cyp1a1 Ren2 transgenic rats. 
3.1.2. Hypothesis  
Hypertension will lead to vascular alterations within the subcortex of the 
young and aged brain consisting of remodelling of the basement membrane, loss of 
BBB integrity and altered endothelial signalling. 
3.1.3. Aims 
The study in this chapter aimed to investigate the effect of hypertension on 
the structural integrity of the vasculature in the young and aged brain of the Cyp1a1 
Ren2 rat model. A detailed examination of vascular width and density, endothelial 
signalling, endothelial blood-brain barrier integrity and the inflammatory response 






Experiments were conducted on Cyp1a1 Ren2 transgenic rats described in 
chapter 2.1, separated into young and aged cohorts. Rats were either attributed to the 
normotensive group, fed a control diet consisting of no I3C or the hypertensive 
group, fed a diet consisting of 0.15% I3C. The young cohort contained two groups, 
run for different durations (4 or 6 months). The young 4-month cohort consisted of 
normotensive (control diet, no I3C, n=12) and hypertensive (0.15% I3C, n=16) 
animals. The young 6-month cohort included normotensive (control diet, no I3C, 
n=21) and hypertensive (0.15% I3C, n=21) animals. At termination, the 6-month 
cohort was separated into those processed for immunohistochemistry; normotensive 
(control diet, no I3C, n=13) and hypertensive (0.15% I3C, n=13) and those processed 
for biochemistry; normotensive (control diet, no I3C, n=8) and hypertensive (0.15% 
I3C, n=8). The aged cohort was run for a duration of 4 months including; 
normotensive (control diet, no I3C, n=10), and hypertensive (0.15% I3C, n=12) 
animals. All animals from the young 4-month cohort survived well. However, 4 
hypertensive animals from the young 6-month cohort and 2 animals (1 normotensive, 
1 hypertensive) from the aged 4-month cohort were prematurely culled due to 
excessive weight loss.  
3.2.2. Measurements of blood pressure  
Throughout the study blood pressure measurements were carried out 
(described in chapter 2.1.3.2), using the tail-cuff plethysmography method. All rats 




blood pressure measurements the animals’ general health was also recorded 
including their weight, gate and grooming.  
3.2.3. Immunohistochemistry 
Pathological assessments were carried out on paraffin embedded brain tissue 
sections (6µm) from young and aged cohorts (chapter 2.2). Sections encompassing 
the subcortical thalamic region of the brain (chapter 2.2.4) were stained to visualize 
components of the vasculature using markers for basement membrane; collagen IV 
(2A), smooth muscle cells; α-smooth muscle actin, endothelial tight junction; 
claudin-5 and ZO-1, endothelial; eNOS and microglial; Iba1. Full technical 
methodology and quantification of vascular markers used within this chapter are 
outlined in detail in chapter 2.2. 
 3.2.4. Global assessment of vascular protein levels 
Investigation of global vascular protein levels were assessed in the young 6-
month cohort, by the generation of a vessel enriched homogenate, from one 
hemisphere  of the brain (excluding the slice used for microarray investigation), 
described in full in chapter 2.3.  Protein levels were assessed using western blotting 
technique, performed to detect α-smooth muscle actin, PECAM, claudin-5 and ZO-1, 
with α-tubulin used as a loading control.  
3.2.5. Statistical analysis  
Statistical comparisons of systolic blood pressure between normotensive and 
hypertensive animals for each individual was firstly analysed using repeated 
measures ANOVA with significance set at p<0.05, to allow an understanding of the 




carried out using student t-test at specific time points of week 0, 5 and end-stage, 
with significance set at p<0.01. Immunohistochemical and western data presented as 
mean ± standard error of the mean, examined by Student’s t-test, apart from 
percentage area stained data, which was analysed by Mann Whitney U test and 
microglia association data, which was examined by Fishers exact test. The 
significance for immunohistochemical data was set at p<0.02 and p<0.05 for 
Western data. Throughout the chapter each cohort was analysed separately and 
comparisons between cohorts were not made.  
3.3. Results  
3.3.1. Indole-3-carbinol caused sustained increased blood pressure  
3.3.1.1. Blood pressure in the young 4-month cohort  
 
Throughout the duration of the study it was found that there was a significant 
difference in blood pressure over time (F(8.98, 4769.38) = 15.66, P<0.01). Interestingly, 
there was a significant deference between blood pressure and treatment (F(8.98, 5535.49) 
= 18.16, P<0.01) in control animals versus those fed a hypertensive diet.  
 The profile of blood pressure was also examined at specific time points 
throughout the study. At week 0, blood pressure for the young 4-month cohort was; 
128 ± 4 mmHg for animals assigned to the control diet group versus 124 ± 2 mmHg 
for animals assigned to the hypertensive diet group (|t|= 1.37, df= 15, p=0.19; Figure 
3.1A) and was found not to be significantly different. At week 5 post dietary 
induction, there were significant differences in systolic blood pressure between 




cohort; blood pressure was 136 ± 3 mmHg for control diet group versus 176 ± 4 
mmHg for hypertensive diet group (|t|= 3.10, df= 17, p<0.01; Figure 3.1A). End-
stage blood pressure was significantly different between animals fed a control diet 
and animals fed a hypertensive diet in the young cohort with blood pressure of 135 ± 
2 mmHg for animals fed a control diet versus 195 ± 2 mmHg for animals fed a 
hypertensive diet (|t|= 13.33, df= 14, p<0.01; Figure 3.1A). 
3.3.1.2. Blood pressure in the young 6-month cohort  
 
Throughout the duration of the study it was found that there was a significant 
difference in blood pressure over time (F(6.04, 5295.14) = 14.16, P<0.01). Interestingly, 
there was a significant difference between blood pressure and treatment (F(6.04, 
11456.55) = 30.63 P<0.01) in control animals versus those fed a hypertensive diet. At 
week 0, blood pressure for the young 6-month cohort was; 146 ± 2 mmHg for 
animals assigned to the control diet group and 145 ± 3 mmHg for animals assigned to 
the hypertensive diet group (|t|= 0.16, df= 15, p=0.86; Figure 3.1B). At week 5 post 
dietary induction, there were significant differences in systolic blood pressure 
between animals fed a control diet and animals fed a hypertensive diet in the young 
6-month cohort with blood pressure of; 147 ± 3 mmHg for animals fed a control diet 
and 160 ±2 mmHg for animals fed a hypertensive diet (|t|= 3.77, df= 19, p<0.01; 
Figure 3.1B). End stage blood pressure for the young 6-month cohort was 131 ± 2 
mmHg for animals fed a normotensive diet and 185 ± 2 mmHg for animals fed a 





3.3.1.3. Blood pressure in the aged 4-month cohort  
 
Throughout the duration of the study it was found that there was a significant 
difference in blood pressure over time (F(7.14, 2700.54) = 10.47, P<0.01). Interestingly, 
there was a significant difference between blood pressure and treatment (F(7.14, 1195.40) 
= 4.63 P<0.01) in control animals versus those fed a hypertensive diet. At week 0, 
blood pressure for the aged 4-month cohort was; 145 ± 4 mmHg for animals assigned 
to the control diet and 150 ± 2 mmHg for animals assigned to the hypertensive diet 
(|t|= 0.11, df= 15, p=0.91; Figure 3.1C). At week 5 post dietary induction, there were 
significant differences in systolic blood pressure between animals fed a control diet 
and animals fed a hypertensive diet and blood pressure was 128 ± 2 mmHg for 
animals fed a control diet and 158 ± 4 mmHg for animals fed a hypertensive diet (|t|= 
9.06, df= 14, p<0.001; Figure 3.1C). At end stage, the aged 4-month cohort had 
blood pressure of 140 ± 2 mmHg for animals fed a control diet and 182 ± 4 mmHg 





















Figure 3.1: Systolic blood pressure  
Systolic blood pressure increased with dietary addition of I3C and sustained over 
time. (A) Young 4-month cohort blood pressure was significantly increased at week 
5 in animals fed I3C compared to animals fed a control diet. End-stage blood 
pressure was 135 ± 2mmHg for animals fed a control diet and 195 ± 2mmHg for 
animals fed an I3C containing diet. (B) Young 6-month cohort animals fed an I3C 
containing diet had significantly increased blood pressure at week 5 when compared 
to those fed a control diet, end-stage blood pressure was 131 ± 2mmHg control 
versus 185 ± 2mmHg I3C diet. (C) I3C fed animals from the aged 4-month cohort 
had significantly increased blood pressure when compared to those fed a control diet, 
at week 5 with end-stage blood pressure values of 140 ± 2mmHg control diet versus 





3.3.2. Hypertension induced alterations to vascular structure  
Collagen IV (specific for Collagen IV 2A subunit), a marker of basement 
membranes, was used as a general indicator of vascular integrity. Collagen IV clearly 
outlined the structure of all vessels in both cross sectional and longitudinal 
orientations, allowing for the quantification of vascular density, width and number of 
vessels (Figure 3.2). For the analysis of vessel width, only the vessels in a 
longitudinal plane were quantified. In the young 4-month cohort, there was no 
significant difference in the density (p=0.47, Figure 3.2J, Table 3.1), vessel width 
(D= 0.09, p=0.13, Figure 3.2G, Table 3.1 Appendix A.1) or number of vessels (|t|= 
0.64, df=28, p=0.53, Table 3.1, Appendix A.2) in hypertensive animals when 
compared to normotensive. Figure 3 presents the data for each cohort in frequency 
distribution with the raw vessel width presented in Appendix A.1.  
However, in the young 6-month cohort vascular structure was altered in the 
hypertensive compared to normotensive rats. Vessels of the hypertensive animals 
displayed a string-like appearance (Figure 3.2E, Table 3.2), with a significant 
reduction in vessel width (D= 0.15, p<0.01, Figure 3.2H, Table 3.2, Appendix A.1) 
compared to normotensive animals. These alterations were in absence of a significant 
difference in vascular density (p=0.25, Figure 3.2K, Table 3.2) or the number of 
vessels (|t|= 1.29, df=21, p=0.21, Table 3.2, Appendix A.2), in hypertensive animals 
when compared to normotensive. Figure 3 presents the data for each cohort in 





In the aged 4-month cohort, there was a significant increase in both the 
density (p=0.01, Figure 3.2L, Table 3.3) and number of vessels (|t|= 3.10, df=18, 
p=0.01, Table 3.3, Appendix B.2) in hypertensive animals when compared to 
normotensive, but there was no evidence of any difference in vascular width (D= 
0.07, p=0.33, Figure 3.2I, Table 3.3, Appendix A.1). The vasculature of the aged 
hypertensive animals did not exhibit the string like appearance, as seen in the young 
6-month cohort but they appeared denser. Figure 3 presents the data for each cohort 
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Figure 3.2: Assessment of cerebrovascular structure using Collagen IV staining 
Representative images of cerebrovascular structure using antibody specific for Collagen IV 
(A2), in normotensive (A, B, C) and hypertension (D, E, F) animals from each cohort. In the 
young 4-month cohort there was no change in vascular width (G) or density (J) in the 
hypertensive animals (D) when compared to normotensive (A). In the young 6-month cohort 
hypertensive animals displayed thinner string like vessels (E), throughout a range of vessel 
sizes with an overall significant decreased in vessel width (H) represented by *, but not 
density (K), when compared to normotensive animals (B). The aged 4-month cohort had 
increased density of vessels in hypertensive (F,L) when compared to normotensive animals 
(C), with no alterations in vessel width (I). Scale bar = 100µm. Graphs show mean ± SEM. 




3.3.3. Hypertension does not induce overt structural alterations to the large arteries 
and arterioles 
 
Smooth muscle actin was used as a general indicator of larger artery and 
arteriole integrity, as small arterioles and capillaries have minimal or no smooth 
muscle actin (Drake and Iadecola, 2007). This was shown in the profile of staining, 
with immunopositive vessels mainly large in size, in comparison to the array of 
vessels stained with collagen IV. In the young 4-month cohort, no significant 
difference in the density of smooth muscle actin was found between hypertensive 
and normotensive animals (p=0.26, Figure 3.3G, Table 3.1). Similarly, there was no 
significant difference in the density of staining of smooth muscle actin between 
hypertensive and normotensive animals from the young 6-month (p=0.26, Figure 
3.3H, Table 3.2) and the aged 4-month (p=0.03, Figure 3.3I, Table 3.3) cohort. This 
is indicative that hypertension in this model primarily affects the smaller arterioles 
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Figure 3.3: Structural assessment of large arteries and arterioles 
Representative images of the structural integrity of large arteries and arterioles using 
an antibody specific for α-smooth muscle actin in normotensive (A, B, C) and 
hypertensive (D, E, F) animals. Overall, there was no significant difference in the 
density of vascular smooth muscle actin between normotensive (A, B, C) and 
hypertensive (D, E, F) animals from the young 4-month cohort (G), young 6-month 






Vascular data for the Young 4-month cohort 
Collagen IV Smooth muscle actin 
Vessel width (µm) % area stained Number of vessels % area stained 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
5.98 5.46 6.49 6.13 22.20 24.86 0.46 0.40 
6.46 5.11 5.57 4.97 19.50 15.60 0.42 0.37 
6.41 6.82 6.47 6.03 23.60 27.60 0.41 0.39 
6.96 6.02 6.15 6.32 23.60 21.40 0.39 0.40 
6.38 6.72 4.58 6.15 23.00 24.00 0.37 0.48 
6.72 6.60 5.99 5.58 28.00 24.20 0.37 0.41 
6.68 6.97 5.47 5.59 21.40 26.20 0.42 0.36 
6.74 7.25 7.28 6.93 23.50 24.40 0.37 0.39 
5.60 5.86 7.44 5.54 16.33 28.20 0.41 0.40 
6.53 6.52 7.43 7.07 20.00 25.00 0.41 0.39 
6.43 5.82 6.67 5.71 25.60 25.40 0.37 0.37 
6.40 5.69 5.73 5.53 26.80 18.40 0.40 0.37 
 6.52  6.46  23.00  0.43 
 6.45  7.33  26.40  0.38 
 6.64  6.11  18.75  0.34 
 6.53  6.65  26.75  0.35 
 
Table 3.1: Vascular data values for the young 4-month cohort 
 The above data table shows raw data values analysed for Collagen IV measurements; vessel width, % area stained and number of vessels 






Vascular data for the Young 6-month cohort 
Collagen IV Smooth muscle actin 
Vessel width (µm) % area stained Number of vessels % area stained 
Normotensive Hypertensive Normotensive Normotensive Normotensive Hypertensive Normotensive Hypertensive 
5.55 5.31 8.16 6.72 27.00 24.91 0.37 0.41 
6.33 5.81 6.64 6.61 21.50 24.00 0.41 0.41 
6.24 5.77 6.95 6.92 19.40 21.25 0.38 0.36 
6.12 4.91 6.77 6.44 17.00 26.20 0.36 0.39 
6.30 5.13 8.26 6.23 26.75 21.50 0.40 0.38 
5.57 5.80 8.08 7.16 24.40 26.00 0.37 0.43 
6.92 5.94 6.88 5.92 22.80 23.00 0.35 0.40 
6.14 6.09 6.53 6.87 19.40 28.00 0.40 0.37 
6.32 5.59 6.03 6.44 17.80 23.25 0.42 0.32 
6.38  7.41  24.60  0.37  
6.32  6.39  29.20  0.40  
6.16  5.93  22.80  0.42  
5.80  6.50  24.20  0.44  
 
Table 3.2: Vascular data values for the young 6-month cohort 
The above data table shows raw data values analysed for Collagen IV measurements; vessel width, % area stained and number of vessels 








Vascular data for the Aged 4-month cohort 
Collagen IV  Smooth muscle actin  
Vessel width (µm) % area stained Number of vessels % area stained 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
6.00 6.88 2.60 5.74 17.88 21.70 0.40 0.48 
7.30 6.45 3.40 3.35 22.25 25.38 0.34 0.35 
6.26 5.51 3.49 3.45 20.25 22.00 0.13 0.34 
6.53 7.29 1.98 5.67 19.88 21.63 0.26 0.61 
6.59 7.06 2.07 5.22 20.25 23.25 0.44 0.56 
7.51 7.09 1.84 3.81 18.63 17.50 0.33 0.34 
6.47 6.80 4.77 5.04 22.25 22.88 0.20 0.35 
6.57 6.66 4.15 5.82 20.00 24.88 0.31 0.36 
7.36 6.41 4.81 3.65 19.50 22.88 0.43 0.51 
 6.58  3.38  25.63  0.36 
 7.00  4.19  28.00  0.58 
 
Table 3.3: Vascular data values for the Aged 4-month cohort 
The above data table shows raw data values analysed for Collagen IV measurements; vessel width, % area stained and number of vessels 




3.3.4. Prolonged hypertension caused structural alterations to the endothelial blood-
brain barrier  
 
To further investigate the endothelium, the structure of the endothelial BBB 
was assessed and in the majority of cohorts found to be unaltered, apart from 
hypertensive animals within the young 6-month cohort. Claudin-5 a tight junction 
marker was used to assess the intensity and density of protein expression. Staining 
was found to be similar to that of collagen IV, labelling both large and small vessels, 
clearly outlining the vasculature structure. 
In the young 4-month cohort there was no significant difference in the 
intensity (|t|= 0.25, df=27, p=0.80, Figure 3.4(a) H, Table 3.4) or density (p= 0.63, 
Figure 3.4(b) A, Table 3.4) of claudin-5 in hypertensive animals when compared to 
normotensive. However, claudin-5 expression in hypertensive animals from the 
young 6-month cohort was found to be significantly increased in intensity of staining 
when compared to normotensive animals (|t|= 3.77, df=21, p<0.01, Figure 3.4(a) G, 
Table 3.5). Whilst vessels from the hypertensive animals were intensely stained, 
there was no significant difference in the density of claudin-5 staining when 
compared to normotensive animals (p=0.10, Figure 3.4(b) B, Table 3.5). In a 
previous experiment, vessels stained with collagen IV were found to have a string-
like morphology; therefore vessel width was measured using claudin-5. In agreement 
with previous collagen IV findings, the vessel width was also was found to be 
decreased in hypertensive animals as compared to normotensive, when 
measurements were made using claudin-5 as a marker (D= 0.34, p<0.01, Appendix 
B.4). To further investigate these alterations, the effect of hypertension on the 




claudin-5 to the cytoskeleton and altered expression could represent structural loss of 
the BBB. However, there was no significant difference in the density of ZO-1 
staining, in hypertensive animals when compared to normotensive (p=0.22, 
Appendix A.3), suggesting that claudin-5 may be more tightly clustered or 
redistributed but still structurally linked to the cytoskeleton.  
  In turn, the distribution of claudin-5 was also investigated in the aged 4-
month cohort. Similar to findings in the young 4-month cohort, there was no 
significant difference in the intensity (|t|= 1.89, df=18, p= 0.08. Figure 3.4(a) I, Table 
3.6) or density (p=0.32, Figure 3.4(b) C, Table 3.6) of claudin-5, in hypertensive 
animals when compared to normotensive. Therefore, structural alterations in claudin-
5 expression were only found in hypertensive animals from the young 6-month 
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Figure 3.4a: Assessment of the endothelial blood-brain barrier 
Representative images of tight junction protein claudin-5 in normotensive (A, B, C) 
and hypertensive (D, E, F) animals from each cohort. In the young 4-month cohort, 
there was no difference in the intensity of claudin-5 staining between normotensive 
(A, H) and hypertensive (D, H) animals. However, in the young 6-month cohort, 
claudin-5 staining was significantly increased in hypertensive (E, G) when compared 
to normotensive (B, G) animals. On the other hand, in the aged 4-month cohort there 
was no difference in the intensity of claudin-5 in normotensive (C, I) and 
hypertensive (F, I) animals. Graphs show mean ± SEM. Significance *=p<0.01 








Figure 3.4b: Assessment of the endothelial blood-brain barrier 
There was no significant difference in the density of Claudin-5 staining in 
hypertensive animals when compared to normotensive from the young 4 month (A), 





Claudin-5 data from the Young 4-month cohort 
Intensity (ROD) % area stained 
Normotensive Hypertensive Normotensive Hypertensive 
0.20 0.15 2.20 2.07 
0.15 0.19 1.03 0.94 
0.17 0.19 2.06 2.20 
0.18 0.23 1.26 1.56 
0.15 0.15 3.85 1.52 
0.18 0.16 1.90 1.27 
0.23 0.20 0.72 1.32 
0.17 0.16 1.22 1.41 
0.16 0.16 1.61 2.67 
0.22 0.22 1.16 1.45 
0.18 0.17 0.81 1.19 
0.19 0.18 1.17 1.81 
 0.24  1.63 
 0.21  1.59 
 0.17  1.15 
 0.15  1.10 
 
Table 3.4: Claudin-5 data values for the young 4-month cohort 







Claudin-5 data from the Young 6-month cohort 
Intensity (ROD) % area stained 
Normotensive Hypertensive Normotensive Hypertensive 
0.16 0.17 0.97 1.43 
0.14 0.20 0.73 2.67 
0.13 0.19 1.21 1.61 
0.16 0.25 1.05 1.89 
0.15 0.21 1.52 1.77 
0.17 0.23 1.36 1.54 
0.16 0.18 1.18 1.57 
0.18 0.18 1.67 0.75 
0.17 0.19 1.70 1.32 
0.18  2.40  
0.16  0.94  
0.18  1.73  
0.16  1.15  
 
Table 3.5: Claudin-5 data values for the young 6-month cohort 










Claudin-5 data from the Aged 4-month cohort 
Intensity (ROD) % area stained 
Normotensive Hypertensive Normotensive Hypertensive 
0.19 0.19 3.41 3.44 
0.19 0.18 2.02 2.23 
0.19 0.19 3.13 3.23 
0.18 0.18 3.53 3.44 
0.19 0.19 3.42 3.28 
0.18 0.18 2.52 2.48 
0.18 0.18 2.35 3.14 
0.19 0.18 3.27 2.13 
0.19 0.18 3.42 1.98 
 0.19  3.08 
 0.16  1.45 
 
Table 3.6: Claudin-5 data values for the Aged 4-month cohort 








3.3.5. Hypertension induced alterations to endothelial signalling  
ENOS, an enzyme crucial for the production of vasodilatory NO was used as 
a marker of the endothelium and to provide mechanistic insight as to endothelial 
signalling in response to hypertension. The immunolabelling of this marker was 
strongly expressed and mainly observed in vessels cut in a cross-sectional 
orientation.  
In the young 4-month cohort, there was an increased number of vessels 
immunopositive for eNOS in hypertensive animals when compared to normotensive 
(|t|= 2.63, df=28, p= 0.01, Figure 3.5, Table 3.7). In contrast, in the young 6-month 
cohort, there was no significant difference in the number of vessels expressing eNOS 
in hypertensive animals versus normotensive (|t|= 0.82, df=21, p=0.42, Figure 3.5, 
Table 3.7). Similar to the young 4-month cohort, hypertensive animals from the aged 
4-month cohort had a significant increase in the number eNOS expressing vessels, 











Figure 3.5a: Assessment of endothelial signalling using eNOS  
Representative images of eNOS expression - eNOS (brown), counterstained with haemotoxylin (blue). In the young 4-month cohort (A, D) there was a 
significant increase in the number of eNOS expressing vessels in hypertensive animals (D) versus normotensive (A). No change in eNOS expression in 
hypertensive animals (E) from the young 6-month cohort when compared to normotensive (B). In the aged 4-month cohort (C, F) there was evidence of 







Figure 3.5b: Assessment of endothelial signalling using eNOS  
Quantification of eNOS expression by counting the total number of vessels positive for eNOS within a 1mm
2
 area. In the young 4-month 
cohort there was a significant increase in the number of vessels immunopositive for eNOS in hypertensive animals (G) versus 
normotensive (G). There was no change in eNOS expression in hypertensive animals (H) from the young 6-month cohort when compared 
to normotensive (H). In the aged 4-month cohort there was evidence of increased eNOS expression in hypertensive animals (F, I), 






Young 4-month cohort Young 6-month cohort Aged 4-month cohort 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
11.0 11.0 5.0 8 8 13.5 
11.0 8.0 8.0 14 10.5 12.5 
12.2 7.0 6.0 10 10.5 9 
8.0 11.0 8.0 8 8 12.5 
6.0 11.0 9.8 11 10 16.5 
10.0 16.0 12.0 5 7 9 
8.0 13.0 9.0 8 11 10.5 
8.0 9.0 9.0 8 11 12 
8.0 13.0 12.0 11 10 13 
11.0 16.0 11.0   11.5 
5.0 8.0 3.0   18 
6.0 13.0 13.0    
 15.0 6.0    
 9.0     
 12.1     
 7.0     
 
Table 3.7: Number of vessels positive for eNOS within the subcortex for each cohort 
The table above shows raw count data for the total number of vessels positively stained for antibody specific for eNOS within the 




3.3.6. Microglia were commonly associated with the vasculature in hypertensive 
animals 
Iba1 a marker of microglia activation was used to investigate whether there 
were alterations in the inflammatory response with hypertension. Overall, there was 
evidence that hypertension caused vascular inflammation in the vessels of the young 
6-month and the aged 4-month cohort. Microglia were observed to have a distinct 
cell body with surrounding processes and those found to be in association with the 
vasculature were counted. In the young 4-month cohort, there was no evidence that 
microglial cells were associated with the vasculature in any of the normotensive and 
hypertensive animals examined (Figure 3.6 A,D). In the young 6-month cohort, 
microglial cells were found to be closely associated with the vasculature in 9 out of 9 
hypertensive animals, which was significantly different as compared to 2 out of 13 
normotensive animals (p<0.01, Figure 3.6 B, E). Similarly, in the aged 4-month 
cohort, microglia were significantly associated with the vasculature of 11 out of 11 
hypertensive animals, compared to 3 out of 9 normotensive animals (p<0.01, Figure 
3.6 C, F). Additionally, as fully discussed in the chapter 5 the numbers of Iba1 
positive microglia were counted and found to be significantly increased in the 
subcortex of hypertensive animals from the young 6-month (|t|= 2.88, df=21, p<0.01: 
Figure 5.9H) and aged 4-month cohort (|t|= 2.70, df=18, p=0.01: Figure 5.10H) but 
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Figure 3.6: Assessment of microglia  
Representative images of the microglial association with the vasculature, stained 
with microglial antibody IBA1 (brown) and vasculature counterstained with periodic 
acid schiffs reagent,  in normotensive (A, B, C) and hypertensive (D, E, F) animals 
from each cohort. There was no evidence of microglia associated with the 
vasculature of normotensive (A) and hypertensive (D) animals of the young 4-month 
cohort. In the young 6-month cohort microglia were located in close association and 
contacting the vasculature of hypertensive animals (E), which was significantly 
different when compared to normotensive (B). The same was observed in the aged 4-
month cohort, with a significant number of microglia associated with the vasculature 




 3.3.7. Vascular protein levels  
3.3.7.1. Hypertension did not alter vascular protein levels  
Within this study, hypertensive animals from the young 6-month cohort 
provided evidence of structural alterations to multiple components of the vasculature. 
To investigate whether these alterations were accompanied by changes to protein 
levels throughout the brain, western blot analysis of a vessel enriched homogenate 
was carried out.  
3.3.7.2. Smooth muscle actin  
There was no evidence of structural alterations in smooth muscle actin in any 
of the cohorts examined previously. Similar results were found with protein 
expression, with no significant difference in the protein levels of smooth muscle 
actin in hypertensive animals compared to normotensive (|t|= 0.07, df=13, p= 0.94., 
Figure 3.7). 
3.3.7.3. Endothelial blood-brain barrier 
PECAM is located on endothelial cells and can be upregulated with 
endothelial proliferation or during periods of inflammation (Williams et al., 1996).  
There was no significant difference in protein levels of PECAM in hypertensive 
animals when compared to normotensive (|t|= 0.45, df=13, p= 0.66., Figure 3.7). 
Since the structural alterations were found in endothelial tight junction 
protein expression in hypertensive animals, the protein levels of claudin-5 and ZO-1 
were assessed. No significant difference in protein levels of claudin-5 (|t|= 0.32, 
df=13, p= 0.76., Figure 3.7) or ZO-1 (|t|= 0.52, df=13, p=0.61., Figure 3.7) were 
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Figure 3.7: Assessment of vascular protein levels 
Protein levels of vascular components were unaltered in hypertensive (HT) animals 
from the young 6-month cohort when compared to normotensive (NT). Western 
blotting for ZO-1 (A), Pecam (B), α-smooth muscle actin (C) and Claudin-5 (D) 
showed no significant difference in protein level between normotensive and 





3.4. Discussion  
Previous evidence has indicated that hypertension is associated with 
structural alterations to the cerebrovasculature in humans and animal models. 
However, due to discrepancies in the ability to model hypertension in isolation, 
without confounding factors, the exact mechanisms are unknown. The present study 
sought to investigate hypertension induced alterations to the cerebrovasculature in 
the brains of three separate cohorts; the young 4-month cohort, the young 6-month 
cohort and the aged 4-month cohort, within the subcortex, a region commonly 
affected by hypertension in humans. The key findings of this study were that 
hypertension caused subcortical vascular alterations associated with endothelial 
changes and an inflammatory response, which were observed in the young and aged 
brain. Overall, the findings within this study are suggestive that hypertension, when 
modelled in a controlled sustained fashion with the use of genetically matched 
controls, does lead to alterations in the structure of the cerebrovasculature, 
particularly endothelial related, albeit relatively subtle.  
3.4.1. Blood pressure in the Cyp1a1 Ren2 rat model 
Dietary induced hypertension by the addition of I3C was found to cause a 
sustained and gradual increase in systolic blood pressure levels of animals fed an I3C 
inclusive diet, in each of the cohorts studied. The cohorts were analysed separately, 
as although similar methodology of dietary induction was used, they were carried out 
at different times, in different animals units and ran as three distinct cohorts. 
However, it does need to be discussed that within the aged cohort around week 8 
there is a sudden increase in blood pressure of both animals fed a control diet and 




technical fault within the animal unit, in which the air conditioning unit broke one 
evening and the animals were immediately rehoused. The animals were extensively 
examined by the vet and they were all observed to have consumed their diet as 
normal, but this event appeared to cause a period of distress, which is reflected 
within their blood pressure recordings for that period. In general, the level of blood 
pressure generated was comparable to previous studies in this model (Huang et al., 
2012; Mitchell et al., 2006). However, the profile of blood pressure is different from 
that of the commonly used models; the SHR (Okamoto and Aoki, 1963) and SHRSP 
(Okamoto, 1974; Yamori and Horie, 1977), which have been found to evoke 
increased blood pressure in a sudden, spontaneous manner, with the latter model 
causing elevations in blood pressure equivalent to that in malignant hypertension. 
The advantage of raising blood pressure in a gradual manner, (as in the Cyp1a1 Ren2 
rat), is that it is representative of how hypertension develops in humans. In turn, the 
controllable nature of the severity of blood pressure in this model ensures that 
hypertension, rather than malignant hypertension is modelled. Commonly 
hypertension is referred to as the ‘silent’ killer, as many people are un-aware they are 
hypertensive, therefore modelling hypertension of a lower severity would allow the 
deduction of several mechanisms more indicative of the general population, which 
may have been missed in other models and may contribute to its role as a risk factor 
for the gradual developing neurodegenerative conditions (Stevens, 2008). Another 
advantage is that the increased blood pressure in this model can be directly compared 
to genetically matched, litter-mate controls, making pathological observations 




consequences of hypertension on the vascular alterations could then be studied and 
compared to normotensive controls.  
3.4.2. Hypertension induced alterations to the cerebrovasculature 
The present study investigated the structural integrity of the 
cerebrovasculature, examining basement membrane specific protein, collagen IV. 
For each antibody examined within this thesis a blank slide (which received the same 
immunohistochemical treatment apart from primary antibody) was contained within 
each run of immunohistochemical staining to ensure that specific staining was not 
attributed to background. There was no evidence of overt structural alterations to the 
cerebrovasculature in the young 4-month cohort, indicating that this duration of 
hypertension is not sufficient to induce vascular remodelling. However, with 
increased duration of hypertension in the young 6-month cohort, the vasculature was 
found to be markedly reduced in width in hypertensive animals only, with the vessels 
observed to be string-like in morphology. Even though the vessels were thinner, this 
was not accompanied by any alterations in the density of collagen IV. In addition, 
these morphological differences were not found in any of the normotensive controls 
within the young 6- month cohort. In the present study, the finding that hypertension 
did not alter vascular density of collagen IV is in agreement with 
immunohistochemical studies in the SHRs and SHRSPs (Bailey et al., 2011; Lin et 
al., 2001). On the other hand, there is evidence of increased density of collagen IV in 
6 month old SHRSPs (Liebetrau et al., 2005), which cannot be exclusively attributed 
to hypertension as this is an age when SHRSPs commonly develop stroke like 
symptoms (Tagami et al., 1987; Yamori and Horie, 1977). However, the present 




young 6-month cohort and this is not in agreement with findings in either the SHR 
(Knox et al., 1980; Nordborg and Johansson, 1980; Sabbatini et al., 2001) or SHRSP  
(Fredriksson et al., 1985; Tagami et al., 1987) models, which have shown evidence 
of basement membrane thickening, luminal narrowing and collagen deposition. 
Nonetheless, vascular remodelling has been found to occur in SHRs and SHRSPs as 
young as 15 days old, prior to the development of hypertension (Nordborg and 
Johansson, 1980; Okamoto, 1974). In addition, vascular remodelling in the SHRSPs 
has also been found shortly after the development of hypertension, with evidence 
indicating the SHRSPs may have constitutively smaller vessels than their WKY 
normotensive controls (Mies et al., 1999; Zanchi et al., 1997). In turn, a recent study 
carried out to examine vascular integrity in 10 month old stroke free SHRSPs found 
no evidence of small vessel vasculopathies, thus it is unclear whether vascular 
alterations documented in the SHRSPs are solely due to hypertension or due to stroke 
(Brittain et al., 2012).  
In the present study, the lack of alterations to vascular structure with the 
shorter duration of hypertension indicates that this model does not have a 
predisposition for vascular remodelling, and that alterations with increased duration 
are indicative of the type of hypertension induced.  The morphological alterations 
found in the young 6-month hypertensive animals may represent aberrant 
vasoconstriction with hypertension, a concept induced by Folkow et al., who 
proposed that chronic hypertension would lead to increased vascular resistance 
caused by an aberrant vasoconstrictive response leading to a form of vascular 
remodelling known as eutrophic (Folkow et al., 1958): when the outer and lumen 









Angiotension II infusion (ANGII) mouse models of hypertension, which induced 
hypertension, similar to our model, by targeting the RAAS (Baumbach et al., 2003; 
Moreau et al., 1997) and this form of remodelling has been observed peripherally in 
our model (Kantachuvesiri et al., 2001).  In the present study initial mechanisms 
underlying decreased vessel size could be due to alterations in myogenic tone (Davis 
and Hill, 1999) resulting from increased pressure and may represent endothelial 
dysfunction. In turn, modelling acute hypertension has also been shown to induce an 
aberrant vasoconstrictive response, due to altered sympathetic nervous system 
activation (Tamaki and Heistad, 1986). Although in the present study, the functional 
consequences of these morphological alterations to the vasculature are not yet 
known, it could be proposed that they may lead to alterations in vascular resistance, 
blood flow and energy supply. However, it needs to be said, one limitation of the 
present study is that cerebral blood flow in response to hypertension was not 
measured. Even though one would postulate that the morphological alterations of 
string like vessels would decrease blood flow within the subcortex, this has not been 
measured and remains unknown. In turn, it is unknown how these morphological 
alterations would have impacted on the integrity of the vessels in the form of BBB 
leakiness. The only conclusion which can be gleaned from the present study is that 
hypertension in the young brain leads to structural alterations to the 
cerebrovasculature and how this impacts on the gross structural integrity of the brain 
is examined later within this thesis.   
In addition the present study also examined the effect of hypertension on the 




comparable to middle age in humans. The present study found that hypertension in 
the aged brain leads to increased vascular density and number of vessels, in absence 
of the string-like vessels found previously. In general, there is limited data in aging 
animal models of hypertension but our findings are in disagreement with a study in 
9-16 month old SHRs finding evidence of reductions in arteriolar end point density 
and surface anastomic connections, indicative of decreased vascular density 
compared to WKY (Hutchins et al., 1996). The reason for the disagreement could be 
due to the duration of hypertension being far longer in the SHR model than the 
duration induced in ours, as in the present study the animals were allowed to age 
naturally and induced to become hypertensive in adulthood. However, the present 
data is in agreement with findings in the young SHR brain with studies reporting 
increased numbers of vessels (Gesztelyi et al., 1993; Lin et al., 1990; Ritz et al., 
2009), but these alterations have also been found in prehypertensive animals, making 
data concerning number of vessel in relation to hypertension difficult to interpret in 
the SHR model. In addition, it does need to be highlighted that there appears to be an 
overall decreased vascular density in both the normotensive and hypertensive aged 
animals compared to the young. Unfortunately, as the three cohorts were run distinct 
to each other with many conflicting factors the cohorts cannot be statistically 
compared. It is unknown if there is a difference in antibody penetration as the tissue 
from the aged cohort was processed in a different facility. These studies were carried 
out as initial characterisation studies to investigate the overall effect of hypertension 
on the structural integrity of the brain, future studies would need to be set up with the 




In the present study the increased number of vessels in the aged brain may be 
a response to hypoxia, as previous studies modelling ischemia/hypoxia have shown 
an angiogenic response with an increased number of vessels, specifically within the 
thalamus (Hayward et al., 2011). Additionally, individuals with various forms of 
dementia have been found to have an increased expression of angiogenic growth 
factors (Tarkowski et al., 2002). However, the present study did not address regional 
atrophy of the brain in response to hypertension, which may lead to an over-
representation of the number of vessels, but work carried out by Dr P Holland in 
these animals found no evidence of regional atrophy using T2 MRI (P Holland et al., 
in preparation, Appendix I). Studies carried out in aged Fischer F344 animals have 
reported brain atrophy at 24 months of age (Hajdu et al., 1990) and studies in the 
SHR model have reported that hypertension can induce atrophy in the young brain 
(Tajima et al., 1993).  Nonetheless, these previous findings have assessed atrophy in 
post-fixed tissue. The fixing of tissue brain tissue can lead to shrinkage, therefore, a 
true indication of atrophy would need to be assessed using in-vivo imaging (Stowell, 
1941).  Moreover, the findings in the present study indicate that age in combination 
with hypertension exacerbates the effects of hypertension, as there was no evidence 
of vascular alterations in the young cohort, modelled for a similar duration of 
hypertension.  
One limitation of the present study, is that only one component of the 
basement membrane was measured. The basement membrane, is a key component of 
the vasculature, providing both structural support and a substrate for cellular 
interactions (Perlmutter and Chui, 1990; Schwarzbauer, 1999). Collagen IV is highly 




1990), forming the structural backbone onto which other components bind 
(Schwarzbauer, 1999). This endows the structure of collagen IV crucial for the 
function and maintenance of the basement membrane (Poschl et al., 2004), an 
intermediate layer juxtaposed to astrocytic end-feet and endothelial cells, whose 
structural alterations can impair connections between communicating cells (Farkas et 
al., 2001).Therefore, in the present study it is unknown if there is deposition of other 
components i.e., laminin or fibronectin but, as collagen IV is the most abundant and 
forms the backbone of the basement membrane, any overt morphological alterations 
would likely be mimicked by other components to which it anchors, or one would 
expect to have evidence of separation of the basal lamina, which was not observed 
with collagen IV staining in any of the animals, in any of the cohorts. Additionally 
the 2A subunit of Collagen IV was examined as this has been found to be commonly 
affected in adults with small vessel disease (Dichgans and Hegele, 2007). 
  Overall, these studies have provided evidence of hypertension induced subtle 
structural alterations to the vasculature, which may lead to alterations in CBF within 
the subcortical thalamic region of the brain. These vascular alterations may impair 
vascular function within this region, leading to alterations between cortical-
subcortical regions of the brain and may lead to alterations to the overall structural 
integrity of the brain, including the WM, which is sensitive to alterations in blood 
flow. The present study represents alterations to the general structural integrity of the 
vasculature in the young and aged brain without discrimination between different 





3.4.3. Hypertension does not induce structural alterations to the large arteries and 
arterioles  
 
To follow on from the assessment of the basement membranes, alterations in 
the large arteries and arterioles were examined. Smooth muscle actin was used to 
define these vessels as it is absent in small arterioles and capillaries (Drake and 
Iadecola, 2007). Overall, the present study found that hypertension did not alter the 
density of smooth muscle actin, suggestive of no overt vascular remodelling in larger 
arteries and arterioles. These findings were also confirmed with no evidence of 
alterations in smooth muscle actin protein levels (Figure 3.7). The findings in the 
present study are in disagreement with both the SHR (Knox et al., 1980) and SHRSP 
(Bailey et al., 2011; Lin et al., 2001) models providing evidence of smooth 
hypertrophy at around 3 months and 12-16 weeks respectively. As described 
previously, it is unclear as to whether these results in the SHRs and SHRSPs are 
exclusively due to hypertension, as the large arteries in particular, of both SHRs 
(Nordborg and Johansson, 1980) and SHRSPs (Johansson, 1984; Zanchi et al., 1997) 
show remodelling as young as 15 days. Alternatively, the level and method of 
inducing hypertension in the present study may not be a sufficient insult to alter the 
smooth muscle layers and it remains to be said that only a crude investigation of the 
large arteries and arterioles was carried out. However, the findings are suggestive 
that hypertension in our model, targets the smaller vasculature of the brain. This is in 
agreement with previous findings in the SHR model, which shows vascular 
remodelling occurs more often in small arterioles and capillaries than the large 
arteries and arterioles proposed to be more susceptible due to a lack of anatosomes 




3.4.4.1. Hypertension induced alterations to the endothelial blood-brain barrier   
 
To determine whether alterations in the vasculature may be accompanied by 
BBB changes the integrity of the endothelial BBB was investigated by examining the 
integrity of tight junction protein claudin-5. It was found that hypertension did not 
induce alterations in claudin-5 expression, in the young 4-month cohort, in the 
absence of alterations to cerebrovascular structure. Interestingly, in the young 6-
month cohort at a duration when the vascular structure was altered, hypertension 
caused an increased expression of claudin-5 in absence of alterations to the 
expression of claudin-5 tethering protein ZO-1 (Figure 3.7). In addition, there was no 
evidence of alterations to protein levels of either claudin-5 or ZO-1 (Appendix B.1). 
This may represent a redistribution of claudin-5 rather than a change in protein 
levels, due to the alterations in vascular structure, leading to a clustering of tight 
junctional strands, similar to the SHRSPs showing a redistribution of endothelial 
tight junctional proteins associated with a loss in endothelial polarity (Lippoldt et al., 
2000). There is also evidence in the SHRSPs that there is a decrease in claudin-5 
levels prior to hypertension, which may predispose them to endothelial BBB 
alterations (Bailey et al., 2011). However, findings in the SHRs are dissimilar from 
ours showing no evidence of alterations in tight junction proteins: ZO-1, occludin 
and claudin-5 with hypertension alone and the combined insult of hypertension with 
MCAO (Hom et al., 2007b).   
It was hypothesized that in the ageing brain alterations in the BBB would be 
exacerbated with hypertension, but the present study did not find evidence of 




normotensive controls. The lack of alterations in Claudin-5 expression observed in 
the aged brain may indicate that this severity of hypertension is not sufficient to 
cause alterations, in agreement with the SHR literature described above (Hom et al., 
2007a) and that these alterations observed in the young 6-month cohort may be a 
response to alterations in vascular structure.  
Taken together the results in the inducible transgenic rat model suggest that 
the BBB is modestly altered after a prolonged period of hypertension and in 
association with morphological vascular alterations. The function of the endothelial 
BBB is critical, limiting the flow of harmful stimuli into the brain. A link between 
endothelial dysfunction, BBB disruption and vascular inflammation has been 
proposed (Saavedra et al., 2011; Wolburg and Lippoldt, 2002; Yenari and Han, 
2006).  In turn, alterations to intracellular ionic concentrations have also been 
associated with alterations to the structure of the endothelial BBB (Huber et al., 
2001; Wolburg and Lippoldt, 2002). The tight junctional protein claudin-5 was 
chosen in the present study as evidence has shown that claudin-5 is integral to the 
formation of the endothelial BBB. The findings within the study may be a response 
of the vasculature to sheer stress, since tight junctional proteins have been observed 
to redistribute and cluster during periods of sheer stress, strengthening the BBB 
(DeMaio et al., 2001; Yoshida et al., 1995). In turn, the increased expression of 
inflammatory molecules such as Interleukin-1, which can be released from microglia 
have been found to cause a de-polymerisation of the cytoskeleton leading to a 
redistribution of tight junctional proteins (Eisenhut and Wallace, 2011). However, it 
cannot be excluded that morphological alterations to vascular structure are not a 




defined, it can be postulated that these alterations in claudin-5 expression may impair 
transcellular flow and could even prevent the entry of nutrients into the brain or 
impair the removal of harmful stimuli. 
A limitation of the present study is that it did not measure whether these 
alterations to endothelial BBB structure caused BBB leakage. Using different 
approaches such as horse radish peroxides, the BBB has been found to be impaired in 
both the SHR and SHRSP models. However, BBB leakage is not found in every 
vessel and is proportional to the severity of hypertension evoked, being more readily 
observed in malignant hypertension. Notably, the level of hypertension induced in 
this inducible model is a lower severity of the SHRs (Knox et al., 1980; Ueno et al., 
2004a; Ueno et al., 2004b) and SHRSPs (Fredriksson et al., 1985; Fredriksson et al., 
1987; Fredriksson et al., 1988), therefore this overt BBB leakage may not be 
expected. Another limitation of this study is that it only examined one tight junction 
protein. Although, claudin-5 is imperative for the formation of the endothelial BBB it 
is unknown what effect alterations to other components of the BBB may have in this 
study. Nonetheless, the pathological effect of these alterations is investigated in the 
following experiment, examining endothelial signalling and vascular related 
inflammatory response.   
3.4.5. Hypertension induced alterations to endothelial signalling 
 
Previous experiments in the present study had provided evidence of 
morphological alterations to vascular structure and evidence of endothelial BBB 
alterations. Due to links between disruption of endothelial signalling and vascular 




of the endothelial enzyme, eNOS, crucial for the production of vasodilatory NO. 
ENOS expression was analysed by counting the number of vessels, which were 
immunopositive for the eNOS antibody. Interestingly, eNOS was found to be 
increased in vessels of hypertensive animals from the young 4-month cohort in 
absence of any structural alterations. However, there was no difference in eNOS 
expression between normotensive and hypertensive animals in the young 6-month 
cohort. The data suggests alterations in endothelial signalling may precede alterations 
in vascular structure in the young brain. In agreement with the present findings, 
global investigation of eNOS expression has been found to be decreased in SHRs and 
SHRSPs, shortly prior to vascular remodelling, with a more severe decrease during 
malignant hypertension in the SHRSP model (Chou et al., 1998; Hojná et al., 2007; 
Jesmin et al., 2007). Nonetheless, there has been evidence of increased eNOS 
expression in regions of the brain crucial for blood pressure control, linking eNOS to 
the maintenance of hypertension (Paton et al., 2007a).  Overall previous studies 
demonstrate that the activity of eNOS is dependent on the region of the brain and 
also severity of hypertension induced. However, the SHR and SHRSP data is 
difficult to interpret, as the WKY normotensive control strain has been found to 
exhibit decreased expression of eNOS with age (Chou et al., 1998). 
The present study also examined eNOS expression in the aged 4-month 
cohort and found that hypertensive animals had increased number of vessels 
positively expressing eNOS when compared to normotensive controls. Unlike the 
young brain this increased eNOS expression with hypertension is accompanied by an 
increase in vascular density. The exact cause for the increased number of vessels is 




(Bouloumie et al., 1999; Drummond et al., 2000; Förstermann, 2010). VEGF not 
only increases eNOS production but can cause an increased vascular permeability 
and release of proinflammatory mediators, prior to endothelial proliferation and 
angiogenic response (Croll et al., 2004).  Therefore the increased expression of 
eNOS in the aged brain coinciding with subtle vascular alterations may represent the 
eNOS pathway as an important pathway early in hypertensive related alterations..  
However, the present study did not investigate the number of vessels with age 
alone. It is possible that increased eNOS expression with hypertension in the aged 
brain is functioning to prevent loss of vessels. Studies have shown that eNOS and the 
generation of NO prevents apoptosis (Burger et al., 2006; Dimmeler et al., 1999). 
Therefore, the aged normotensive animals may have a loss of vasculature density, 
which increased eNOS expression is preventing. 
All in all, the present study highlights alterations in endothelial signalling as 
an initial mechanism of hypertension in the brain. Endothelial function is crucial for 
providing energy to the brain, allowing the appropriate entry on ions and preventing 
the entry of harmful stimuli, by correct signal transduction between the blood and 
brain. Increased blood pressure, alterations in blood flow, sheer stress and oxidative 
stress promote the release of eNOS (Paravicini and Touyz, 2006; Sase and Michel, 
1997; Zhang et al., 2006). Hypertension has been associated with dysfunction of 
endothelial signalling, leading to the production of ROS and inflammation 
(Endemann and Schiffrin, 2004). In turn, alterations in endothelial signalling have 
been linked to an aberrant vasoconstrictive response, which could lead to altered ion 
channel function, recruitment of inflammatory cells and production of ROS 




could be postulated that in the present study, increased blood pressure activates a 
signalling cascade promoting the endothelium to release eNOS, in an aim to lower 
blood pressure, reduce the possibility of sheer stress and alterations in blood flow, in 
both the young and aged brain. With increased duration of hypertension, the 
vasculature undergoes morphological alterations and eNOS expression is dampened, 
which may be representative of endothelial dysfunction. None the less, it is crucial to 
highlight that this model induces hypertension through an increase in peripheral 
RAAS system, which leads to the increased expression of a well-known hypertension 
related culprit Angiotension II. It is not clear whether Angiotensin II crosses the 
BBB in this model, but studies have found Angiotensin II to stimulate the production 
of eNOS (Paton et al., 2008). Since eNOS is not constitutionally increased in this 
model, the alterations observed cannot be exclusively due to model specific induced 
Angiotensin II levels and are more likely due to hypertensive induced mechanisms.   
Studies have shown that activation of the endothelium and astrocytes leads to 




which can lead to alterations in endothelial 
signalling pathways, causing phosphorylation of the cytoskeleton and opening of 
tight junctions (Huber et al., 2001; Wolburg and Lippoldt, 2002). Alterations in ionic 
influx could lead to an increased inflammatory response, through Ca
2+
 signalling. In 
turn, increase intracellular Ca
2+ 
has traditionally been associated with vasodilation, 
but can also lead to vasoconstriction during periods of decreased K
+
 channel activity 
(Filosa et al., 2004) (Mulligan and MacVicar, 2004). Even though the cause and 
consequence of these alterations in endothelial signalling is not fully known, the 




prior to cerebrovascular remodelling and a possible therapeutic window of 
intervention. 
3.4.6. Alterations in vascular structure are associated with increased inflammatory 
response 
 
Microglia are recognised to be sensitive to changes in the brain/cellular 
homeostasis, thus this study sought to determined whether localised changes in 
microglia may accompany vascular alterations by examining the association of 
microglia with the vasculature. In support of this, whilst no changes were observed in 
the young 4-month hypertensive animals, increased microglia were observed to be 
localised to the vasculature of hypertensive animals from the young 6-month cohort. 
Not only was there evidence of increased numbers of microglia associated with the 
vasculature, they were subsequently found to be increased in number within the 
region as a whole, when compared to normotensive animals. Additionally the 
location of microglia was also examined in the aged brain, finding that hypertensive 
animals from the aged 4-month cohort had increased number of microglia associated 
with vasculature and similar to the young 6-month cohort, there were significantly 
increased numbers of microglial within the region as a whole, when compared to 
normotensive animals. The findings in present study are in agreement with early 
histological studies in both the SHR and SHRSP, providing evidence of increased 
numbers of perivascular microglia and macrophages surrounding remodelled 
vasculature (Hazama et al., 1975; Knox et al., 1980). In parallel, an increased 
expression of other pro-inflammatory markers such as JAM-1 and an increased 
number of leukocytes have been found in the SHR models, prior to the development 




evidence that vascular inflammation plays a role in the development of hypertension 
in the SHR model. Collectively, evidence from the SHR and SHRSP models 
suggests that the severity of hypertension is a key factor in vascular inflammation. 
Comparison of alterations between the SHR and SHRSP models have found that 
although there is evidence of vascular inflammation in the SHR model, this is far less 
severe when compared to age matched SHRSPs (Lin et al., 2001).  
The present study provides evidence that vascular inflammation occurs with 
increased severity of hypertension in association with vascular remodelling. 
Microglia were examined as they are the brain’s resident innate immune cell, which 
are extremely sensitive to alterations in their microenvironment (Ransohoff and 
Perry, 2009). These cells are continually active, scanning the brain for alterations to 
their environment and are able to promote proliferation, migration and phagocytosis 
in other microglial cells, in response to alterations (Davalos et al., 2005; Nimmerjahn 
et al., 2005). However, during injury the increased expression of microglia can be 
both neuroprotective, due to the removal of harmful material and also 
neurodegenerative, due to the release of pro-inflammatory mediators (Meda et al., 
1995; Tan et al., 1999).  
The recruitment of microglial cells can be stimulated by glia-vascular Ca
2+
 
signalling, though astrocytes, which due to their position receive signals from 
neurons and blood vessels. Evidence has shown that during endothelial and 
astrocytic activation there is an increase in intracellular Ca
2+
 concentration, which 
can promote alterations to endothelial signalling, phosphorylation of the cytoskeleton 
and opening of the endothelial BBB (Huber et al., 2001; Wolburg and Lippoldt, 




production of ROS, which themselves can release factors, promoting 
vasoconstriction but can also lead to increased inflammatory signalling and thus 
recruitment of inflammatory cells (Paton et al., 2006; Vanhoutte, 2009). Moreover, 
the increased numbers of microglia may themselves lead to alterations to vascular 
structure by the production of TNFα, which can lead to increased expression of 
prostaglandin E2 (Engblom et al., 2002; Schiltz and Sawchenko, 2003) and aberrant 
vasoconstriction (Vanhoutte, 2009), as found in the young 6-month cohort. 
Conversely, the recruitment of microglia in the present study may be due to 
alterations of intracellular ions, paracellular flow or nutrient supply to the brain, as a 
result of vascular structural alterations. Thus, the present study indicates that 
hypertension in the inducible model provides evidence of a link between alterations 
in endothelial signalling, vascular remodelling and inflammation. 
 Limitations of the present study are that only one inflammatory marker was 
used to examine microglia. In turn, the study did not take into account other 
inflammatory cells such as leukocytes, which have been found to be highly 
upregulated in the SHRSPs (Takemori et al., 2000), but chose to examine microglia 
as a cellular component of the neurovascular unit. In general, the present study 
provides a link between alterations in endothelial signalling, vascular remodelling 
and inflammation in the young and aged brain. The exact aetiology and function of 
increased microglia in the brain is unclear in the present study but provides a crucial 
therapeutic target and also an appropriate intervention period. It has been shown in 
previous animal studies that anti-hypertensive treatment, which decreases the 
inflammatory response prevents vascular remodelling when compared to non-treated 




treatment in the brain is related to how strongly they cross the endothelial BBB.  The 
present study highlights the importance of endothelial signalling and vascular 
inflammations and identifies possible therapeutic potential.  
3.4.7. Hypertension induced structural alterations to the vasculature without 
alterations to protein levels 
 
The present study found alterations to the structural integrity of the 
cerebrovasculature, but it is unknown if these changes are due to cellular re-
organisation or alterations to protein levels. To investigate the link between structural 
alterations and protein levels, a vessel enriched homogenate was used to investigate 
the levels of several vascular proteins including, smooth muscle actin, endothelial 
specific PECAM, claudin-5 and ZO-1 in the young 6-month cohort, which had 
previously been shown to have several vascular alterations. It was found that there 
was no evidence of alterations in protein levels in any of the proteins examined. 
These findings are in agreement with previous findings in the SHR model, which 
found no alteration in the protein expression of actin, ZO-1 and claudin-5 using 
western blot method for identification (Hom et al., 2007a). However, these findings 
may be in part due to the detection method, with western blot being a semi-
quantitative method requiring a difference of more than 10% to reveal a significant 
difference. In house within the lab, liquid chromatography- mass spectrometry (LC-
MS) was used as a more sensitive approach; however this required a vessel enriched 
homogenate from the whole brain and still revealed small levels of the endothelial 
BBB proteins. In turn, another method which could have been used would have been 




to investigate vascular proteins only allow the detection of one protein at a time, 
meaning the use of a large volume of sample per marker. Overall, the findings in this 
study indicate that hypertension leads to structural cellular reorganisation or a 
redistribution but does not cause overt alterations in protein expression. 
 
3.4.8. Summary of vascular alterations 
Overall, the present study provided evidence that hypertension in isolation 
leads to alterations in vascular structure, endothelial signalling and an inflammatory 
response. These changes occurred at levels of blood pressure more akin to humans 
prior to the development of malignant hypertension. From the present study it would 
appear that alterations in endothelial signalling are the initiating factor leading to 
structural and inflammatory alterations.  As in humans, there is also evidence that the 
effects of hypertension are present within the aged brain. This study whilst providing 
a basis to show structural changes in the vasculature, in response to modest 
hypertension associated with localised cellular response has several limitations 
(discussed previously), of these the mechanism leading to these changes remain to be 
explored. In the next chapter alterations in gene expression in response to 
hypertension will be investigated as a means to probe alterations in functional 







4. The effect of hypertension on gene expression and functional gene pathways  
4.1. Introduction  
In humans, the majority of studies examining alterations in gene expression 
have focused on genes that may predispose individuals to hypertension, rather than 
those altered in response to hypertension. Generally, studies have found that 
hypertensive individuals have altered gene expression within the RAAS pathway, ion 
transport and endothelial NO signalling pathways (Levy et al., 2009; Salvi et al., 
2012). Recent improvements in microarray technology have allowed gene expression 
studies in animals to be more robust and accessible. Although still within their 
infancy, to date studies in the SHR and SHRSP models have generally found 
alterations in the expression of genes concerning vascular inflammation, endothelial, 
lipid metabolism, oxidative stress, ischemic response, and novel vascular specific 
genes (Iwanaga et al., 2008; Qiu et al., 2010; Ritz et al., 2012; Waki et al., 2008). 




Hypertension will lead to alterations in gene expression in particular those 
related to vascular remodelling, endothelial signalling and inflammation.   
4.1.3. Aims 
 
The present study aimed to investigate whether hypertension leads to 
alterations in gene expression and functional pathways, with a particular interest in 




collagen, endothelial signalling and inflammation and also any genes differentially 
expressed related to I3C. 
4.2. Methods 
4.2.1. Animals 
Experiments were conducted on Cyp1a1 Ren2 transgenic rats processed as 
described in chapter 2.3.  This studied examine gene expression in the same animals 
from the young 6-month cohort (control diet, no I3C, n=8) and hypertensive (0.15% 
I3C, n=8), which were used for the vascular protein levels experiments (Chapter 3). 
Briefly, these animals were run as part of the young 6-month cohort and were saline 
perfused, the brains snap frozen and then stored at -80˚C until they were processed 
for microarray analysis. 
4.2.2. RNA extraction 
RNA was extracted from a subcortical dissection (-3.14mm to -5.15mm from 
Bregma), inclusive of both grey and white matter regions (Paxinos and Watson, 
1998)) using Trizol protocol according to manufacturer’s instructions (Invitrogen, 
Paisley, UK), as covered in detail in chapter 2.3.3. 
4.2.3. Microarray analysis  
Microarray RNA was collected from 8 animals per group. Samples were 
hybridized to Affymetrix Genechip rat gene 1.1 array representing >27 000 genes, 
using Gene Titan multi-channel instrument carried out by Alison Downing as 




Genomic data was analysed by myself with assistance from Alison Downing 
when needed and was analysed by ANOVA with significance set at p<0.005. 
Pathway analysis was carried out using Ingenuity software on differentially 
expressed genes at a significance of p<0.01.  
4.3. Results 
4.3.1. Hypertension induced significant alterations in gene pathways of cell 
morphology, development, nervous system development and function 
 
 Microarray analysis was undertaken in animals from the young 6-month 
cohort to investigate alterations in gene expression, in response to hypertensive 
induced vascular alterations. Of the 27 000 genes investigated, 48 were differentially 
expressed, with 23 upregulated and 25 downregulated (Table 4.1), in hypertensive 
animals compared to normotensive (p<0.005). To provide evidence of biological 
functions, pathway analysis was carried out on 109 genes, differentially expressed at 
a less conservative significance of p<0.01. There was evidence of alterations to 4 
functional pathways, which were ranked by their significance (Figure 4.1). The most 
significant was pathway 1; cellular morphology, development, nervous system 
development and function (score 44, Figure 4.2). Followed by pathway 2; lipid 
metabolism, molecular transport, small molecules biochemistry (score 20, Appendix 
B.1), pathway 3; organ development and morphology (score 19, Appendix B.2) and 
pathway 4; cell morphology, function and maintenance (score 15, Appendix B.3). 
Overall, hypertension induced alterations in many growth factor genes; including 




Insulin like growth factors (IGFs), and also Collagen IV, ion channels and 
















Upregulated genes at p<0.005 
Gene Assignment p-value (x10
3
) Fold change (normotensive vs. hypertensive) 
- unannotated  0.249 1.103 
- unannotated  0.277 1.291 
- unannotated  0.315 1.155 
- unannotated  0.319 1.123 
Sox12 
SRY (sex determining region Y)- box 
12  0.725 
1.097 
Tbc1d10a TBC1 domain family, member 10a 0.918 1.154 
Prss53 Protease, serine 53 1.391 1.112 
Zbtb3 
Zinc finger and BTB domain 
containing 3  1.429 
1.136 
- Unannotated 1.912 1.200 
Nfkbia 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor 1.977 
1.384 
Usp21 Ubiquitin specific peptidase 21  2.022 1.072 
Prdm4 PR domain containing 4 2.127 1.056 
Nmnat3 
Nicotinamide nucleotide 
adenylytransferase 3  2.339 
1.096 
RGD1309036 Hypothetical LOC292874 2.419 1.158 






Similar to coated vesicle membrane 
protein  3.100 
1.114 
RGD1566359 
Similar to RIKEN cDNA 
B230219D22 3.159 
1.168 
Col4a2 Collagen, type IV, alpha 2 3.331 1.135 
- unannotated  3.660 1.130 




- unannotated  4.053 1.205 
RGD1560880 Similar to RIKEN cDNA 2310002J15 4.671 1.196 
Downregulated genes at p<0.005 
Gene Assignment p-value (x10
3
) Fold change (normotensive vs. hypertensive) 
Rpe65 Retinal pigment epithelium 65  0.335 -1.274 
Cetn4 Centrin 4 0.545 -1.070 
Ctsr Cathepsin R 0.944 -1.152 
Paip2 
Poly (A) binding protein interacting 




serine/threonine kinase family  1.101 
-1.172 
Lifr 
Leukemia inhibitory factor receptor 
alpha 1.146 
-1.089 
Ccdc59 Coiled-coil domain containing 59  1.561 -1.129 
Adipor2 Adiponectin receptor 2 1.746 -1.168 
Slc38a2 Solute carried family 38, member 2 1.924 -1.188 
LOC683538 Similar to metaxin 3 1.965 -1.233 
- Unannotated 2.147 -1.112 
Usp54 Ubiquitin specific peptidase 54 2.674 -1.192 
Cdc42bpa CDC42 binding protein kinase alpha 2.903 -1.111 
LOC686547 
Similar to TBC1 domain family 
member 4 3.114 
-1.191 
Sass6 Spindle assembly 6 homolog 3.222 -1.100 
LOC100364673 Hypercoagulability related protein  3.248 -1.143 
LOC687856 
Similar to myeloid cell surface antigen 
CD33 precursors 3.272 
-1.161 
Hist1h2bb Histone cluster 1  3.846 -1.137 
- Unannotated 3.935 -1.137 
Mcc Mutated in colorectal cancers 4.027 -1.163 




- Unannotated 4.184 -1.229 
Gpr116 G- protein coupled receptor 116 4.341 -1.210 
Hpgd 
Hydroxyprostaglandin dehydrogenase 
15  4.357 
-1.175 
- Unannotated 4.910 -1.105 
 
Table 4.1: Upregulated and Downregulated gene expression with hypertension 
Details of the genes found to be upregulated and those downregulated in expression in hypertensive animals compared normotensive 














Figure 4.1: Pathway analysis of differential gene expression  
Pathway analysis provided evidence of alterations within 4 different biological 
pathways. The most significantly altered gene pathway with hypertension is the 
pathway for cell morphology and development, nervous system development and 
function. Within this pathway there is differential gene expression of growth factors 





Figure 4.2: Pathway 1- Cell morphology and development, nervous system 
development and function 
The most significantly altered pathway with hypertension. Upregulated genes are in 
green and downregulated genes are in red in hypertensive animas versus 
normotensive. Each gene is attributed a status symbol, with the key included within 
the figure. Within this pathway hypertension leads to differential gene expression of 




4.4. Discussion  
Within the hypertensive literature there is a lack of knowledge as to the genes 
that are altered as a result of hypertensive induced cerebrovascular pathology. The 
present study sought to investigate gene alterations in the young 6-month cohort, 
which had previously shown evidence of alterations to vascular structure, endothelial 
signalling and inflammatory response. The present study, consistent with 
immunohistochemical findings from the previous chapter, provided evidence of 
differential expression in collagen IV, eNOS signalling pathway and inflammatory 
genes. Crucially the present study also found evidence that hypertension caused 
differential expression of growth factor and ion channel genes, which had not been 
identified or examined in the previous study. Thus, the findings within the present 
study indicate that hypertension leads to alterations at the cellular gene expression 
level as well as the structural level. These findings provide a crucial insight into the 
mechanism of hypertensive cerebrovascular alterations.  
4.4.1. Differential gene expression with hypertension 
The present study identified a small number of genes differentially expressed 
with hypertension. This was not surprising, as although the previous study identified 
vascular alterations, these were relatively subtle. Additionally gene expression was 
investigated within a subcortical dissection, which unlike the previous chapter would 
have included white matter regions such as the internal capsule. The presence of a 
larger region may have diluted some of the gene changes observed. To provide 
mechanistic insight these genes were characterised into functional pathways, 4 of 
which were found to be significantly altered with hypertension when compared to 




downregulated with hypertension than upregulated, indicating that hypertension 
affects normal gene response in a negative manner, silencing gene expression.  The 
functional pathways are discussed in the following sections.  
4.4.1.1. Pathway 1- Cellular morphology and development, nervous system 
development and function  
 
The present study found the most significantly altered pathway as a result of 
hypertension was: cellular morphology, development, nervous system development 
and function. Overall, this pathway provided evidence of differential gene expression 
of collagen IV, growth factors and eNOS signalling pathway.  
4.4.1.2. Differential expression of collagen with hypertension 
 
The present study found evidence of increased expression of the collagen 
4A2 gene (COL4A2) and is in agreement with evidence of altered collagen IV 
expression in chapter 3 of this thesis. However, this finding is in disagreement with 
the SHR and SHRSP models, which have failed to provide evidence of altered 
COL4A2 gene expression at similar durations of hypertension (Iwanaga et al., 2008; 
Ritz et al., 2012), but alterations in collagen IV gene expression has also been found 
in humans, with small vessel disease (Dichgans and Hegele, 2007). Therefore, 
presenting a similarity between gene alterations found with hypertension in our 
model and those observed in humans with cerebrovascular and WM pathology. The 
increased collagen gene expression may indicate that the structural alterations found 
in the previous study will progress to basement membrane thickening. Thus, this 
finding both supports previous data found within this thesis and provides a 




4.4.1.3. Differential expression of growth factors 
 
A large population of genes differentially expressed with hypertension were 
found to be growth factor genes. Firstly, there was a decreased expression of vascular 
endothelial growth factor (VEGF) and VEGFb genes, in hypertensive animals when 
compared to normotensive. VEGFb gene has been found to bind to the FLT-1 VEGF 
receptor negatively regulating angiogenesis (Roberts et al., 2004). In addition within 
this pathway, VEGF is associated with a decreased expression of G-protein coupled 
receptor 116 (GPCR 116) gene and poly (a) binding protein interacting protein 2 
(PAIP2). The function of GPCR 116 is not fully known but it has been shown to be 
localised on the vasculature (Wallgard et al., 2008). PAIP2 on the other hand is 
crucial for VEGF mRNA stabilisation and activation (Takahashi and Shibuya, 2005). 
These findings are in agreement with the SHR model, which has shown VEGF to be 
increased during the developmental stage of hypertension  (Ritz et al., 2012) but 
decreased during established hypertension (Wang et al., 2004). These alterations in 
VEGF expression in the SHR models were also found to be associated with impaired 
angiogenesis (Wang et al., 2004). Similar findings have been observed in the SHRSP 
model with decreased VEGF mRNA expression (Jesmin et al., 2007). Functionally, 
VEGF is a signalling protein produced by cells to signal angiogenesis but it also 
plays a role in endothelial function, as VEGF forms part of the MAP-kinase pathway 
and can activate the expression of eNOS – promoting vasodilation (Lal et al., 2001; 
Servos et al., 1999). The present findings may indicate endothelial dysfunction due to 
a decreased expression of a key promoter of vasodilation coinciding with 
morphological findings of string-like vessels. Notwithstanding, the evidence of 




animals, in vessels that did not exhibit signs of vascular remodelling represents 
alterations in the eNOS pathway as a result of hypertension. 
Within this pathway there was also differential gene expression of fibroblast 
growth factor (FGF) genes, which can influence cell growth and differentiation and 
bind to the extracellular matrix through linkage with heperan sulphate. FGFs have 
also been found to induce activation of the MAP-kinase pathway and associated with 
NO dependant and independent angiogenesis, unlike VEGF (Bonneh-Barkay and 
Wiley, 2009). Within the present study there was increased gene expression of FGF 
16 and a decreased gene expression of FGF 21. The specific role of both of these 
genes is not fully understood, but FGF 16 knockout studies have found it to be 
crucial in the formation of the cardiovascular system (Lu et al., 2008) and FGF 21 
has been associated with alterations to energy metabolism (Coskun et al., 2008).  It is 
difficult to directly compare these findings to those documented in the SHR models, 
but it has been shown that the SHRs have decreased expression of FGFs (Cuevas et 
al., 1996) and impaired energy metabolism (Ritz et al., 2012).  
FGF21 has been characterised as playing a pivotal role in metabolic 
regulation of glucose and leptin metabolism (Cuevas-Ramos et al., 2009). As well as 
FGF 21, there was also an increased expression of Insulin growth factor binding 
protein (IGFBP), important for insulin energy metabolism. IGFBP regulates the 
expression of Insulin growth factor (IGF) in an inhibitory fashion and importantly 
IGF has been found to be decreased in expression in the aging brain (Trejo et al., 
2004). Thus, the finding of increased IGFBP gene expression is suggestive of 
decreased IGF expression. This is in agreement with a study carried out in the 




decreased VEGF and eNOS expression (Yoshitomi et al., 2011). This is due to 
upregulation of IGF being stimulated by the expression of PI3K-ARK, members of 
the MAP-Kinase pathway, also responsible for VEGF and eNOS expression 
(Burgering and Coffer, 1995; Michell et al., 1999). Within the present study 
alterations in the expression of growth factors that are related to energy metabolism 
could represents a possible de-harmonisation between neurons and capillaries, with 
energy reserves not being met in the subcortical region of the brain. Interestingly, 
studies have investigated the role of IGFBP in relation to myelination and found that 
there is interplay between IGFBP and thus IGF expression and myelin integrity. 
Overexpression of IGFBP is linked with demyelination and increased neuronal 
apoptosis (D'Ercole et al., 2002; Doublier et al., 2000; Ni et al., 1997), whereas 
decreased expression of IGFBP is linked with hypermyelination (D'Ercole et al., 
1996; D'Ercole et al., 2002; Dentremont et al., 1999; Ye et al., 1995). Following 
studies in this thesis will examine the expression of myelin with hypertension and 
investigate if there is any relationship between the gene expression, vascular 
alterations and myelin integrity.  
Moreover, alterations in IGFBP expression may also relate to the vascular 
inflammation observed with hypertension in the previous study, as the IGF can be 
regulated by the expression of cytokines, reactive oxygen species and hemodynamic 
alterations (Delafontaine et al., 2004). IGF receptors have been found to be located 
on neurons and require insulin transport through the BBB. Interestingly, studies have 
also found IGF receptors on vascular smooth muscle and endothelial cells (King et 
al., 1985) and overexpression has been associated with aberrant vascular contractility 




soon after injury leading to an increased expression of IGFBP located on microglia 
and astrocytes (Beilharz et al., 1998). This indicates a possible mechanism between 
vascular remodelling, endothelial signalling alterations and inflammation, which 
could cause alterations to myelin integrity.  
4.4.1.4. Differential inflammatory gene expression  
 
Previous studies within this thesis found increased expression of microglial 
cells associated with the vasculature in hypertensive animals when compared to 
normotensive. Microglial cells are known to have both neuroprotective and 
degenerative actions. Gene alterations within this study also provides evidence of a 
protective inflammatory response with an increased expression of Nuclear factor of 
Kappa light polypeptide gene enhancer in B cells (NFκB) Inhibitor alpha (NFκBIA) 
gene with hypertension, found to be neuroprotective and increased in response to 
oxidative stress (Traenckner et al., 1994; Xu et al., 2002). NFκB is a transcription 
factor responsible for pathogen response, immune activation and cell survival. 
During inactivation, NFκB is anchored to the cytoplasm by inhibitors such as 
NFκBIA. Studies in ischemia have shown that the inhibition of NFκB by activation 
of NFκBIA protects the brain from injury (Treadwell and Singh, 2004; Xu et al., 
2002). However, NFκB can be neuroprotective, preventing pro-apoptotic c- Jun N-
terminal kinase (JNK), signalling through TNF receptors (De Smaele et al., 2001). 
NFκBIA is linked with downregulated hydroxyprostaglandin dehydrogenase-15 
(HPGD), which is involved in the inactivation of prostaglandins and inflammatory 
cytokines (Otani et al., 2006; Tong et al., 2006a). Within the present study it is 




mediators released by microglia or activated by another signalling mechanism but it 
does suggest a form of inflammatory response.  
In addition, the present study also found downregulation of Leukemia 
inhibitory factor (LIHF) gene, known to be upregulated in the acute inflammatory 
phase response and can release both anti-inflammatory and pro-inflammatory 
mediators (Gadient and Patterson, 1999; Suzuki et al., 2005). LIHF can act on a 
broad range of cells and can be expressed on endothelial cells, regulating energy 
dependent astrocytic differentiation (Mi et al., 2001; Suzuki et al., 2005). Decreased 
LIHF gene expression has also been associated with demyelination (Butzkueven et 
al., 2002).  In turn, associated with the LIHF gene, the SLC25A13 gene known as 
Centrin was downregulated. Centrin is a mitochondrial aspartate-glutamate carrier, 
expressed in subcortical neurons of the brain and a major component of the malate 
aspartate shuttle pathway transferring reducing agents from NADH to mitochondria. 
Within this study there is a decrease in the Centrin gene expression, which may 
impair energy formation in neurons (Contreras et al., 2010). Overall, these findings 
further indicate that hypertension induces alterations to the energy metabolism 
associated with altered inflammatory gene expression.  
 Another inflammatory marker which is downregulated with hypertension in 
this study is the chemokine CD84 involved in cellular and signal transduction and 
associated with the acute phase of inflammatory response (De la Fuente et al., 1997).  
Within this pathway CD84 is associated to RAC-alpha serine/threonine-protein 
kinase (AKT) part of the eNOS activation pathway. The downregulation of CD84 is 
likely due to the loss of eNOS expression with increased duration of hypertension. 




hypertension as eNOS is increased in the young 4-month cohort. There is also 
downregulation of other genes associated with the ARK pathway.  RASGRP3 gene 
encodes for guanine nucleotide exchange factor which activates small GTPases. 
RASGRP3 has a calcium binding EF hand motif and interacts with Protein kinase C 
(Lorenzo et al., 2001). Although the role of this gene is not fully understood, in the 
human brain RASGRP3 has been shown not only to be associated with the ARK 
pathways but can directly activate eNOS expression (Lorenzo et al., 2001).  
As discussed previously a limitation of the vascular study carried out in 
chapter 3 was that microglia was the only inflammatory cell measured. In the present 
study there is evidence of upregulation of the inflammatory cells- leukocytes with 
hypertension, as there is upregulation of Protein tyrosine phosphatase 22 (PTP N22), 
a regulator of the immune system and the expression of T lymphocytes (Kyogoku et 
al., 2004). There is also an increased expression of lymphocyte antigen 9 (LY9) with 
hypertension, a receptor on T and B lymphocytes and has been shown to be activated 
in the mouse brain in response to hypoxic ischemia insults (De la Fuente et al., 2001; 
Hedtjarn et al., 2004). Increased expression of leukocytes has been found in acute 
severe surgically produce hypertension in the transverse aortic coarctation model 
(Poulet et al., 2005) and the malignant hypertensive SHRSP model with occurrence 
of vascular remodelling (Kimoto-Kinoshita et al., 1999). In the SHRSP model 
increased leukocyte expression was associated with decreased NO (Kimoto-
Kinoshita et al., 1999). Studies in the SHR model have also provided evidence that 
leukocytes can express angiotensinogen, which can contribute to vascular 
remodelling (Takemori et al., 2000).  In addition, it has also been found that in 




lymphocytes fail to become hypertensive (Guzik et al., 2007) and that vascular 
inflammation can be stimulated by other mechanism not exclusively due to 
Angiotensin II overexpression (Marvar et al., 2010). Therefore, the findings within 
this study provide evidence of generalised inflammatory response with hypertension, 
which can be associated with alterations in endothelial signalling.  
4.4.1.5. Differential gene expression of genes related to ion and small molecule 
transport 
 
Ion channels are crucial for the trafficking of ions across cell membranes, 
alterations in the concentration of ions can lead to alterations in brain function 
through changes in membrane potential and action potential firing. Within the 
present study hypertension induced alterations to ion channel gene expression. The 
sodium channel, non voltage-gated 1 beta (SCNN1B), was found to be upregulated. 
SCNN1B is amiloride sensitive, located on the epithelium and also found to be 
increased in patients with Liddle’s syndrome - a genetic form of hypertension 
(Shimkets et al., 1994; Tong et al., 2006b). Studies in experimental models of 
hypertension have investigated the role of gene polymorphisms and the 
predisposition for the development of hypertension but have not found significant 
results (Grunder et al., 1997).  Peripheral studies have found that this gene and 
several others of similar function are activated in the kidney by increased aldosterone 
expression and correlate with increased blood pressure (Jin et al., 2010). The 
SCNN1B gene has been shown to be expressed in the rat brain and is associated with 
the regulation of cerebrospinal fluid, interstitial sodium concentration and neuronal 
excitation (Amin et al., 2005). Alterations in CSF sodium concentrations, which 




salt and were attributed to altered activity of Na
+
 channels within the brain (Wang et 
al., 2010).  
Another ion channel found to be altered with hypertension in this study was 
the SLC9A3 gene, which was found to be downregulated. This gene is located within 
chromosome 1 coding the Na+/H+ exchanger 3 and has been associated with blood 
pressure control in the SHR model (Szpirer et al., 1997) and hypertensive individuals 
(Zhu et al., 2004). Since ion channels can be located on endothelial cells, it could be 
postulated that the alterations in BBB tight junction expression shown in the previous 
study could also be associated with alterations to ion channels, allowing alterations in 
ion concentrations within the brain, which could signal to recruit microglia.  
4.4.1.6. Metabolism of Indole-3-carbinol 
 
Lastly, the CYP1a1 Ren2 rat model used within this thesis induces 
hypertension through dietary addition of I3C, allowing increased expression of 
mouse Ren2 gene coupled to CYP1a1 promoter. Microarray analysis yielded 
increased gene expression of CYP2a6, which is involved in the metabolism of aryl 
hydrocarbons and may been increased due to increased I3C (Fujii-Kuriyama et al., 
1995; Loub et al., 1975).  CYP2a6 also plays a role in the metabolism of Coumarin 
and nicotine (Rao et al., 2000). However, the application of I3C in this model leads 
to increased hepatic expression of Angiotensin II. It is not fully elucidated whether 
Angiotensin II can cross the BBB but a study by Paton et al., suggested Angiotensin 
II can enter the brain through the circumventricular organs and signal to the 
endothelium to release various vasoactive mediators including eNOS (Paton et al., 




related gene expression with hypertension it is suggestive that the vascular alterations 
are not exclusive to Angiotensin II expression.  
All in all, the gene changes observed with hypertension in pathway 1 indicate 
that there are model specific alterations, coupled with hypertensive induced 
alterations in collagen, growth factors, energy metabolism, inflammatory and ion 
channel gene expression. The pathway analysis also yielded a further 3 pathways 
differentially expressed with hypertension. However, the remainder of genes that 
were altered formed the following functional pathways - pathway 2 concerning lipid 
metabolism, molecular transport, small molecule biochemistry, followed by pathway 
3 concerning organ development and morphology and pathway 4 concerning cell 
morphology, cellular function. These pathways contained a small number of 
differentially expressed genes that had similar functional characteristics as those 
altered in pathway 1. Thus, pathway 1 being the most significant and including 
several differentially expressed genes was discussed in full and the genes altered 
within the remaining pathways can be found within Appendix C.   
4.4.1.7. Summary  
The present study provided evidence of genes altered with hypertension, at a 
time point when initial structural alterations to the cerebrovascular had occurred and 
is in agreement with previous findings in the SHR literature showing differential 
expression in genes related to energy metabolism, ion channels and inflammatory 
markers (Zhou et al., 2005). However, the present study did not find any differential 
expression of soluble epoxide hydrolase (sEH) identified as a novel gene altered with 
hypertension in the SHR model. This may be due to sEH being identified from 




hypertension could also explain for the relatively small amount of genes altered in 
this model. 
A limitation of the present study is that it chose to examine gene expression 
within the whole region rather than using a vascular specific sample. Examining gene 
expression from a vascular enriched sample may have allowed for amplification of 
genes altered in response to hypertension. However, extracting vessels from the brain 
may have impaired the integrity of RNA, impairing the overall sample integrity and a 
larger volume of tissue would have been required to allow for sufficient sample to 
carry out microarray analysis. Thus, the present study decided to analyse gene 
expression using subcortical tissue, detecting gene expression within the whole 
region that had previously been found to be susceptible to hypertension and 
providing a global region specific assessment of the underlying mechanisms. 
Additionally this study did not carry out any post hoc qPCR assessments of the gene 
alterations found within the microarray. The rational was that firstly the alterations 
found within the microarray were relatively subtle and the gene alterations found 
were not overtly different from those morphological alterations observed within the 
previous chapter. It would have undoubtedly been useful to carry out follow up 
qPCR examination but both financial and time limitations need to be taken into 
account and the results found from this characterisation microarray are a useful tool 
for more in depth future studies, in which the severity of hypertension could be 








The present study indicated that hypertension leads to alterations in gene 
expression. The differentially expressed genes are in agreement with findings in the 
previous chapter showing alterations in collagen, endothelial signalling and 
inflammatory gene expression. Novel mechanistic insight was provided with the 
findings that hypertension also leads to altered expression of growth factor and ion 
channel genes. In particular the identification of differential expression of IGFBP 
gene may indicate alterations in myelin integrity. The following study will build on 
the findings to investigate whether hypertension also leads to structural alterations in 












5. The effect of hypertension on white matter integrity in the young and aged 
brain 
5.1. Introduction 
White matter occupies over half of the human brain (Fields, 2008) and is 
crucial for effective communication between brain regions, facilitating the flow of 
electrical signals over long distances (Arai and Lo, 2009; Bartzokis, 2004). However, 
with age WML are frequently observed, with around 50% of individuals over the age 
of 65 found to have WML (Enzinger et al., 2006), which are associated with age 
related cognitive decline (Van Swieten et al., 1991). Age aside, hypertension has 
been associated as the number one risk factor for the formation and exacerbation of 
WML (Pantoni and Garcia, 1995). The mechanisms that associate hypertension with 
the formation of WML in humans, are difficult to establish due to the coexistence of  
hypertension with other vascular risk factors such as diabetes (Epstein and Sowers, 
1992; Mellitus, 2006). It is postulated that hypertension exerts deleterious effects to 
the cerebrovasculature, which promote alterations to the structural integrity of the 
brains more vulnerable regions, the WM (Pantoni and Garcia, 1995). Building on 
previous work within this thesis, this study sought to determine whether sustained 
hypertension may cause pathological alterations to the brains WM in the inducible 
model. 
5.1.2. Hypothesis  
Hypertension will lead to alterations to the integrity of white matter in the 





The study described in this chapter aimed to investigate the effects of 
hypertension on white matter integrity of the brain using the Cyp1a1 Ren2 rat model. 
White matter integrity was investigated in the young and aged brain. A detailed 
examination of myelin, oligodendrocytes, axons and microglial response was carried 
out and in the same animals it was determined whether there was any evidence of 




Experiments were conducted on the same Cyp1a1 Ren2 transgenic rats used 
for vascular immunohistochemical assessment described in chapter 2.1.2. 
Experiments were conducted on animals from the young 4-month, young 6-month 
and aged 4-month cohorts. 
5.2.2. Histology and immunohistochemistry  
Pathological assessments were carried out on paraffin embedded brain tissue 
sections (6µm) from both the young and aged cohorts as described in chapter 2.2. 
Sections were used for immunohistochemical assessment to investigate the integrity 
of white matter in the corpus callosum, fimbria, internal capsule and subcortical 
thalamic region of the brain. Adjacent sections were stained with H&E to determine 




5.2.3. Statistical analysis  
Data from MBP intensity values, CC1 positive cell counts and number of 
microglia were analysed using unpaired t-tests. APP data was analysed by Fisher’s 
exact test. Data for MBP and microglia activation is presented as a percentage of 
normotensive, although the raw average per hemisphere was statistically analysed. 




















5.3.1. Hypertension induced alterations to myelin basic protein in the young but not 
the aged brain 
 
MBP immunohistochemistry was used as a marker of myelin integrity in 
normotensive and hypertensive animals. Each cohort was run, stained and analysed 
distinct to the other. The integrity of myelin was examined by measuring the 
intensity of MBP staining in the corpus callosum, fimbria, internal capsule and 
subcortical thalamic region. MBP was found to stain myelinated fibres and in general 
the distribution of staining was similar between all animals in the corpus callosum, 
fimbria and internal capsule. However, it was noted that there were variations in 
staining within the subcortex.   
It was found that there was no significant difference in intensity of MBP in 
hypertensive animals from the young 4-month cohort, in the corpus callosum (|t|= 
1.34, df= 27, p=0.19; Figure 5.1E, Table 5.1), fimbria (|t|= 1.13, df= 27, p=0.27; 
Figure 5.1F, Table 5.1) and internal capsule (|t|= 1.13, df= 27, p=0.27; Figure 5.1G, 
Table 5.1), when compared to normotensive animals. However, the intensity of 
subcortical thalamic MBP was found to be significantly increased in hypertensive 
animals when compared to normotensive (|t|= 2.60, df= 27, p=0.01; Figure 5.1H, 










Figure 5.1: Increased subcortical thalamic MBP in the young 4-month cohort 
Representative images of myelin basic protein (MBP) staining in the white and grey 
matter. In the corpus callosum MBP staining was not significantly different in 
normotensive animals (A, E) compared to hypertensive (B, E). The same finding was 
observed in other white matter tracts investigated; (F) fimbria and (G) internal 
capsule. In the subcortical thalamic region MBP staining was significantly increased 
in hypertensive animals (D, H) when compared to normotensive (C,H). Scale bar = 




MBP data for the Young 4-month cohort 
Intensity per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
0.34 0.46 0.40 0.36 0.42 0.41 0.36 0.37 
0.41 0.45 0.50 0.46 0.54 0.47 0.44 0.43 
0.51 0.46 0.43 0.45 0.46 0.45 0.38 0.41 
0.43 0.51 0.46 0.47 0.48 0.53 0.39 0.43 
0.40 0.41 0.41 0.50 0.42 0.53 0.38 0.43 
0.43 0.42 0.45 0.43 0.44 0.46 0.35 0.38 
0.42 0.48 0.41 0.41 0.45 0.47 0.40 0.41 
0.38 0.43 0.36 0.47 0.42 0.45 0.40 0.45 
0.39 0.45 0.45 0.49 0.46 0.46 0.41 0.45 
0.45 0.40 0.45 0.46 0.44 0.54 0.38 0.42 
0.42 0.40 0.43 0.39 0.44 0.38 0.39 0.39 
0.45 0.50 0.44 0.38 0.46 0.42 0.39 0.37 
0.44 0.43 0.40 0.53 0.45 0.56 0.40 0.45 
 0.44  0.45  0.49  0.40 
 0.47  0.42  0.44  0.40 
 0.35  0.46  0.47  0.41 
 
Table 5.1: MBP intensity values for each region from the young 4-month cohort 





Similarly in the young 6-month cohort there was no significant difference in 
the intensity of MBP staining in the corpus callosum (|t|= 1.01, df= 27, p=0.32; 
Figure 5.2E, Table 5.2), fimbria (|t|= 0.92, df= 27, p=0.38; Figure 5.2F, Table 5.2) or 
internal capsule (|t|= 0.05, df= 27, p=0.96; Figure 5.2G, Table 5.2) of hypertensive 
versus normotensive animals. In contrast to the young 4-month cohort, the intensity 
of MBP was significantly decreased in the subcortical thalamic region of 
hypertensive animals compared to normotensive (|t|= 3.3, df= 21, p<0.01; Figure 
5.2H, Table 5.2). 
In the aged 4-month cohort there was no significant difference in the intensity 
of MBP between normotensive and hypertensive animals in the corpus callosum (|t|= 
0.55, df= 18, p=0.59; Figure 5.3E, Table 5.3), fimbria (|t|= 0.17, df= 18, p=0.86; 
Figure 5.3F, Table 5.3), internal capsule (|t|= 0.61, df= 18, p=0.77; Figure 5.3G, 
Table 5.3) or subcortical thalamic region (|t|= 0.29, df= 18, p=0.76; Figure 5.3H, 
Table 5.3).  
5.3.2. Hypertension does not induce alterations to the number of oligodendrocytes 
 
To analyse whether myelin alterations may be due to underlying alterations in 
the oligodendrocyte cell population, the number of mature oligodendrocytes 
immunopositive for CC1 were counted within the subcortical thalamic region. CC1 
stained oligodendrocyte cell bodies and the expression was found to be similar in all 
animals. There was no significant difference in the number of oligodendrocytes in 
hypertensive animals when compared to normotensive in young 4-month cohort (|t|= 




21, p=0.77; Figure 5.4H, Table 5.4) and the aged 4-month cohort (|t|= 0.28, df= 18, 











Figure 5.2: Decreased subcortical thalamic MBP in the young 6-month cohort  
Images represent myelin basic protein (MBP) in the white and grey matter. In the 
corpus callosum MBP staining was not significantly different in normotensive 
animals (A, E) compared to hypertensive (B, E). The same finding was observed in 
other white matter tracts investigated; (F) fimbria and (G) internal capsule. In the 
subcortical thalamic region MBP staining was significantly decreased in 
hypertensive animals (D, H) when compared to normotensive (C,H). Scale bar = 




MBP data for the Young 6-month cohort 
Intensity per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Normotensive Normotensive Hypertensive Normotensive Hypertensive 
0.14 0.11 0.13 0.11 0.15 0.12 0.12 0.10 
0.20 0.17 0.17 0.17 0.17 0.17 0.15 0.11 
0.15 0.18 0.17 0.11 0.15 0.15 0.13 0.11 
0.19 0.14 0.14 0.13 0.10 0.22 0.13 0.12 
0.19 0.20 0.19 0.18 0.18 0.17 0.15 0.13 
0.19 0.18 0.15 0.16 0.16 0.18 0.13 0.10 
0.20 0.17 0.16 0.16 0.19 0.14 0.13 0.11 
0.17 0.09 0.16 0.09 0.16 0.12 0.12 0.11 
0.21 0.17 0.17 0.17 0.15 0.14 0.12 0.12 
0.18  0.16  0.18  0.14  
0.16  0.16  0.18  0.14  
0.17  0.14  0.20  0.13  
0.12  0.10  0.13  0.11  
 
Table 5.2: MBP intensity values for each region from the young 6-month cohort 






Figure 5.3: No alterations in MBP staining in the aged 4-month cohort 
Representative images of myelin basic protein (MBP) in the white and grey matter 
tracts, visualized using an antibody specific for myelin basic protein (MBP). In the 
corpus callosum MBP staining was not significantly different in normotensive 
animals (A, E) compared to hypertensive (B, E). The same finding was observed in 
other white matter tracts investigated; (F) fimbria and (G) internal capsule. In the 
subcortical thalamic region MBP staining was not significantly different in 
normotensive animals (C,H) when compared to hypertensive (D, H). Scale bar = 





MBP data for the Aged 4-month cohort 
Intensity per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
0.63 0.54 0.30 0.26 0.37 0.28 0.20 0.20 
0.67 0.70 0.33 0.34 0.32 0.33 0.24 0.22 
0.56 0.59 0.28 0.31 0.30 0.33 0.19 0.18 
0.55 0.68 0.31 0.35 0.35 0.38 0.20 0.22 
0.64 0.64 0.35 0.33 0.38 0.37 0.21 0.18 
0.70 0.68 0.36 0.34 0.35 0.37 0.23 0.23 
0.65 0.63 0.36 0.29 0.37 0.28 0.21 0.20 
0.66 0.73 0.30 0.36 0.30 0.35 0.21 0.21 
0.71 0.71 0.35 0.33 0.31 0.31 0.20 0.24 
 0.62  0.33  0.32  0.21 
 0.67  0.29  0.30  0.18 
 
Table 5.3: MBP intensity values for each region from the aged 4-month cohort 








Figure 5.4: No change in the number of oligodendrocytes within the subcortical 
thalamic region 
Representative images of mature oligodendrocytes visualized by staining with 
antibody specific for CC1
+
 in the subcortical thalamic region in (A, D) young 4-
month, (B E) young 6-month and (C, F) aged 4-month cohort. There were no 
significant differences in the number of CC1
+ 
oligodendrocytes in hypertensive 
animals (D, E, F) versus normotensive (A, B, C). Scale bar =50µm. Graphs show 







 oligodendrocytes within the subcortex of each cohort 
Young 4-month cohort Young 6-month cohort Aged 4- month cohort 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
241.0 184.5 201.0 203.5 196.0 178.5 
207.5 160.5 176.5 163.5 223.5 250.0 
147.0 180.0 283.0 298.5 230.0 325.0 
241.0 269.5 196.0 265.5 314.0 223.0 
211.5 149.0 154.0 245.5 269.5 305.5 
240.0 193.5 180.5 250.0 327.0 259.0 
179.0 170.0 210.5 189.0 310.5 405.0 
259.5 190.0 205.5 337.5 349.0 337.5 
182.5 148.5 258.0 149.0 353.0 270.5 
148.5 212.0 268.0   335.0 
214.5 202.0 273.0   341.5 
206.0 301.0 283.0    
 232.5 242.5    
 245.5     
 226.0     
 207.0     
 
 
Table 5.4: Number of CC1
+
 oligodendrocytes within the subcortex 
The above table represents the raw number of CC1
+
 oligodendrocytes within the subcortex for each of the cohort analysed. Although the 
cohorts are presented together they were analysed separately.  
 
 
5.3.3. Hypertension induced minimal axonal pathology 
APP is an axonal transport protein and is normally localised to the cytoplasm 
of neurons, but when there is axonal disruption APP becomes accumulated at the site 
of injury. Axonal pathology was examined by the presence or absence of APP 
positive axonal bulbs. There was no evidence of axonal bulbs in the young 4-month 
cohort (Figure 5.5 A-D). In 6 out of 9 animals analysed from the young 6-month 
cohort, there was no evidence of axonal bulbs, but in the remaining 3 out of 9 
hypertensive animals small areas of axonal bulbs were observed in the subcortical 
thalamic region (Figure 5.5 E,F). 
Overall there was no significant difference in presence of axonal bulbs 
between normotensive and hypertensive animals (p=0.05) from the young 6-month 
cohort.  In the aged 4-month cohort small patches of axonal bulbs were observed 
within the subcortical thalamic region in 6 out of 9 normotensive and 9 out of 11 
hypertensive animals, with no significant difference between normotensive and 
hypertensive animals (p=0.62.,Figure 5.5 G,H).  
5.3.4. Hypertension induced no overt damage to neuronal perikarya in the young and 
aged cohorts 
 
H&E staining was used to determine the presence of ischemic neuronal 
perikarya and overall structural integrity of the brain. WM regions were investigated 
for the presence or absence of tissue pallor, microbleeds and haemorrhages. The 
hippocampus, fimbria and subcortical thalamic regions were investigated for the 



































































Figure 5.5: Minimal axonal pathology 
Axonal pathology was assessed by the presence of axonal bulbs, visualised by aggregation of 
antibody specific for amyliod precursor protein (APP) (arrows). In the majority of white and 
grey matter regions there was no evidence of axonal bulbs in each cohort with none found in 
either normotensive (A) or hypertensive animals (B) in the young 4-month cohort. Similar 
findings were observed in animals from the young 6-month cohort. However, in a subset of 
hypertensive (D) animals in the young 6-month cohort there were small areas of subcortical 
thalamic axonal pathology, which was not observed in any normotensive animals (C). In the 
aged 4-month cohort small areas of the subcortical thalamic region contained axonal bulbs, 
which were found in normotensive (E) and hypertensive (F) animals with no significant 
difference between them. Scale bar =100µm. 
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perikarya, tissue pallor, microbleeds and haemorrhages.  Changes to ischemic 
neurons were identified by the appearance of eosinophilic cytoplasm and pyknotic 
nuclei (Jortner, 2006). There was no evidence of damaged neurons or overt structural 
pathology in the young 4-month cohort (Figure 5.6). In the majority of animals from 
the young 6-month cohort there was no evidence of neuronal damage or overt 
structural pathology (Figure 5.6). However, one hypertensive animal had evidence of 
small microbleeds within the corpus callosum, with pallor to the surrounding tissue 
(Figure 5.6E).  In the aged 4-month cohort, the majority of animals had no evidence 
of neuronal damage, except one hypertensive animal that had evidence of 
hippocampal neuronal damage, represented by eosinophilic (pink) staining around 
the cell and was also observed to be associated with a region of vaculation (Figure 
5.6F). No overt structural pathology was observed with H&E in the corpus callosum, 
hippocampus, fimbria, internal capsule or the subcortical thalamic region in either 
hemisphere at any time point.  
Previous studies in the inducible hypertensive model described gross 
morphological alterations within the kidneys of hypertensive animals. As this study 
found evidence of minimal alterations to the structural integrity of the brain, the 
kidneys of animals from the young 4 and 6 month cohort were qualitatively 
examined for evidence of gross morphological alterations. Previous studies had 
found that the kidneys of hypertensive animals had vascular enlargement, tubule 
dilation, accumulation of inflammatory cells and protein accumulation or necrosis of 
the glomeruli in I3C induced animals (Graciano et al., 2007) and these finding were 
replicated in hypertensive animals from the present study (Figure 5.7). Indicating that 
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hypertension is exerting deleterious effects to the periphery which are far less severe 



















Young 6 month cohort Aged 4 month cohort
 
Figure 5.6: No overt structural alterations with hypertension 
Representative images of the structural integrity of white and grey matter visualised 
using Haematoxylin and Eosin (H&E) histology. In several white matter tracts H&E 
was used to investigate the presence of tissue pallor, microbleeds and haemorrhages. 
(A) Normotensive and (B) hypertensive, images representative of no structural 
alterations within the white matter of all three cohorts investigated. Investigations in 
the subcortical thalamic region of (C) normotensive and (D) hypertensive animals 
found no overt alterations (images representative of no structural or neuronal 
damage) in all three cohorts investigated. Thus, hypertension did not induced overt 
structural alterations in the majority of animals investigated apart from one animal 
from the young 6-month cohort (E); which was observed to have small areas of 
microbleeds in the corpus callosum with pallor to the surrounding tissue. In addition 
one hypertensive animal from the aged 4-month cohort (F) was observed to have 
subtle evidence of ischemic damage to the neuronal perikarya (pink stained 
surrounding cells)  shown by the blue arrow and surrounding areas of cellular 
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Figure 5.7: Kidney pathology  
Representative images of structural alterations induced by I3C hypertension in the 
kidney, visualised by H&E, in agreement with previous findings reported in this 
model (Graciano, Mouton et al. 2007). (A-B) representative images of glomeruli 
structure; (B) hypertensive animals were found to have protein accumulated within 
the glomerulus and dilated tubules, (A) normal glomeruli in normotensive animals 
with no evidence of protein accumulation or tubule dilation. (C-D) representative 
images of vascular integrity; (D) hypertensive animals were found to have marked 
vascular thickening surrounded by proliferation of possible inflammatory cells when 




5.3.5. Hypertension induced increased microglial activation 
Iba1 was used to identify activated microglia within several regions of the 
brain. In chapter 3, Iba1 staining was used in a qualitatitive manner to investigate the 
association of microglia with the blood vessels. It was commented that along with 
hypertensive animals from the young 6-month cohort and the aged 4-month cohort 
there is evidence of increased numbers of vessels within specific regions as a whole, 
which was due to the following data.  Immunopositive cells with a distinct cell body 
and surrounding processes were counted; processes without a cell body were not 
counted. In the young 4-month cohort there was no difference in the morphology of 
microglia between hypertensive and normotensive animals in all regions analysed. 
There was no significant difference in the number of microglia in white or grey 
matter regions examined between normotensive and hypertensive animals: corpus 
callosum (|t|= 0.100, df= 27, p=0.920; Figure 5.8E, Table 5.5), fimbria (|t|= 1.83, df= 
27, p=0.08; Figure 5.8F, Table 5.5), internal capsule (|t|= 1.91, df= 27, p=0.07; 
Figure 5.8G, Table 5.5) and subcortical thalamic region (|t|= 1.16, df= 27, p=0.26 
Figure 5.8H, Table 5.5). 
In the young 6-month cohort there was no difference in the number of 
activated microglia within white matter tracts; corpus callosum (|t|= 0.27, df= 21, 
p=0.82; Figure 5.9E Table 5.6) and fimbria (|t|= 0.12, df= 21, p=0.90; Figure 5.9F, 
Table 5.6) in hypertensive animals when compared to normotensive. However, there 
was a significant increase in the number of microglia in hypertensive animals 
compared to normotensive in the internal capsule (|t|= 4.02, df= 21, p<0.01; Figure 
5.9G, Table 5.6) and subcortical thalamic region where loss of MBP was observed 
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(|t|= 2.88, df= 21, p<0.01; Figure 5.9H, Table 5.6). These results show that with 
increased duration of hypertension there is a subcortical inflammatory response. 
In the aged 4-month cohort there was a significant increase in the number of 
activated microglia between hypertensive compared to normotensive animals in the 
corpus callosum (|t|= 3.44, df= 18, p<0.01; Figure 5.10E, Table 5.7), internal capsule 
(|t|= 2.73, df= 18, p=0.01; Figure 5.10, Table 5.7) and subcortical thalamic region 
(|t|= 2.70, df= 18, p=0.01; Figure 5.10H, Table 5.7).The only exception was in the 
fimbria where no significant difference between normotensive and hypertensive 
animals was found (|t|= 2.25, df= 18, p=0.04; Figure 5.10F, Table 5.7). Hypertension 









Figure 5.8: No change in the number of microglia in the young 4-month cohort 
Representative images of microglia expression in the white and grey matter. 
Microglia visualised by antibody specific for IBA1 (brown) and counterstained with 
periodic acid schiffs (pink) vascular marker. In the corpus callosum there was no 
significant difference in the number of microglia between normotensive (A, E) and 
hypertensive animals (B, E). As in other white matter tracts investigated; (F) fimbria 
and (G) internal capsule. In the subcortical thalamic region the number of microglia 
were not significantly different between normotensive (C,H) and hypertensive 
animals (D, H). Scale bar = 50µm. Graphs show mean ± SEM. 
 
 
IBA1 data for the Young 4-month cohort 
Number of microglia per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
26.67 35.00 36.67 28.33 36.25 27.92 31.94 31.81 
38.33 42.50 40.00 46.67 33.75 38.75 34.19 30.31 
35.00 37.50 46.67 25.00 38.33 39.58 33.38 31.25 
15.83 21.67 30.00 20.00 28.33 21.67 33.50 28.44 
27.50 41.67 28.33 45.00 41.67 41.25 29.44 40.06 
36.67 22.50 20.00 25.00 29.58 37.08 27.56 30.13 
20.83 30.83 40.00 23.33 45.00 21.67 33.13 25.56 
19.17 35.83 25.00 23.33 22.08 32.50 31.13 36.38 
22.50 14.17 33.33 25.00 35.42 24.58 32.25 28.75 
30.83 18.33 31.67 35.00 39.58 31.67 31.00 28.38 
22.50 14.17 40.00 16.67 36.25 24.58 31.75 23.88 
20.83 17.50 31.67 33.33 35.42 30.42 29.00 30.19 
26.67 14.17 36.67 18.33 36.25 21.25 31.94 20.31 
 22.50  21.67  20.83  23.81 
 29.17  38.33  41.25  37.38 
 24.17  18.33  30.42  26.06 
 
Table 5.5: The number of microglia within the gray and white matter of the young 4-month cohort 




Figure 5.9: Increased number of subcortical microglia in the young 6-month 
cohort 
Representative images of microglia expression in the white and grey matter. 
Microglia visualised by antibody specific for IBA1 (brown) and counterstained with 
periodic acid schiffs (pink) vascular marker. In the corpus callosum there was no 
significant difference in the number of microglia between normotensive (A, E) and 
hypertensive animals (B, E). The same finding was observed in the fimbria (F). An 
increased expression in the number of microglia was found with hypertension in the 
internal capsule (G). Similar finding in the subcortical thalamic region with increased 
number of microglia in hypertensive (D, H) when compared to normotensive animals 




IBA1 data for the Young 6-month cohort 
Number of microglia per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Normotensive Normotensive Hypertensive Normotensive Hypertensive 
21.50 41.00 11.50 28.50 25.00 46.50 29.00 48.00 
24.00 26.50 28.00 25.50 41.50 59.00 55.00 67.00 
24.00 26.50 28.00 25.50 41.50 59.00 56.00 62.00 
21.00 28.00 23.50 22.00 38.50 49.00 50.00 58.00 
27.00 31.00 23.50 27.50 30.50 58.50 61.00 68.00 
27.00 26.50 23.50 18.00 30.50 43.50 36.00 58.00 
26.00 26.50 18.00 16.50 37.50 58.50 46.00 56.00 
19.00 43.00 10.50 28.50 28.50 60.00 52.00 58.00 
25.00 21.00 18.00 11.50 32.50 31.50 31.00 53.00 
44.00 16.50 15.50 17.00 32.50 34.50 48.00 40.00 
49.00  38.00  48.00  52.00  
28.00  20.00  38.00  29.00  
26.00  24.00  38.00  34.00  
 
Table 5.6: The number of microglia within the gray and white matter of the young 6-month cohort 





Figure 5.10: Increased numbers of microglia in the aged 4-month cohort 
Representative images of increased microglia expression in the white and grey 
matter. Microglia visualised by antibody specific for IBA1 (brown) and 
counterstained with periodic acid schiffs (pink) vascular marker. In the corpus 
callosum there was a significant increase in the number of microglia between 
normotensive (A, E) and hypertensive animals (B, E), which was also found in the 
internal capsule but not in the fimbria (F). The number of microglia was also 
increased in the subcortical thalamic region in hypertensive animals (D, H) when 
compared to normotensive animals (C,H). Scale bar = 50µm. Graphs show mean ± 
SEM. Significance * = p ≤ 0.02 vs. Normotensive.
 
 
IBA1 data for the Aged 4-month cohort 
Number of microglia per region 
 Corpus Callosum Fimbria Internal Capsule Thalamus 
Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive Normotensive Hypertensive 
27.50 42.50 18.50 24.50 42.00 75.00 33.25 46.50 
21.00 25.00 12.00 35.50 48.50 60.00 39.00 36.00 
21.00 42.00 12.00 17.50 48.50 55.00 33.75 42.75 
27.50 26.00 18.50 18.00 42.00 60.00 39.00 40.00 
26.50 45.00 18.50 25.50 54.50 76.00 36.25 36.50 
26.00 41.50 23.50 18.50 31.00 102.00 34.00 36.00 
26.00 38.00 23.50 37.00 31.00 76.00 33.50 49.75 
33.50 46.00 25.00 36.00 55.50 109.00 30.00 39.25 
43.50 50.00 19.50 21.50 70.00 61.00 35.00 37.75 
 35.50  24.00  37.00  36.50 
 50.00  21.50  61.00  36.00 
 
Table 5.6: The number of microglia within the gray and white matter of the aged 4-month cohort 





The present study suggests that sustained hypertension results in modest 
alterations to the brains WM. In particular evidence was provided to indicate 
subcortical myelinated axons may be vulnerable to the effects of hypertension. In 
addition a more pronounce widespread microglial response was found subcortically 
and in a number of white matter regions suggesting that there are underlying 
pathological changes occurring in response to hypertension.  
The WM of the brain has been shown to be particularly vulnerable to 
cerebrovascular alterations, due to receiving its blood supply end of the line, from the 
penetrating arterioles. Thus the central focus of this study was to examine myelin 
integrity in response to hypertension in the young and aged brain. Myelin integrity in 
the present study was examined by measuring the intensity of an abundant myelin 
protein, myelin basic protein. Myelin alterations in this model were restricted to the 
subcortical thalamic region, with the majority of regions analysed found to be 
unaffected. These findings suggest a vulnerability of the subcortex to hypertensive 
pathology.  In hypertensive patients, areas of the brain in which WML frequently 
occur such as the periventricular and subcortical regions of the brain, are those which 
have a marginal blood supply under physiological conditions (De Reuck, 1971; 
Marinkovic, 1986; Pantoni and Garcia, 1997a; Van Den Bergh, 1969). The 
subcortical thalamic region myelin may be vulnerable to hypertensive driven 
alterations due to a lack of vascular reserve, receiving its blood supply end of the line 
from the thalamopenetrating arterioles. These arterioles originate from the 
vertobasilar system and form few anatosomes, which would leave this region 
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sensitive to alterations in blood flow (De Reuck, 1971; Marinkovic, 1986; Pantoni 
and Garcia, 1997b; Van Den Bergh, 1969). The vulnerability of the subcortex has 
been identified in hypertensive patients demonstrating decreased thalamic blood flow 
during cognitive testing, which correlated with impaired performance (Fujishima et 
al., 1995b; Jennings et al., 2005). In addition, a previous chapter within this thesis 
found that hypertension alters cerebrovascular morphology. The susceptibility of 
subcortical WM was identified using MBP, although other components of the myelin 
sheath exist. MBP accounts for 30% of the total myelin sheath (Boggs, 2006) and has 
been shown to be essential for the formation of the myelin sheath with mutant MBP 
models lacking compact myelin (Carre et al., 2002; Readhead et al., 1990). 
The subcortical myelin alterations found in this study were specific to the 
young brain. Surprisingly hypertension in the young 4-month cohort was found to be 
increased in the intensity of MBP expression, in comparison to normotensive 
animals, suggestive of hypermyelination. This result was consistent with the MRI 
data (Appendix E.1) showing myelin alterations consistent with increased myelin and 
this was also only found to be within the thalamus. The function of increased 
intensity of MBP is unknown in this study, but may represent an adaptive response of 
the brain to hypertension. Hypermyelination has been associated with hypoxic-
ischemia in the prenatal condition of Status marmoratus, characterised by neuronal 
loss and myelin growth  in the subcortex and basal ganglia (Yikilmaz and Taylor, 
2008). However, increased myelin is not always a function of repair as was shown in 
hypermyelinating squirrel monkeys, where increased myelin was associated with 
cognitive decline (Lyons et al., 2004).   
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In addition previous studies within chapter 4 of this thesis identified altered 
gene expression of IGFBP within the subcortex, which regulates the expression of 
IGF. Overexpression of IGF has been found to cause hypermyelination in transgenic 
mice (Mozell and McMorris, 1991; Ye et al., 1995). The link between these findings 
and those of the present study may indicate a mechanism by which a relatively short 
duration of hypertension led to alterations in vascular signalling, which may have 
caused increased myelin. 
Although the mechanisms of increased myelin at this time point are not 
understood, the findings are validated by imaging, which was undertaken in-vivo 
prior to study termination. MRI imaging provided evidence of increased 
magnetisation transfer ratio (MTR) within the same subcortical region measured in 
immunohistochemical assessment (Appendix E.1). MTR measurements are deemed 
more sensitive than the traditional T2 weighted MRI, and represents the ability of 
molecules located within the tissue matrix of the brain to exchange magnetisation 
with the surrounding water molecules. Alterations in the MTR can reflect changes in 
the structure of myelin or axons (McDonald et al., 1992). Since no evidence of 
axonal disruption was found, using other MRI matrices and no change in the 
microstructural organisation analysed by diffusion tensor imaging, it is likely that the 
increased MTR is reflective of increased myelin. However, to fully discard the 
presence of axonal alterations further investigation into axonal pathology such as 
electron microscopy or immunohistochemistry would have been required.  
However in the present study, with increased duration of hypertension, there 
was a reduction in MBP intensity in the subcortical thalamic region, suggesting a 
loss of myelin. In both human and animal models, mechanisms underlying WML are 
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still unknown but have been linked to vascular remodelling and reductions in blood 
flow (Fisher, 1969; Lin et al., 2000; Lin et al., 2001; Wakita et al., 1994, 1995). 
Myelination is an energy-rich mechanism and not only has hypertension been shown 
to impair subcortical thalamic activity dependent blood flow, but there is also 
evidence for decreased glucose utilisation (Fujishima et al., 1995b).  Within this 
study the initial increase in myelination may deplete energy stores required for the 
maintenance of the myelin sheath, coupled with the possible underlying vascular 
alterations, which have been associated with hypertension in humans and 
experimental models (Alistair, 2002; Lin et al., 2001; Pantoni and Garcia, 1995). In 
turn, a previous study within this thesis examining differential gene expression 
within the subcortex at the same duration of hypertension found alterations in energy 
metabolism. In addition, hypertension was also found to alter the structure of the 
cerebrovasculature, with vessels appearing smaller and string-like.  This may have 
left the brain with insufficient blood flow and energy to maintain structural integrity.  
In turn, the hypermyelination found with the shorter duration of hypertension may 
have destabilised the myelin sheath predisposing this region to myelin loss.  
Additionally, as shown in the previous chapter gene expression was analysed 
in a separation cohort ran for the same duration. Although there was no alteration 
found in MBP gene expression there was differential expression of the IGFBP gene, 
which was found to be differentially expressed with hypertension. With the same 
duration of hypertension in the same region, IGFBP was found to be upregulated, 
which would have lead to a downregulation of IGF. Literature has shown that 
decreased IGF expression leads to decreased myelination and loss of myelin integrity 
(Ye et al., 1995). The present study may have identified a novel signalling pathway, 
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which may be altered as a result of hypertension. The lack of alterations in MBP 
gene expression may be due to the microarray study sampling a larger area including 
multiple regions - inclusive of the entire subcortex, including parts of the internal 
capsule etc. However, a limitation of this study is that MBP levels were not further 
investigated by other means of analyses such as western blotting. As the significance 
difference found was strong and the majority of alterations found within this cohort 
in chapter 3 were vascular, it was decided that the tissue suitable for western blotting 
was processed into a vascular enriched homogenate to yield more of an indication as 
to the vascular alterations observed.   
Overall, in the young adult brain hypertension caused alterations in 
subcortical MBP expression, which within the young 4-month cohort corresponded 
to MRI findings. At the outset it was hypothesised that in the aged cohort, 
hypertension would cause loss of the integrity of the brains WM. Thus, in this study 
it was surprising to find no evidence of alterations to myelin with hypertension in the 
aged 4-month cohort. In human studies there is an increased prevalence of WML 
with age (Van Swieten et al., 1991). However, the age of animals examined within 
this study is more akin to midlife hypertension in humans, which has been associated 
as a risk factor and predictor for WML in later life (Launer Lj, 1995; Swan et al., 
1998; Vuorinen et al., 2011). It is interesting that with age there was no evidence of 
increased intensity in MBP, as found in the hypertensive animals from the young 4-
month cohort. Since myelination is associated with higher glycolytic levels, the lack 
of hypermyelination in the aged brain, may represent an underlying decrease in 
energy availability, which is exacerbated by hypertension (Fern et al., 1998; Morland 
et al., 2007). In turn, studies have shown a decrease in IGF levels with age which 
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may also prevent increased myelination (Florini et al., 1981; Florini et al., 1985). In 
addition, there may have been methodological issues within this study, as one would 
expect alterations to occur with normal ageing. These alterations may have caused an 
increased variability in the study, thus the power of animals used may have not been 
sufficient to uncover subtle alterations in myelin integrity caused by hypertension. 
Prior to the start of this study power calculations were calculated based on previous 
findings within this thesis found in the young brain, but due to the novelty of this 
study examining animals at this age and lack of literature examining a similar insult 
to based calculations on, the power calculations may have underrepresented the 
number required.   
However, there are minimal alterations found to myelin integrity in each 
cohort examined. In support of this, a recent study presented findings in COX10 
deficient mice, which fail to metabolise glucose. Remarkably these mice have 
demonstrated intact CNS myelin, with evidence that oligodendrocytes have the 
ability to yield sufficient energy from a concurrent increase in lactate (Funfschilling 
et al., 2012). Therefore, under normal conditions as one would expect the brain has 
adaptive mechanisms in place to protect the myelin sheath. However, with prolonged 
duration of hypertension in the young 6-month cohort, which was previously shown 
to exhibit morphological alterations to the vascular structure, the adaptive response is 
insufficient to prevent alterations in myelin integrity. This protective response of 
increased lactate was also found to be dampened in the CNS grey matter myelin of 
the COX10 mutant mice, which may also explain the susceptibility of the subcortical 
myelin within the present study. Overall, this study found that hypertension leads to 
minimal alterations to the brains myelin. These observations are not in agreement 
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with previous findings in the SHR and SHRSP models - in particular none of the 
studies had observed hypermyelination. In general, previous studies in the SHR 
model have provided evidence of subtle WML, occurring firstly in the hippocampus 
and striatum at around 20 weeks of age (Lin et al., 2001; Sabbatini et al., 2001), 
which progressed to small focal areas of cystic and rarefied WM in the cortex and 
subcortex (Hazama et al., 1977). Imaging studies have shown a subtle increase in T2 
weighted MRI measurements in the corpus callosum and internal capsule which 
represent small areas of decreased MBP intensity (Yang et al., 2011). The presence 
of increased myelin has not been found within the brain of the SHR model, although 
it has been reported in the aortic depressor nerve of mature SHRs (Fazan et al., 
2005). Even though evidence has found that the SHRs have WML these are still 
relatively subtle, but as to be suspected, due to the increased severity they are more 
prevalent, than those found in the present study. 
On the other hand, the SHRSP model has provided stronger evidence of 
WML throughout many regions of the brain; corpus callosum, anterior commissure, 
internal capsule and caudate at 20 weeks (Lin et al., 2001). These lesions have been 
shown to increase in severity with age, with WM fibres becoming dispersed and 
rarefied. The SHRSPs also show increased presence of haemorrhagic and cystic 
lesions in both the cortex and subcortex (Fredriksson et al., 1985; Fredriksson et al., 
1988; Ogata et al., 1982), and by 1 year of age there is an increased frequency of 
bilateral WML (Henning et al., 2010).  However, ischemic lesions have been found 
in 80% of SHRSPs by 30 weeks, and studies have also found ischemic lesions as 
early as 12 weeks (Tagami et al., 1987; Yamori and Horie, 1977). In turn, at 20 
weeks when WML are observed, the SHRSP model exhibits malignant systolic blood 
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pressure of >220 mmHg. Therefore, WML occurring in the SHRSP models cannot 
be exclusively attributed to hypertension with a predisposition for stroke and 
malignant hypertension more likely. To further justify this, a recent study carried out 
to investigate aged stroke free SHRSPs found no evidence of WML (Brittain et al., 
2012). Thus, the levels of hypertension and predisposition for the development of 
stroke likely explain differences in findings between the SHRSPs and our model.   
The present study demonstrates that the myelin component of white matter is 
not overtly affected by hypertension in isolation, when modelled in a sustained 
manner and compared to genetically matched controls. This study highlights region 
specificity of hypertension and initial mechanisms of myelin alterations, which could 
be a target for therapeutic intervention. However, a limitation of the present study is 
that it only examined one component of the myelin sheath, myelin basic protein. 
Myelin associated glycoprotein (MAG), an architectural protein connecting the axon 
and myelin sheath has been shown to be lost prior to alterations in myelin or axonal 
integrity in response to hypoperfusion (Reimer et al., 2011).  It is unknown within 
this study what effect hypertension has on the other components, which may impair 
the function of the brains WM. 
Axons are also a critical component of WM for transmission of signals from 
neurons. Previously it was presumed from MRI findings that axonal integrity was 
unaltered with hypertension. Axonal disruption was assessed in the present study 
using APP immunohistochemistry, since under normal conditions APP is trafficked 
along the axon but when there is axonal disruption accumulations of APP are 
formed, which appear as axonal bulbs (McKenzie et al., 1996).  Overall the present 
study found no evidence of axonal pathology in the majority of animals from each of 
239 
 
the cohorts examined. In a minority of hypertension animals from the young 6-month 
cohort, there were small subcortical areas of axonal pathology, which occurred after 
the onset of myelin alterations. Overall there was no significant difference in axonal 
integrity when compared to normotensive animals. Small areas of subcortical axonal 
pathology were also found in a subset of animals from the aged 4-month cohort. 
Interestingly these findings of axonal pathology in both normotensive and 
hypertensive animals represent alterations which occur naturally with age and may 
make it more difficult to unmask those alterations caused exclusively by 
hypertension. In addition lack of axonal damage may be a result of the myelin 
sheath, as it protects the axon from exposure to harmful stimuli, therefore, the subtle 
axonal pathology found in hypertensive animals may represent exposed axons that 
have lost their myelin sheath. It is not surprising that the present study did not find 
significant evidence of axonal pathology with hypertension as studies in humans 
examining WML have found axonal pathology only occurs in small and variable 
areas of the brain after severe demyelination (Van Swieten et al., 1991). Data from 
the present study is in agreement with a prior hypertensive imaging study carried out 
in 4 month old SHR, which failed to provide evidence of axonal pathology (Yang et 
al., 2011). Furthermore, previous literature in the SHRSP model provided evidence 
that within ischemic lesions axonal integrity is unaffected (Fredriksson et al., 1988).  
The myelin of the WM is formed by oligodendrocytes. These cells project 
processes, which enwrap the intermodal segments of axons to form the myelin sheath 
allowing effective propagation of axon potentials, whilst sheltering the axon from 
harmful stimuli (Bunge et al., 1961; Mayhan et al., 1987; Nave, 2010). This energy-
rich process of myelination and its maintenance is carried out in an energy limited 
240 
 
environment, making oligodendrocytes vulnerable to periods of energy disruption 
(Todorich et al., 2009). Thus the numbers of oligodendrocytes were measured within 
the subcortical thalamic region of each cohort to determine whether they were altered 
in response to hypertension. We found no evidence of alterations within the number 
of oligodendrocytes in each of the cohorts investigated, but did not use markers to 
investigate the integrity of corresponding myelination processes or take into account 
other populations of oligodendrocytes such as precursors of immature 
oligodendrocytes. However, our data is in agreement with findings in the SHR model 
observing minimal alterations to the WM, which were not accompanied with 
alterations in the number of oligodendrocytes (Yang et al., 2011). It does need to be 
addressed that there appears to be an overall increase in the number of 
oligodendrocytes in the aged cohort. This was not statistically analysed as the three 
cohorts were set up under differing conditions and both immunohistochemistry and 
analysis was carried out at the different times, thus it is unknown whether there is a 
difference with age or due to experimental conditions. The data in these studies 
suggests that hypertension in isolation causes minimal myelin alterations and these 
alterations do not affect the number of oligodendrocytes or the integrity of axons in 
the brain.  
The present study did not address the effect of hypertension on the astrocytic 
component of the WM. Proliferation of astrocytes has been observed in the SHR 
model at >6 months of age in the cortical and subcortical WM (Tomassoni et al., 
2004) after the development of WM pathology. Astrocytes have also been shown to 
be proliferated after >2 months of age in the SHRSP models in response to malignant 
hypertension (Hazama et al., 1995).  
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Overall the alterations caused by hypertension in this chapter and present 
chapters have been found to be modest. A non-specific qualitative investigation of 
the overall structural integrity of the brain was carried out using H&E staining to 
investigate if there were any signs of overt pathological structural alterations. H&E 
staining was used for the identification of ischemic damage to the neuronal 
perikaryia, microbleeds, haemorrhages and infarcts. Overall, hypertension did not 
lead to any overt structural alterations to the brain in each of the cohorts examined, 
aside from two hypertensive animals: one from the young 6-month cohort; observed 
to have small areas of microbleeds in the corpus callosum with overall tissue pallor 
and one animal from the aged 4-month cohort; observed to have signs of neuronal 
damage in the corpus callosom. It does need to be discussed that H&E is a very crude 
maker of neuronal damage and many other makers of ischemic neurons could have 
been used in this study. However, the H&E findings indicated that overall there was 
no evidence of ischemic neurons and overt structural pathology in hypertensive 
animals from each cohort when compared to their respective normotensive controls 
thus these findings were not further investigated. These findings are in disagreement 
with histological studies in the SHR and SHRSP models observing structural 
alterations to the brains gray and WM (Hazama et al., 1977; Knox et al., 1980; Ogata 
et al., 1980; Sabbatini et al., 2000). The SHRSP model has also been found to have 
areas of microinfarcts and bleeds, which frequently occur around the same time when 
stroke-like symptoms appear (Ogata et al., 1980). Overall the lack of overt alterations 
found with the previous study may be due to the induction of blood pressure in a 
slow gradual manner, unlike the SHRs and SHRSPs (Okamoto and Aoki, 1963; 
Okamoto, 1974).  In turn, the vascular alterations found previously were relatively 
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subtle and one would not have expected these to have caused gross overt structural 
alterations, rather more subtle specific protein alterations within the most vulnerable 
regions of the brain such as the WM. 
However, as shown in chapter 3 hypertension led to vascular inflammation, 
which was associated with structural alterations to the vasculature. In addition, 
differential gene expression also suggested that there was evidence that hypertension 
caused an inflammatory response. The present study chose to examine whether there 
is an increased inflammatory response in the WM of the brain, which might be 
related to the alterations to myelin.  The presence of an inflammatory response was 
analysed by counting the number of microglia immunopositive for Iba1, which binds 
to the actin cytoskeleton of microglia and is expressed during proliferation, migration 
and phagocytosis (Ahmed et al., 2007).  
Although hypertension induced minimal alterations to myelin and axons, 
there was a marked inflammatory response. There was no change in the number of 
microglia in the young 4-month cohort, but with increased duration of hypertension 
in the young 6-month cohort, there was a marked increased in the number of 
microglia in hypertensive animals when compared to normotensive. This increased 
inflammatory response was located within the subcortical thalamic region, which had 
loss of MBP and also the WM tract- the internal capsule.  
In the aged 4-month cohort, an increased microglial response was found in 
multiple regions. Increased numbers of microglial cells were found to be induced by 
hypertension in the majority of regions analysed.  In the aged 4-month cohort there 
was no evidence of alterations in myelin therefore microglia may be recruited in 
response to other pathological insults. These findings of increased microglia with 
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hypertension are in agreement with other experimental models of hypertension such 
as the SHR, SHRSP, renal models and Angiotensin II infused mice and may 
represent an early mechanistic feature of hypertension (Knox et al., 1980; Lin et al., 
2001; Nag, 1984; Shi et al., 2010; Zubcevic et al., 2011).  
Although it is unknown within this study whether the increased expression of 
microglial is a protective response or contributing to a pathological process it is 
notable that microglial respond more prominently than other components of the WM 
such as myelin, oligodendrocytes and axons, being described as sensors of 
pathology. In the transverse aortic coarctation (TAC) model of transient hypertension 
with marked alterations to CBF, microglia were found to be upregulated prior to 
structural alterations in the brain (Carnevale et al., 2012). Similar findings have been 
shown in other ischemia studies (Gehrmann et al., 1992) representing the early 
response of microglia to alterations in blood flow. Thus, the increased microglial 
response in the present study may indicate that microglia are acting as early sensors 
of damage.  
Microglia can be recruited in response to structural and ionic alterations in 
the brain (Ransohoff and Perry, 2009). Previously within this thesis, structural 
alterations to BBB tight junction proteins were identified, which may have lead to 
alterations in ionic concentrations and caused an increased microglial response. 
These results were also accompanied by alterations in vascular structure found in 
both the young 6-month and aged 4-month cohort. Alterations in endothelial 
signalling and/or vascular structure may have altered blood flow. Mechanisms are in 
place to normalised blood flow, by neuron-astrocyte signalling. The glia often used 
Ca
2+
 signalling, therefore there may be an increased astrocytic Ca
2+
 signalling, in 
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attempt to normalised blood flow which may have also signalled to recruit microglia 
(Aloisi et al., 1997; DeWitt et al., 1998; Verderio and Matteoli, 2001). 
In both human and aged animal studies there are alterations in transcellular 
transport across the BBB (Hunt et al., 2007; Mooradian, 1990; Mooradian et al., 
1994; Mooradian et al., 1991; Mooradian and Smith, 1993), which although not 
examined may be exacerbated with hypertension in the aged cohort when compared 
to the young cohort therefore, leading to a marked inflammatory response. In turn, as 
previously shown with the axonal integrity data, aging alone predisposes the brain to 
structural alterations, which may lead to an exacerbated inflammatory response with 
hypertension. On the other hand, the increased number of microglial cells within the 
subcortical thalamic region is accompanied by loss of MBP in the young 6-month 
brain. As shown previously at this time point there are alterations to the structural 
integrity of the vasculature, with vessels appearing string-like and also evidence of 
BBB alterations. Overall, these alterations may predispose the brain to decreased 
blood flow, leading to loss of myelin and an inflammatory response.  
However one limitation of the present study is within the induction of 
hypertension in the Cyp1a1 Ren2 rat model using Indole-3-carbinol, which have 
been the focus of several research studies as a possible cancer treatment due to it is 
anti-inflammatory properties (Bradlow et al., 1991; Higdon et al., 2007; Kojima et 
al., 1994; Weng et al., 2010). Therefore, the findings in this study may have been 
underplayed due to the method of hypertension induction. To find out the true extent 
I3C had on this study you would need to compare inflammatory levels between 
animals fed I3C and those not under normal conditions and in response to an 
inflammatory stimuli such as lipopolysaccharide (LPS), which has been used to 
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investigate the inflammatory response in other animal models (Espinosa-Oliva et al., 
2013). 
In conclusion, hypertension in the inducible rat model caused alterations in 
WM. These alterations were subtle in comparison to WM changes documented in 
human, which may be due to hypertension commonly coexisting with other vascular 
related risk factors such as diabetes, leading to an exacerbation of pathological 
findings and cognitive abilities (Messerli et al., 2007). To date work in this thesis has 
assessed the structure of the brain but has not examined the effect of hypertension on 














6. The effect of hypertension on spatial reference and working memory  
6.1. Introduction 
For many decades hypertension has been associated with impaired cognitive 
function (Wilkie and Eisdorfer, 1971). However, as indicated previously there are 
many factors, which contribute to hypertension related alterations in the brain such 
as: duration, severity and onset of hypertension, added to many subjects being under 
the influence of treatment and the common coexistence of hypertension with other 
vascular risk factors, all of which can have a dramatic effect on study findings.   
The gold standard models; SHR and SHRSP have provided a wealth of 
knowledge as to the possible actions of hypertension in the periphery and the brain, 
but have been less successful in providing robust evidence of an association of 
hypertension leading to cognitive decline, with one main limitation is the lack of 
genetically identical control rats.  
The present study chose to examine cognitive function in the CYP1a1 Ren2 
model in which sustained, controlled hypertension can be directly compared to age 
matched litter-mate normotensive controls. The forms of memory chosen to assess 
were spatial reference and working memory as these have been found to be impaired 
in humans with age (Salthouse, 2004; Salthouse, 2009).   
6.1.2. Hypothesis  





The study described in this chapter aimed to investigate the cognitive abilities 
including spatial reference and working memory of hypertensive compared to 
normotensive Cyp1a1 Ren2 rats.  
6.2. Methods  
6.2.1. Subjects  
Cognitive testing was carried out on young Cyp1a1 Ren2 transgenic rats; 
normotensive fed either a control diet (no 13C, n=12) or hypertensive (0.15% 13C, 
n=12) diet for a 4 month period as described in detail in chapter 2. Throughout the 
duration of the study blood pressure results followed the same profile as to those 
described in chapter 3 (Appendix G.1). 
6.2.2. Assessment of spatial reference and working memory using the Morris water 
maze 
The Morris water maze was carried out corresponding to protocols detailed in 
chapter 2.4. Prior to behavioural testing animals were habituated to handling due to 
weekly blood pressure measurements. In order to exclude animals with gross motor 
or visual impairments, a cued version of the water maze task was carried out, in 
which animals had to locate a cued visible platform. This cued version of the water 
maze also provided training of the task and was carried out for 3 trials per day for 4 
consecutive days.  No animals were excluded on this basis from the study. Spatial 
reference memory training began 3 days after the end of the cued task. Animals were 
allowed 4 trials per day for 5 days, to locate the hidden platform with an inter-trial 
interval of 10 minutes. Platform location was constant throughout the trials with 
animals starting location counter balanced to platform location. Probe tests were 
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carried out 10 minutes and 24 hours after the final trial of spatial reference memory 
task.   
Further cognitive assessment was carried out using delayed matching to place 
task, 3 days after the end of the spatial reference memory task. As described in 
chapter 2.4.1.3, delayed matching to place task was carried out according to the 
protocol established by Steele and Morris, including alteration in platform location 
between trials (Steele and Morris, 1999). Animals were allowed 4 trials per day for 4 
consecutive days, with trials 1 and 2 having an inter-trial interval of 20 minutes and 
trials 2, 3 and 4 having a shorter inter-trial interval of 15 seconds.   
 
6.2.3. Hippocampal Myelin basic protein levels 
 
As described in Chapter 5.3.1 MBP was used to assess the integrity of 
myelin. As performance of the above cognitive assessment is reliant on hippocampal 
function, MBP levels within the hippocampus were analysed by measuring the 
intensity of MBP in the young 4-month immunohistochemical cohort (same animals 
used in the chapter 5). 
6.2.4. Statistical analysis 
Behavioural data was analysed using two-way ANOVA with repeated 





6.3.1. Blood pressure 
Hypertension was induced by the addition of I3C as described previously 
(Chapter 2.2). The blood pressure followed the same profile as the young 4-month 
cohort examined for immunohistochemistry described in chapter 3 (Appendix G.1). 
6.3.2. Hypertension does not induce gross motor or visual impairments 
Initially rats were trained in a cue task with a visible platform, showing that 
sensory function and basic learning were not impaired. There was no significant 
difference in performance between hypertensive and normotensive groups (F(1, 21) = 
0.46 p=0.51; Figure 6.1). In both groups performance improved significantly across 
days (F(4.325, 90.809) = 3.79, p<0.01; Figure 6.1) and escape latencies averaged less than 
10 seconds by the end of training. Swim speed measured across all trials did not 
differ between normotensive (28.11 ± 0.38 cm/s) and hypertensive (27.92 ± 0.36 
cm/s) animals (F(1, 21) = 0.21 p = 0.65). 
6.3.3. Spatial reference memory is conserved after hypertension 
 
Spatial reference memory was investigated using the Morris water maze. 
Animals were given 4 trials per day to locate a hidden, non-cued platform, which 
remained in a constant location throughout the trial. There was no significant 
difference between normotensive and hypertensive rats, in the latency to locate the 
hidden platform across training (F(1, 21)=1.08, p=0.31; Figure 6.2A). Both groups of 
animals demonstrated improvement in the ability to learn the location of the 
platform.  The latency of both normotensive and hypertensive animals significantly 
decreased over the training period (F(19, 399)=5.48, p<0.001; Figure 6.2A). In addition, 
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normotensive and hypertensive animals showed a similar preference for the quadrant 
in which they had been trained when memory was probed at 10 minutes (group x 
quadrant interaction, F(3, 63)=0.75, p=0.53; Figure 6.2B) and 24 hours (group x 
quadrant interaction, F(3, 63)=0.45, p=0.72; Figure 6.2C) after the final trial of spatial 
reference training.  
6.3.4. Hypertension did not impair performance in the delayed matching to place 
task 
 
In the delayed matching to place task, the location of the hidden platform 
changed each day. This was carried out to assess working memory capabilities in 
hypertensive animals when compared to normotensive controls. There was no 
significant difference in performance between normotensive and hypertensive 
animals (F(1, 21)=0.83, p=0.37; Figure 6.3) but the animals did improve over time with 





































Figure 6.1: Cue task performance in the young 4-month cohort  
There was no significant difference in performance between normotensive and 
hypertensive animals over the training period of the cued version of the water maze. 







































































































Figure 6.2: Water maze performance during spatial reference memory trials 
There was no significant difference in the latency to locate the hidden platform 
between normotensive and hypertensive animals (A). Both groups displayed equal 
retention of platform location at 10 minutes (B) and 24 hours (C) after training.  





























Figure 6.3: Water maze performance during delayed matching to place trials 
There was no significant difference in performance during delayed matching to place 
task in hypertensive when compared to normotensive animals. Both groups show an 











6.3.4 Hypertension did not cause alterations to hippocampal MBP levels 
 
The integrity of myelin was investigated by analysing the intensity of MBP staining. 
Although chapter 4 found evidence of hypertension leading to an increased intensity 
of subcortical thalamic MBP in the young 4-month cohort, the intensity of 
hippocampal MBP was not significantly different between normotensive and 
hypertensive animals (Figure 6.4, |t| = 1.508, df = 26, p = 0.668), representing at this 


















Figure 6.4: MBP levels in the Hippocampus 
Representative images of MBP levels within the hippocampus of the young 4-month cohort. 
MBP was visualised using DAB immunohistochemistry using an antibody for anti-MBP. It 
was found that overall there was no significant different in the intensity of MBP (measured 






6.4. Discussion   
In humans, hypertension is a risk factor for the development of age related 
cognitive decline (Kilander et al., 1998b). A previous study within this thesis found 
that hypertension caused modest alterations to the WM with more marked alterations 
observed to the cerebrovasculature. The present study demonstrated that sustained 
hypertension did not lead to alterations to spatial reference and working memory at a 
time when modest subcortical WM alterations were evident 
Firstly spatial reference memory was assessed using a standard Morris water 
maze protocol (Morris, 1981). All animals were trained and assessed for the presence 
of overt motor and visual deficits. Due to the albino strain of these animals there was 
a concern that there may be underlying visual deficits and additionally since no 
behavioural assessments had been previously carried out in this model, at this 
severity of blood pressure, it was unknown at the onset if the animals could complete 
the water maze task. However, during the cued task all animals were able to swim 
equally well and at comparable speeds and showed positive evidence of an ability to 
learn to locate the hidden platform. At this point there was no indication that the 
hypertensive and normotensive animals performed any differently during the training 
phase and all animals learned the task equally well. 
After the animals had shown suitable performance in the cued task, spatial 
reference memory was assessed. It was found that there was no difference in the 
performance of hypertensive and normotensive animals in the spatial reference 
memory task. All animals were found to learn the task, with the latency of platform 
location decreasing over time and the following probe trial showing evidence of 
quadrant preference. These findings are suggestive that hypertension at this duration, 
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where initial structural alterations to myelin and additionally endothelial signalling 
are found, are not sufficient to alter cognitive function. Similar to the present finding, 
a study in 3 month old SHRs have found no evidence of impaired spatial reference 
memory, with SHRs found to perform the task better than the WKY (Widy-
Tyszkiewicz et al., 1993).These findings are not exclusive to the Morris water maze, 
with investigations carried out using the radial arm maze in SHRs aged 3-4 months 
and 16-17 months showing no evidence of impaired spatial reference memory in the 
young SHR (Mori et al., 1995). However, other studies have shown evidence of 
impaired spatial reference memory in SHRs aged 4 weeks (Gattu et al., 1997b), 12 
weeks (Gattu et al., 1997a) and 15 months (Terry et al., 2000). Interestingly these 
findings suggest that the SHRs have impaired cognitive function prior to the 
development of hypertension at 4 weeks, which may indicate evidence of 
background genetic differences between SHRs and WKYs  (Gattu et al., 1997b). In 
turn, the examination of spatial reference memory in SHRSPs, SHRs and WKYs, 
found that spatial reference memory is impaired in SHRSPs but not SHRs or WKYs 
(Matsuo, 2007). Therefore, the evidence in SHRs and SHRSPs is overall difficult to 
interpret as there appear to be differences in strain performance. In fact, it has been 
reported that WKY exhibit altered and erratic swim speeds (Diana, 2002; Knardahl 
and Sagvolden, 1982; Randich and Maixner, 1981; Robertson et al., 2008; Wyss et 
al., 2000). 
To further investigate cognitive function, the delayed matching to place 
paradigm was carried out to examine working memory. It was found as with spatial 
reference memory that hypertension did not cause alterations to the performance 
measured by latency to located the platform during the delayed matching to place 
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task. This task was chosen as it is more taxing on memory performance, as the 
location of the platform is moved each day, meaning that animals are required to 
relearn the location of the platform and more subtle difference can be uncovered. The 
protocol used for the present study was devised by Steele and Morris and allowed a 
longer inter-trial interval after trail 1, for encoding of the  new platform location 
(Steele and Morris, 1999). There was no evidence of any difference in the 
performance between hypertensive and normotensive animals during the task as a 
whole or even between trials. In support of the present findings many studies have 
shown in the SHR model that there is no impairment in working memory but a 
superior performance when compared to normotensive WKY (Robertson et al., 2008; 
Wyss et al., 1992). However, there are also studies in the SHR model, which have 
found evidence of impaired working memory (Hernandez et al., 2003; Mori et al., 
1995; Nakamura-Palacios et al., 1996; Wyss et al., 2000). Robertson et al., provided 
evidence that working memory is impaired in the SHR models when compared to the 
normotensive Sprague Dawley strain. However, WKY control animals also showed 
impairment in performance, which was comparative to that found in the SHR model, 
thus impairments may be not due to hypertension and as indicated previously can be 
strongly influence by control strain comparisons (Robertson et al., 2008). 
The present study chose to examine cognitive function using the Morris water 
maze. As can be seen in table 6.1, key studies in the SHR and SHRSP have examined 
spatial memory using the Morris water maze and Radial arm maze with relatively 
similar results. The rational for choosing the Morris water maze in the present study 
was to avoid any alteration to the dietary induction of hypertension. Since the radial 
arm maze relies on food reduction and reward, as a stimulus, this may have led to 
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alterations to blood pressure levels, as the hypertension is induced through dietary 
admission.  
Overall, the present study found no evidence of any alterations to spatial or 
working memory, even though there are alterations to the myelin integrity and 
endothelial signalling. The previous chapter presented alterations to the integrity of 
myelin within the subcortex; however the hippocampus is a crucial structure in water 
maze performance (Macdonald et al., 1973; Morris, 1981; Steele and Morris, 1999). 
Within this chapter it was also shown that hypertension does not cause an alteration 
to the intensity of hippocampal MBP, thus the lack of cognitive alterations observed 
within the functions assessed may be due to an overall lack of structural alterations. 
However, thalamic lesion studies have shown a key role for the integrity of thalamic 
nuclei in performance of spatial reference memory (van Groen et al., 2002a; van 
Groen et al., 2002b). In studies of cognitive function in humans with hypertension it 
has been shown that there are impairments in spatial memory, working memory, 
attention, psychomotor abilities and perceptual skills (Elias et al., 2004; Waldstein, 
2003), many of which can be associated a disconnection to the cortical-subcortical 
circuits (Bonelli and Cummings, 2007; Charlton et al., 2006; Jellinger, 2007). 
However, the alterations found within the present study were relatively subtle and 
were not sufficient to cause any impairment in the cognitive functions assesed.  
Therefore, this may suggest that in the young brain the structural alterations cause by 
hypertension are not sufficient to cause a functional impairment. 
Another limitation of the present study is that the effect of hypertension on 
cognitive function was studied in the young brain. The rationale for investigating 
cognitive function in the young brain was to decipher the role of hypertension at a 
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time point where initial structural alterations had appeared. The majority of human 
studies associate hypertension in midlife as a predictor of cognitive decline in late-
life (Elias et al., 2004; Haan Mn, 1999; Kilander et al., 2000; Piguet et al., 2003; 
Reinprecht et al., 2003; Tzourio et al., 1999). Ageing has also been shown to lead to 
alterations in spatial learning and memory in animal models (Gallagher and Rapp, 
1997).  Arguably, the young brain may be able to adapt to hypertension induced 
alterations. Thus future studies in the current model should focus on examining 
cognitive function with hypertension in the aged brain.  
 
Overall the present study provided evidence that hypertension does not lead 
to functional alterations in spatial and working memory. The major conflicting factor 
in human literature is the coexistence of hypertension with other vascular risk factors 
such as diabetes. Research into ageing has linked vascular risk factors such as 
diabetes and obesity to age-related cognitive decline (Kilander, 2000). It may be an 
additional effect of vascular risk factors, which lead to cognitive decline. In turn, the 
lack of cognitive impairment found in the present study may be reflective of the 
overall impact on hypertension on the structural integrity of the brain. This thesis 
found that hypertension leads to alterations to the cerebrovasculature and WM but 
these were relatively subtle and region specific. Thus it appears from the present 
study and other findings within this thesis that hypertension when studied in 
isolation, in a controlled sustained manner caused subtle alterations to the brain, 








Number of animals Evidence of cognitive impairment 
Mori et al 1995 Radial arm 
maze 
3-4 months and 16-17months 19 SHR 
8WKY 
- : in young 
+: in aged  




6-8 per group  
Sprague Dawley (SD) was used 
as a normotensive control strain 
-: in young 
+: in aged  
Nakamura-




3 months  12 SHR 
11 WKY 
+ 






9-12 per group  + 
Gattu et al 1997 





9-12 per group +/-: only impairment in reversal 
memory in the young animals 
+: impairment in both spatial and 
reversal memory in aged animals  
Terry et al 2000 Morris water 
maze 
15 months 12 per group + 
Widy- 




Exact age not reported but 
testing was carried out when 








6-7 weeks 12-14 per group +:SHR performed worse than SD 
strain 
-: No difference in performance 
between SHR an WKY 
Table 6.1: Summary of key behavioural studies in the SHR model 
Findings from the SHR model using either the Radial arm or the Morris water maze. + = cognitive impairment in the hypertensive model, - 
= no cognitive impairment in the hypertensive model. In general the results of cognitive assessments using the radial arm and water maze 




7. General Discussion 
7.1. Summary 
 
The findings within this thesis provided insight as to the role of hypertension 
in isolation, induced in a controlled sustained manner. Hypertension was found to 
cause alterations to the cerebrovasculature consisting of: altered endothelial 
signalling, vascular remodelling and vascular inflammation. The cerebrovascular 
alterations were accompanied with differential gene expression of many growth 
factors, ion channels, energy metabolism and inflammatory related genes. Followed 
by evidence that hypertension caused modest alterations to the WM, in the young 
brain, which showed a specific predisposition to the subcortex. Accompanied with 
these alterations there was evidence of hypertension inducing a marked inflammatory 
response within subcortical grey and white matter tracts in the young brain and 
additionally several WM regions and subcortical grey matter in the aged brain.  To 
provide a functional assessment of hypertension, cognition was assessed examining 
spatial reference and working memory, at the earliest point when structural 
alterations were observed but was found to be unaffected. This finding is suggestive 
that initial alterations caused by hypertension do not have a functional effect on the 
brain functions assessed. The alterations found within this thesis support several 
aspects of the hypothesis in that hypertension leads to structural alterations to the 
cerebrovasculature and WM, in the young and aged brain at varying severity but 
there was no evidence of cognitive impairment.  
Interestingly this thesis identified several signalling pathways which appear 
to have been altered in part due to hypertension. As described in the introduction, 
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previous literature had associated hypertension with alterations to the MAP-Kinase 
pathway, in particular eNOS expression (Lassegue et al., 2001; Ungvari et al., 2003). 
In the present study eNOS is found to be altered with hypertension in the young and 
aged brain, which is associated with several of the growth factor genes found to be 
differentially expressed. Thus, the findings within this thesis are suggestive of 
alterations to endothelial function and the MAP-kinase pathway (Figure 7.1) and also 
many other pathways, which are associated with increased expression of ROS. 
Furthermore, the gene expression study yielded evidence of alterations to the Insulin 
growth factor binding protein gene, which can be associated with alterations in the 
MAP-kinase pathway and can impact on WM integrity. This may represent evidence 
of a target gene, which shows altered expression prior to overt hypertensive induced 
structural alterations and could be monitored in humans to further investigate its role. 
Moreover, the present study identified a vascular specific and global inflammatory 
response to hypertension. Evidence of this inflammatory response was found after 
alterations to eNOS expression in the young brain suggestive of alterations in 
endothelial signalling, which although not tested could lead to an altered endothelial 
function, which in turn may have caused an increased inflammatory response. 
Markedly this increased vascular response can also induce alterations to Insulin 
growth factor binding protein and components of the MAP-kinase pathway. 
Furthermore the evidence of altered BBB structure, endothelial signalling and 
microglial recruitment is indicative of possible alterations to ion channels, as found 
in differential gene expression. Therefore, by studying hypertension in a sustained, 
controlled manner the present study has isolated initial mechanisms, which are 
altered with hypertension. Additionally the structural alterations found were overall 
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subtle and in absence of a functional cognitive impairment, thus providing an ideal 
therapeutic window for the treatment of hypertensive related cerebrovascular 





















   
 
Figure 7.1: Major pathways activated by the generation of reactive oxygen 
species (ROS) and those found to be activated by hypertension  
In the introduction, it was described that hypertension was thought to cause 
alterations to ROS expression leading to the activation of the above pathways, which 
can influence endothelial function by promoting or hindering vasodilation and 
activate pro-inflammatory state. Those marked in red represent the pathways found 








7.2. Hypertension leads to modest structural alterations to the integrity of the 
cerebrovasculature and white matter in the brain of the Cyp1a1 Ren2 inducible rat 
model 
 
In the Cyp1a1 Ren2 inducible rat model, hypertension was induced in a 
gradual, controlled and sustained manner, in an aid to replicate hypertension in 
humans and to avoid modelling malignant hypertension.  The controlled modelling 
of hypertension allowed clarity within the literature establishing hypertension in 
isolation leading to modest structural alterations to the integrity of the brain. 
However, this model did not examine all features of hypertension in humans, as more 
recent studies have provided evidence that blood pressure variability is strongly 
associated with WML (Havlik et al., 2002). This has lead to studies examining 
ambulatory blood pressure (daytime, night-time and 24 hour blood pressure 
averages) and correlating the variability of blood pressure throughout the day with 
the presence and severity of WML. 
In humans, blood pressure is altered with normal daily activity which can be 
exacerbated with hypertension (Staessen et al., 2003), especially in those with 
cerebrovascular pathology (Heckbert et al., 1997). The relationship between high and 
low blood pressure has been observed in a longitudinal imaging study,  which found 
a U-shaped or J-shaped relationship existed between blood pressure and the 
formation of WML (De Leeuw et al., 1999). This study provided evidence that 
periods of low and high blood pressure are both equally harmful to the brain. Data 
from the Honolulu-Asia aging study examined the relationship between blood 
pressure variation in midlife and the late-life presence of WML. This study provided 
a stronger association between blood pressure variation and the formation of WML,  
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versus controlled blood pressure and proposed that periods of high and low blood 
pressure may overcome autoregulation exposing the brain to periods of insufficient 
blood flow (Havlik et al., 2002). The variability of blood pressure and its effect on 
the brain has been examined by correlating periods of high blood pressure at specific 
times of the day, allowing the presence and severity of WML to be associated with 
individual blood pressure profiles. These studies have provided evidence of increased 
blood pressure at specific periods of the day (rather than increased blood pressure 
throughout the day) and this correlates more strongly with the number of lacunes and 
WML (Goldstein et al., 1998; Shimada et al., 1990). 
These fluctuations in blood pressure can become specifically harmful in 
elderly treated and untreated hypertensive patients which have vascular remodelling 
leading to impaired autoregulation. These vascular alterations require a higher 
threshold of blood pressure to maintain sufficient blood flow (Heckbert et al., 1997) 
and can lead to periods of nocturnal hypotension. On this basis, studies have 
examined WML in the context of dippers i.e., patients whose blood pressure drops to 
hypotensive levels and non-dippers. It has been shown that there is an increased 
severity and volume of WML and lacunes in hypertensive patients who are extreme 
dippers and those who are non-dippers; increased nocturnal blood pressure, 
compared to patients whose blood pressure is decreased by a normal but not 
hypotensive nocturnal level (Kario et al., 1996; Shimada et al., 1992). In turn, 
ambulatory blood pressure monitoring is a useful diagnostic tool avoiding 
misdiagnosis and is gradually being introduced within NHS guidelines (Ritchie et al., 
2011). There is a percentage of the population referred to as ‘white coat 
hypertensives’ that experience transient increased blood pressure during blood 
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pressure measurements (Pickering Tg, 1988). Ambulatory monitoring would prevent 
these individuals from being exposed to hypotension by unnecessary blood pressure 
medication.  
7.2.1. Further studies to examine cerebrovascular and white matter integrity 
in the Cyp1a1 Ren-2 rat model 
Although the present study within this thesis chose to examine the effect of 
hypertension in a controlled manner this model could be used to examine the effect 
of blood pressure variation. Previous characterisation studies in this model describe 
hypertension induction by dietary induction or gastric gavage (Kantachuvesiri et al., 
2001). Both methods could be chosen to induce periods of severe hypertension. 
Increasing the concentration of I3C through dietary induction would allow a stress 
free increase in blood pressure; although blood pressure would take 48 hours to rise 
and would be increased until I3C concentration was lowered. Gastric gavage in 
combination with dietary induction would allow for increased blood pressure at 
specific periods of the day. These methods of blood pressure variation could be 
evoked with constant blood pressure monitoring by telemetry measurements. In 
addition the advantage of this model is that blood pressure is fully reversible after the 
removal of I3C. This would allow the establishment of repair mechanism and at the 
time point at which pathology is reversible with blood pressure lowering. This would 
be of great clinical importance as studies examining treatment of hypertension and 
reversibility of brain morphology, finding that not all alterations are reversible 
(Nobili et al., 1993; Raz and Rodrigue, 2006; van Dijk et al., 2004). Therefore, 
modelling hypertension in a reversible model would allow the opportune period for 
antihypertensive treatment to be established.  In turn, knowing the severity of 
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hypertension which leads to irreversible cerebrovascular alterations would allow 
treatment to be adjusted to prevent periods of hypoperfusion.  
7.3. Hypertension leads to a marked inflammatory response in the brain of the young 
and aged Cyp1a1 Ren2 inducible rat model 
 
Even though findings within this thesis provided evidence of minimal myelin 
and cerebrovascular alterations with hypertension the most robust finding was the 
exacerbated inflammatory response. The inflammatory response was measured by 
the increased presence of microglial cells within specific regions as a whole and their 
association with the vascular. In humans there is evidence to suggest that 
inflammation plays a role in the mechanisms of hypertensive pathology. Cross-
sectional studies have found increased serum levels of multiple inflammatory 
markers which are associated with microglia such as C-reactive protein, TNF-α, 
interleukin 6, monocyte chemoattractant protein 1 and ICAM-1 in hypertensive 
patients and have been shown to decrease in some patients with antihypertensive 
treatment (Cachofeiro et al., 2009; Fliser et al., 2004; Koh et al., 2003; Rahman et al., 
2002; Sanz-Rosa et al., 2005). In turn, studies have also shown an association with  
increased inflammatory markers and the presence of WML (Fornage et al., 2008) and 
cerebral atrophy (Baune et al., 2009) in the aged brain. Studies in experimental 
models of hypertension have shown that antihypertensive treatment lowers levels of 
inflammatory mediators comparable to controls and reduces vascular remodelling  
(Ando et al., 2004). Therefore, the importance of the findings within this thesis was 




7.3.1 Further studies examining the inflammatory response in the Cyp1a1 Ren-2 rat 
model 
 
As described above the findings and observations in previous studies 
associate an influential role of microglia and hypertensive induced pathology but the 
mechanisms are not yet defined. Since antihypertensive and other vascular risk 
factors may affect the inflammatory response of hypertension in man, to study 
hypertension in isolation future studies would need to be carried out in animal 
models. The Cyp1a1 Ren2 rat model could provide a tool to examine the role of 
microglia in relation to vascular remodelling using an in-vivo imaging approach as 
described in a previous study (Davalos et al., 2005).  This could have been assessed 
by creating Cyp1a1 Ren2 inducible transgenic rats with GFP tagged microglia and 
vasculature visualised using in-vivo two photon laser capture imaging. This would 
allow the response of microglia to the surrounding environment with hypertension 
and in relation to vascular alterations to be examined. Additionally, the animals 
could be given an anti-inflammatory drug and the response of the microglia in 
relation to the vascular alterations could be examined.  
However, as discussed previously and of great importance the method of 
hypertension induction in this model by I3C, may have lowered the inflammatory 
response, thus this study would also need to examine non-transgenic Fischer animals 
under normal conditions and inflammatory induced conditions to investigate the 
impact of dietary indole-3-carbinol on the inflammatory response. 
In turn, the vascular integrity with hypertension alone and hypertension with 
anti-hypertensive treatment could be further investigated at a higher resolution using 
contrast-enhanced magnetic resonance microangiography (CE-µMRA) as described 
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by Klohs et al., 2012. This form of imaging would allow a three dimensional 
assessment of vascular structure in-vivo and assessment of the number of functional 
vessels within the substance of the brain, which could be correlated to the previous 
microglia assessment study. These studies could also be run in parallel with 
previously suggested studies to investigate varying severities of hypertension on 
vascular integrity and microglia response.     
7.4. Initial mechanisms of hypertension leads to alterations in endothelial signalling 
in the Cyp1a1 Ren2 inducible rat model 
 
Within this thesis data provided evidence of alterations to endothelial 
signalling prior to vascular remodelling and inflammatory response suggestive of an 
initial response of the vasculature to hypertension. Evidence of alterations in 
endothelial signalling in particular decreased NO bioavailability has been reported 
with hypertension in humans and experimental models (Briones and Touyz, 2010).  
The level of endothelial dysfunction may be exacerbated in this study as mature 
endothelial cells have limited regenerative capacity and endothelial progenitor cells 
have been shown to be altered in migratory ability and function with hypertension 
(Imanishi et al., 2005).  In turn, as discussed previously endothelial dysfunction is 
associated with increased endothelial progenitor cells, ROS, vasoconstrictive agents 
and decreased NO availability (Giannotti et al., ; Vanhoutte, 2009; Yao et al., 2006).  
Based on previous literature and data provided within this thesis is suggestive that 




7.4.1 Further studies examining endothelial signalling in the Cyp1a1 Ren2 inducible 
rat model 
 
Further studies could be carried out to investigate whether alterations in the 
number of endothelial progenitor cells contribute to alterations in eNOS expression 
in the Cyp1a1 Ren2 rat model, by fluorescent labelling of endothelial progenitor cells 
with a proliferative marker. This study could examine eNOS levels at earlier time 
points than those investigated in this thesis and with addition of an endothelial 
progenitor marker to establish the initiation of alterations to endothelial signalling. In 
addition, by reversal of hypertension in this model the onset and reversibility of 
endothelial dysfunction could be established. It is accepted in the majority of the 
literature that endothelial dysfunction is an early feature of hypertension, however 
the recommended first stage antihypertensive treatments do not directly address this 
(Krause et al., 2011). Statins directly influence endothelial function through ENOS 
(Endres et al., 2004). However, under NHS guidelines these are prescribed to 
patients as a mode of secondary protection in response to ischemic heart disease or 
peripheral vascular disease i.e., angina or previous myocardial infarction (Krause et 
al., 2011; Network, 2012). Therefore based on data within this thesis prescribing 
therapeutic agents to improve eNOS production at this stage may increase circulating 
ROS and further exacerbate the inflammatory response. Therapeutic interventions 
aimed at improving endothelial function may be more beneficial prior to vascular 
remodelling and also concomitantly with an anti-inflammatory agents to prevent any 





7.5 Overall limitations of the thesis 
 
Although the data containing within this thesis provides evidence of initial 
subtle structural alterations caused by hypertension in isolation, it does not fully 
investigate the functional impact of these alterations. Since there is evidence of 
alterations to the cerebrovascular structure in the young 6-month cohort, it would be 
interesting to analyse what impact these have on blood flow, vessel contractility and 
also vessel leakiness. These functional implications could be anaylsed using laser 
Doppler to investigate blood flow in combination with pharmacological stimulation 
to evoke different pressure values, wire myography to investigate the ability of the 
vasculature to constrict and dilate in response to pharmacological stimuli and vessel 
leakiness could be examined by horse radish peroxidase injections combined with 
immunohistochemistry.  
Additionally it would be interesting to underpin the indirect functional 
alterations cause by these structural alterations to the cerebrovasculature. Within this 
thesis cognitive function in the form of spatial reference and working memory was 
assessed in the young brain when initial but relatively subtle structural alterations 
were found. Although this study found no evidence of alterations to spatial reference 
or working memory, it would be useful to examine the impact of the structural 
alterations found on neuronal connectivity, at each time point. This could be 






7.6 Future direction within the field of hypertension in general 
 
The studies carried out within this thesis choose to examine hypertension 
using the Cyp1a1 Ren2 inducible rat model, for reasons already described, but the 
SHR and SHRSP models have undoubtedly provided a wealth of information to the 
field. Even though there are issues concerning appropriate normotensive control 
comparisons within these models, it would be interesting to carry out studies 
comparing the three models as each invokes different forms of hypertension. It 
would also lean towards strengthening specific hypertensive related findings if they 
were present in each model. 
Animal models are frequently used to study hypertension due to its 
coexistence with several vascular risk factors in humans. However, within the field it 
is necessary that we grasp what impact the con-existence of these vascular factors 
has on the structural and functional alterations observed in the aging human brain. It 
is unclear if it is solely the presence of multiple vascular factors or if it is a specific 
combination of vascular risk factors, which are particularly detrimental to the 
structural and functional integrity of the brain. Thus, further studies are required, 
which use a combination of vascular risk factors to assess their impact on the 
structural and functional integrity of the brain. 
Last but certainly not least, as introduced within the beginning of this 
discussion blood pressure in humans fluctuates temporarily throughout the day but 
patients are prescribed pharmaceutical methods designed to constantly lower blood 
pressure in such that they may be prone to periods of hypoperfusion. This needs to be 
carefully assessed as to the impact on the structure and function of the brain. This 
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may require the development of antihypertensive treatment, targeting populations 
with vascular remodelling, which may be designed with a shortened half-life in an 
aid to prevent blood pressure lowering actions during periods when the patient’s 
blood pressure naturally dips.  
 
     7.6. Concluding remarks 
 
Based on evidence provided within this thesis, hypertension induced in a 
controlled and sustained manner leads to modest alterations to the integrity of 
cerebrovasculature structure and WM. This study highlighted initial endothelial 
dysfunction caused by hypertension, which predisposed the brain to an exacerbated 
inflammatory response and vascular remodelling. Further work, using this inducible 
model of hypertension could help to unravelling the mechanisms leading to 
alterations in endothelial signalling and fully establish the link between endothelial 
function, vascular remodelling and inflammation. Work such as this would impact 
positively on the understanding of hypertension as a risk factor for cerebrovascular 
disease and age related cognitive decline but also in therapeutic approaches 
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Appendix A: Additional vascular data  
























































A1: Vessel width 
Collagen IV vessel width data was presented within the thesis as frequency 
distribution. The above graths show the averge vessel width measurement per animal 
in the (A) young 4 –month cohort, (B) young 6- month cohort and (C) aged 4 month 







A2: Number of vessels 
There was no significant difference in the number of vessels visualised using 
antibody specific for Collagen IV, in hypertensive animals when compared to 
normotensive from the young cohorts (A-B). However there was a significant 
increased in the number of vessels in hypertensive animals from the aged 4-month 









A3; Addition tight junction data from the young 6-month cohort 
(A), vascular width measurement analysed by Claudin-5 staining providing evidence 
that hypertension leads to significantly smaller vessels, analysed by frequency 
distribution. (B) No alteration in the density of ZO-1 staining in hypertensive animals 




Appendix B Additional microarray data from the young 6-month cohort 
 
 
B1: Pathway 2- Lipid metabolism, molecular transport, small molecule 
biochemistry  
Upregulated genes are in green and downregulated genes are in red in hypertensive 
animas versus normotensive. Within this pathway hypertension leads to differential 






B2: Pathway 3- Organ development and morphology  
Upregulated genes are in green and downregulated genes are in red in hypertensive 
animas versus normotensive. Within this pathway hypertension leads to differential 






B3: Pathway 4- Cell morphology, cellular function and maintenance  
Upregulated genes are in green and downregulated genes are in red in hypertensive 
animas versus normotensive. The last pathway is the least significant pathway, with 



























































C1: Representative images of no overt structural alterations in the fimbria. 
H&E was used to analyse the structural integrity of the fimbria in each cohort. No 
evidence of tissue pallor, microbleeds or haemorrhages were found in normotensive 

























































C2: Representative images of no overt structural alterations in the internal 
capsule. 
H&E was used to analyse the structural integrity of the internal capsule in each 
cohort. No evidence of tissue pallor, microbleeds or haemorrhages were found in 
normotensive (A, C, E) or hypertensive (B, D, F) animals. 
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D1: Representative images of MBP staining in the fimbria. 
There was no evidence of alterations in levels of myelin visualised using MBP within 
the Fimbria of hypertensive animals (B, D, F) compared to normotensive (A, C, E) 


























































D2: Representative images of MBP staining in the Internal capsule. 
There was no evidence of alterations in levels of myelin visualised using MBP within 
the internal capsule of hypertensive animals (B, D, F) compared to normotensive (A, 
C, E) from all three cohorts. 
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Appendix E Additional data of Magnetic resonance imaging findings in the 














E1: MRI in the young 4-month cohort 
MRI investigated of the stucutral integrity of the brain with hypertension (A). In 
young 4-month hypertensive animals there was a significant increase in 




Appendix F Additional representative images of microglial expression in the 






















































F1: Representative images of microglia expression in the fimbria. 
There was no evidence of alterations in numbers of microglia, visualised using IBA1 
(brown), within the Fimbria in hypertensive animals (B, D, F) compared to 

























































F2: Representative images of microglia expression in the fimbria. 
No evidence of alterations in the numbers of microglia, visualised using IBA1 
(brown) within the Internal capsule in hypertensive animals (B) compared to 
normotensive (A) from the young 4-month cohort. However, there was a significant 
increase in the number of microglia in hypertensive animals from the young 6-month 
cohort (D) and the aged 4-month cohort (F) when compared to normotensive (C, E).  
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G1: Behaviour cohort systolic blood pressure measurements 
Similar to previous studies animals fed the I3C hypertensive diet have significantly 
increased systolic blood pressure. Anaysed by repeated measures ANOVA as 
previously found there is a significant difference in blood pressure over time 
(p<0.001) and a significant interatction between blood pressure and treatment in 
hypertensive versus normotensive animals (p<0.001) and post hoc t-tests show a 
significant diffenrence at week 5 post dietary induction when compared to animals 
fed a normotensive diet of no I3C. *p<0.01. 
 
 
 
